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ABSTRACT
Streptococcus pyogenes (group A streptococcus, GAS) is a human specific pathogen
responsible for a wide range of diseases. The majority of GAS infections give rise to
uncomplicated disease, however, the migration of GAS from superficial to deep tissue
sites can result in life-threatening invasive infections. GAS secrete streptokinase (SK), a
potent plasminogen (Plg) activator which enables this bacterium to subvert the host Plg
activation system to generate soluble and cell bound protease activity. Unlike the human
Plg activators, u-PA and t-PA, which cleave the Plg activation bond (Arg561-VaI562) to
generate the broad serine protease plasmin, SK lacks intrinsic protease activity. Instead,
SK forms a stoichiometric complex with Plg and through non-proteolytic mechanisms,
generates an active site in the bound Plg molecule to produce an activator complex with
proteolytic activity. Among GAS isolates, SK gene (ska) sequences are polymorphic
and can be grouped into two distinct sequence clusters (termed cluster type-1 and
cluster type-2) with cluster type-2 being further divided into sub-clusters type-2a and
type-2b. Allelic variants of SK produced by GAS isolates display unique Plg activation
properties, however the biological significance of SK polymorphism among GAS
isolates is yet to be elucidated.

This project describes the first comprehensive phenotypic study of GAS SK variants by
characterising the structural, functional and biochemical differences displayed by SK
molecules. Five distinct ska alleles representing examples from the three known
phylogenetic sequence clusters, along with SKc from group C streptococcus were
cloned and expressed as recombinant proteins. Structural analysis using far-UV circular
dichroism spectroscopy indicated that all SK variants displayed similar secondary
structure despite significant variation in amino acid sequence. Active site generation in
Glu-Plg by SK variants was examined using the fluorescent active site titrant 4methylumbelliferyl p-guanidinobenzoate. In these experiments, type-2b SK variants
could not generate an active site in Glu-Plg through non-proteolytic mechanisms, while
all other variants displayed this hallmark capacity of SK action. SKc, type-1 SK, and
type-2a SK variants all bound human Glu-Plg with high affinity (KD ranging from 62 –
88 nM) when analysed by surface plasmon resonance experiments In comparison type-
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2b SK variants displayed a 29-35 fold reduction in affinity for Glu-Plg. All SK variants
had increased affinity (69 - 347 fold) for plasmin relative to Glu-Plg and could activate
substrate Glu-Plg when a SK-plasmin activator complex was pre-formed.

Ligands that bind to Glu-Plg can affect the conformation of the protein which in turn
can influence Glu-Plg activation. Therefore bacterial and human Plg binding ligands
were investigated for their ability to influence the activation of Glu-Plg by SK variants.
Despite type-2b SK not possessing the ability to generate an active site in native GluPlg, when active site experiments were repeated in the presence of fibrinogen, Plgbinding group A streptococcal M protein (PAM) (a Plg receptor constrained to type-2b
expressing GAS strains), fibrinogen fragment D and fibrin, type-2b SK could generate
an active site in Glu-Plg. Additionally, in contrast to the inhibition resistant SKc, type-1
and type-2a SK activator complexes, type-2b SK activator complexes (both those
formed with Pln and those formed with Glu-Plg in the presence of ligands) were
inhibited by the plasmin specific inhibitor, α2-antiplasmin (α2-AP). Interestingly, when a
combination of PAM and fibrinogen was present type-2b SK activator complexes were
resistant to α2-AP inhibition.
To determine if these observations could be translated into assays using more
physiologically relevant conditions, activation assays were performed in pooled human
plasma and in the presence of fibrin clots or whole cell GAS. As expected, in human
plasma type-2b SK-Plg complexes were inhibited by the endogenous α2-AP unless
exogeneous PAM was added to the assay. Additionally, when these assays were
conducted in the presence of whole cell GAS expressing PAM, type-2b SK could
activate Glu-Plg but the complex was only protected from inhibition by α2-AP when
fibrinogen was also present. Similarly, when type -2b SK variants activated Glu-Plg that
was bound to fibrin clots, these activator complexes were resistant to α2-AP inhibition.
Taken together, this distinct Plg activation/inhibition mechanism displayed by type-2b
SK variants would restrict plasmin activity to specific micro-environments within the
host such as fibrin deposits or the bacterial cell surface through the action of α2-AP
inhibition. As epidemiological studies have shown the type-2b streptokinase gene linage
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to be largely restricted to pam positive GAS strains which have a strong tendency to
cause skin infections, we speculate that phenotypic SK variation functionally underpins
a pathogenic mechanism whereby SK variants differentially focus Plg activation,
leading to specific niche adaption within the host.

When the skatype-2a from the M1T1 GAS strain 5448 was exchanged with skatype-2b, the
isogenic mutant displayed reduced virulence which was similar to that displayed by
knockout mutant. Isogenic 5448 mutants that contained a skatype-1 allele displayed
increased virulence. These data indicate that the phenotypic differences displayed by
GAS SK variants do influence the invasive pathogenesis of this organism.

These findings suggest that SK variants produced by GAS isolates utilise distinct Plg
activation pathways which, in turn, directly affects the pathogenesis of this organism.
These findings have implications for the future elucidation of the molecular mechanism
of SK mediated Plg activation, the generation of enhanced thrombolytic therapeutics
and may highlight a potential role for the differential regulation of Plg activation in the
pathogenesis of GAS (or the bacterial species that interact with the Plg activation
system).
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Preface

The chapters of this thesis were written for publication. As a result, each chapter stands
alone and is accompanied by an introductory section that addresses the overall theme
for that portion of work. Consequently, this introduction aims to provide a general
background to the thesis as a whole. Readers will therefore find that there are inevitable
overlap of certain topics addressed in this chapter and the introductory sections of
subsequent chapters.

Publication: McArthur J. D., Cook, S. M., Venturini, C., and Walker, M. J., (2012)
“The role of streptokinase as a virulence determinant of Streptococcus pyogenes Potential for Therapeutic Targeting.” Current Drug Targets 13: 297-307.
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1.1 Overview
Streptococcus pyogenes (group A streptococcus; GAS) is a Gram-positive, beta
haemolytic, human-specific pathogen (Cunningham, 2000). GAS normally inhabit
epidermal and pharyngeal tissue where they most frequently manifest as superficial
cases of pharyngitis or impetigo. However, GAS is an opportunistic pathogen readily
capable of infecting normally sterile deep tissue. Invasive GAS diseases are lifethreatening and include streptococcal toxic shock-like syndrome and the “flesh-eating”
disease necrotising fasciitis (Walker et al., 2014). GAS remain sensitive to penicillin
and the incidence of GAS disease has decreased over the major part of the 20th century
through the use of antibiotics and the implementation of improved hygiene and
sanitation (Weiss and Laverdiere, 1997). However, since the 1980s there has been an
alarming increase in severe invasive infections caused by GAS. This has revived
interest in understanding the pathogenic mechanisms by which this bacterium can
progress from causing localised superficial diseases to severe invasive diseases and
death (Kaplan, 1991). GAS diseases are underpinned by an extensive repertoire of
virulence determinants that are differentially regulated in direct response to a succession
of environmental signals within the host (Tart et al., 2007, Musser and Shelburne, 2009,
Olsen et al., 2010, Cole et al., 2011, Kreikemeyer et al., 2003, Sumby et al., 2006). One
such virulence mechanism is the subversion of the host plasminogen activation system
(PAS), whereby GAS are able to capture and activate the host protease, plasmin(ogen).
The proteolytic activity of the generated broad serine protease plasmin is both soluble
and cell-bound. Plasmin activity at the bacterial cell surface can circumvent host
defence mechanisms and is capable of degrading host tissue barriers and is important in
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allowing bacterial invasion of normally sterile tissues to produce severe systemic
infections (McArthur et al., 2008). To facilitate this process, GAS secrete streptokinase
(SK), a potent plasminogen (Plg) activating protein. This chapter presents a review of
the mechanisms that GAS employ to interact with the host PAS and detailed analysis of
the bacterial Plg activator, SK.

1.2 Classification of Group A Streptococcus
The genus Streptococcus comprises 49 species of Gram-positive cocci that typically
exist as commensal flora of warm-blooded animals, including humans (Patterson,
1996). For the past century, the serological reactivity of cell surface components has
been established as the foundation of streptococcal classification, the most prominent
being that based on immunological variations in cell wall polysaccharides, developed
by Rebecca Lancefield in the early 20th century (Cunningham, 2000). As for several of
the streptococcal species, Lancefield typing of GAS is not fully comprehensive. While
GAS is a single species, variation that occurs within this organism is broad and the
outcome in terms of virulence factor expression and pathogenic progress resulting from
this diversity is extensive. Therefore, additional serological and (more recently)
molecular techniques (M serological typing, T serological typing, emm sequence
typing) have been developed for sub-typing within GAS (Beall et al., 1996, Jones et al.,
1991, Lancefield, 1928).
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1.2.1 Lancefield Classification
The discovery of streptococcal polysaccharides in the early 1900’s allowed for the
development of the first serological classification system for grouping the majority of
streptococcus strains (Lancefield, 1928). The Lancefield serological grouping system
for streptococci identification is a system based on the immunological differences in
cell wall polysaccharides between streptococcal groups A, B, C, F and G (Cunningham,
2000). Confirmation and subsequent grouping of GAS cell wall carbohydrate was
achieved by techniques such as Lancefield capillary precipitin and slide agglutination,
which are highly accurate serological techniques that utilise standardised grouping antisera (Cunningham, 2000).

1.2.2 M-serological Typing
M proteins (encoded by emm) are dimeric, α-helical, coiled-coil protein molecules that
are anchored to the GAS cell surface at the C-terminus. GAS strains are often classified
by their M-serotype (Efstratiou, 2000). The N-terminal region of the protein is the basis
for classification, as it is hyper-variable and contains sequences that are GAS typespecific (Fischetti, 1991). In this technique, M-protein is extracted from the cell surface
of a given bacterial isolate and purified. Anti-sera is then raised against the M-protein
and can be used for M-protein serotyping of GAS strains (Efstratiou, 2000). However,
problems with this technique exist: the identification of strains with low-level
expression of M-protein, strains that express novel M-protein and the difficulty
associated with the preparation of type-specific anti-sera present technical problems
with this procedure (Cunningham, 2000). While M- serological typing was once the
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most commonly used techniques for GAS classification, it has largely been replaced by
emm sequence typing (Walker et al., 2014).

1.2.3 emm Sequence Typing
emm sequence typing is conducted by determining the DNA sequence of the first 160
bp at the 5’ end of emm which encodes the hyper-variable N-terminal region of Mprotein (Beall et al., 1996). emm sequence typing l7rgely reflects the serological
grouping but has allowed for characterisation of isolates previously non-typeable by
other serological methods. Over 200 emm-types have been identified (Beall et al., 1996,
Facklam et al., 1999). emm pattern grouping is a related method of describing the
arrangement of emm genes into one of five classes, designated A through E. The basis
of emm pattern grouping is dependent on the number of emm genes present, the
subfamily to which the emm genes belong and the relative arrangement of emm genes
on the chromosome (Bessen et al., 1999). An emm pattern A - C gene arrangement is
generally considered to be associated with isolates from throat infections, while those
from pattern D are related to skin infections. Isolates containing emm pattern E display
a high affinity for both tissue types (Bessen et al., 1999).

1.3 Diseases and Sequelae Resulting from Group A Streptococcal
Infection
GAS is a specific human pathogen that is responsible for numerous diseases with
diverse clinical manifestations (Carapetis et al., 2005). GAS preferentially colonise the
throat and skin, and are readily transmitted via aerosols and direct contact (Walker et
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al., 2014). While, GAS infection frequently causes superficial infections, these
organisms are opportunistic pathogens, capable of epithelial penetration, intravascular
survival and secondary infection of deep normally sterile tissue, which results in
invasive infections (Patterson, 1996). Furthermore, complications from repeated GAS
infections can occur producing serious post-infection non-supporative sequelae that are
often fatal if left untreated (Efstratiou, 2000). An outline of the most common GAS
pathologies is given in Table 1.1.

1.4 Epidemiology of GAS Disease
On a global scale, GAS is a major cause of morbidity and mortality, primarily in less
developed countries. However, there has been a global resurgence of severe invasive
disease in developed countries since the mid-1980s (Carapetis et al., 2005). The
identification of highly virulent strains of distinct M-serotypes, most notably M1T1,
isolated from severe invasive infections, has been pin-pointed as the main contributor to
GAS related disease resurgence in the developed world. The M1T1 clone is the
dominant clinical isolate within industrialised populations and is frequently associated
with life-threatening cases of invasive disease (Johnston et al., 1992, Cleary et al.,
1992, Musser et al., 1993, Tart et al., 2007). Furthermore, the epidemiology of GAS
disease is not as well-described in developing countries as it has been for developed
countries (Carapetis et al., 2005). While no resurgence of GAS disease has been
specifically reported in developing countries, GAS infection rates are at endemic levels
in many of these regions and may be the result of increased transmission due to factors
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Table 1.1 Common diseases caused by S. pyogenes (Cole et al., 2011, Cunningham,
2000, Efstratiou, 2000)
Category

Superficial

Disease Site

Pharyngitis

Pharynx

Impetigo

Epidermis

Superficial lesions, blisters and
pustules

Erysipelas

Epidermis

Superficial erythema and
inflammation

Cellulitis

Subcutaneous

Redness, inflammation and
fever

Streptococcal toxic
shock syndrome

Various

High fever, rapid-onset
hypotension and
multiple-organ failure

Bacteraemia

Blood

Fever, nausea and vomiting

Puerperal sepsis

Genital Tract

Fever, pelvic pain and
abnormal/odorous discharge.
Specifically, maintained or
recurrent fever in the 10-day
period following childbirth

(van Dillen
et al., 2010)

Septic arthritis

Joints

Fever and enlarged joints of the
lower extremities

(van der
Helm-van
Mil, 2010)

Necrotising
fasciitis

Subcutaneous

Rheumatic heart
disease

Heart

Acute rheumatic
fever

Joints, heart,
epidermis and
nervous system

Acute
poststreptococcal
glomerulonephritis

Kidney

Invasive

Nonsuppurative
Sequelae

Symptoms
Sore throat, swollen lymph
nodes and tonsillar exudates

Reference

Disease

Fever accompanying rapid
destruction of fascia, muscle
and adjacent tissue
Mitral or aortic valve
incompetence later
developing into mitral stenosis
Tissue inflammation giving rise
to carditis, valvulitis, arthritis,
chorea, erythema marginatum
and/or subcutaneous nodules
Rapid onset of gross
haematuria, oedema and
hypertension, usually following
an episode of GAS-mediated
pharyngitis or pyoderma

(Choby,
2009)
(Bisno and
Stevens,
1996)
(Bisno and
Stevens,
1996)
(Bisno and
Stevens,
1996)
(Lappin and
Ferguson,
2009)
(Stevens,
1992)

(Stevens,
1992)
(Carapetis et
al., 2000)

(Carapetis et
al., 2000)

(Bisno,
1995))

such as overcrowded housing, limited medical intervention and inadequate
implementation of hygiene and sanitation (Carapetis et al., 1999). Current estimates on
the burden of GAS disease, suggest that there are at least 517,000 deaths caused each
year by severe GAS diseases (Carapetis et al., 2005). The prevalence of GAS disease in
the global population is currently at least 18.1 million cases, with as many as 1.78
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million new cases each year (Carapetis et al., 2005). The greatest toll on human health
by GAS is due to rheumatic heart disease. Rheumatic heart disease has a prevalence of
at least 15.6 million cases world-wide, with 282,000 new cases and 233,000 deaths
annually. Furthermore, the burden of invasive GAS disease is high, with at least
663,000 new cases and 163,000 deaths annually. Overall, 19% of patients with invasive
GAS disease die within 7 days of infection and the development of STSS further
increases the mortality rate, as 44% of patients with STSS die within a week of
developing the disease. In addition, there are more than 111 million cases of GAS
pyoderma and 616 million incidents of GAS induced pharyngitis each year world-wide
(Carapetis et al., 2005).

The minimum estimate of over 500,000 deaths per year, places GAS among the major
human pathogens in terms of overall burden on the world population. GAS is only
exceeded by such severe pathogens as Human Immunodeficiency Virus, Myobacterium
tuberculosis, Plasmodium falciparum and Streptococcus pneumoniae (Carapetis et al.,
2005). However, GAS causes more long term morbidity than most of these pathogens,
and poor record keeping and documentation in developing countries, where the
majority of GAS infections occur, suggest that the true impact of GAS disease is
significantly underestimated (Carapetis et al., 2005).

1.5 GAS Virulence Factors
In concurrence with the global burden caused by GAS disease, GAS has been a focus of
resolute investigation for over a century. However, it has not been until the advent of
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modern molecular biological techniques that it has been possible to research the myriad
of GAS virulence factors that facilitate bacterial colonisation, evasion of the immune
response and systemic dissemination, which enable GAS to cause a diverse range of
diseases (Tart et al., 2007, Musser and Shelburne, 2009, Olsen et al., 2010, Cole et al.,
2011). Virulence factor expression is exquisitely controlled by 13 two-component
regulatory systems and 30 transcriptional regulators allowing GAS to adapt to the
dynamic

physiological

conditions

encountered

during

the

infection

process

(Kreikemeyer et al., 2003, Sumby et al., 2006). Many of the virulence factors produced
by GAS interact specifically with human plasma proteins including fibrinogen,
plasmin(ogen), IgG, fibronectin, α2-macroglobulin and albumin and numerous
complement factors (Walker et al., 2005, Walker et al., 2014). The ability of GAS to
adhere, invade and colonise human skin and mucosal membranes in a variety of
environments has been attributed to cell surface structures such as M proteins, the
hyaluronic acid capsule and fibronectin-binding proteins (Bisno et al., 2003). While,
extracellular toxins secreted by GAS, including super-antigenic streptococcal pyrogenic
exotoxins, hyaluronidase, cysteine protease (SpeB), DNases A - D and the Plg activator
SK allow GAS to spread through tissue and are believed to initiate the cytokinase
cascade responsible for necrotising facsitis and STSS progression (Hynes, 2004, Bisno
et al., 2003). There are numerous putative GAS cell-associated virulence factors which
are summarised in Table 1.2 and a second class of secreted virulence factors are
summarised in Table 1.3.
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Table 1.2: Established or putative cell-associated virulence factors of group A
Streptococcus compiled from recent reviews (Bisno et al., 2003; Cuningham, 2000;
Hynes, 2004)(Walker et al., 2014)
Virulence
Factor or
Molecular Class
Hyaluronic Acid
Capsule
Plasminogen-binding
proteins (GAPDH,
SEN, PAM/Plr)
Fibronectin-binding
proteins (Fbp54,
Pfbp, FbaA, FbaB,
PrtF1/SfbI,
PrtF2/PFBP,
SOF/SfbII, protein
F,SfbX)

Function(s)
Aids in resistance to phagocytosis, infection
and colonisation
Bind plasmin(ogen) with high affinity

Attachment of streptococcal cells to epithelia
cells

References
(Russell and Facklam, 1975,
Schrager et al., 1998)
(Lottenberg et al., 1992b,
Pancholi and Fischetti,
1992)
(Falugi et al., 2008, Hanski
and Caparon, 1992, Talay et
al., 1994, Jaffe et al., 1996,
Kreikemeyer et al., 1995,
Rakonjac et al., 1995,
Delvecchio et al., 2002,
Terao et al., 2002)

M protein
superfamily

Antiphagocytic, immunoglobin- binding,
collagen-binding, fibronectic binding,
fibrinogen binding

(Fischetti, 1991)

Heme-binding
protein (HtsA)

Iron appropriation

(Lei et al., 2003)

HtrA protease
Lipoprotein (Lsp)
Serum opacity factor
CD15s-related
antigen
Protein GRAB
DNase (SpnA)

Chaperone and protease, required for thermal
stability and resistance to oxidative stress
Matrix glycoprotein interaction, transitional
metal homeostasis
Serum opacification by cleavage of apoprotein
A1, fibronectin/fibrinogen binding

(Weston et al., 2009, Elsner
et al., 2002)
(Kreikemeyer et al., 2005,
Timmer et al., 2006)

Adhesion. Host immune system invasion

(Hirota et al., 1995)

Sequestration of α2-macroglobulin to cell
surface
DNA degradation. Resistance to neutrophil
extracellular traps

Chemotaxis
inhibitors (C5a
peptidase, SpyCEP)

Inhibit C5a and IL-8 components, eliminating
the chemostatic signal from the site of infection

Laminin binding
proteins (Lbp, Shr)

Adhesion to host cells

Streptococcal
collagen-like surface
protein (Scl1, Scl2)

Adhesion to host cells

AgI/II Related
Family
(AspA)

Adhesion to host cells, anti-phagocytosis

Pili (Spy0130,
Spy0128, Cpa)

Pilus structural proteins; collagen binding,
gp340 binding, bacterial aggregation, bioﬁlm
formation, host immune ivasion

(Jones et al., 2001)

(Rasmussen et al., 1999)
(Chang et al., 2011)
(Edwards et al., 2005,
Chiappini et al., 2012)
(Fisher et al., 2008, Terao et
al., 2002)
(Caswell et al., 2008,
Caswell et al., 2010,
Lukomski et al., 2000,
Whatmore, 2001)
Franklin 2012(Franklin et
al., 2013)
(Falugi et al., 2008,
Manetti et al., 2007)
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Table 1.3: Established or putative secreted virulence factors of group A
Streptococcus compiled from recent reviews (Bisno et al., 2003; Cuningham, 2000;
Hynes, 2004)(Walker et al., 2014)
Virulence Factor or
Molecular Class
Streptokinase
Streptococcal inhibitor of
complement
DNase (SdaI)

Function(s)

References

Binds and activates plasminogen to
generate protease activity
Bind to and inhibits C5bC7 complex to
prevent formation of the membrane
attrack complex. Also involved in
adherence and colonization.
DNA degradation. Resistance to
neutrophil extracellular traps

(Tillett et al., 1934,
Malke, 1993)

Streptolysin O and S

Cytotoxins, lysins, pore forming toxins

Hyaluronidases

Organism/toxin spreading

Immunoglobulin Gdergrading enzymes (IdeS,
EndoS)
Streptococcal pyrogenic
exotoxins (A-C, F-H, J-M,
SSA, SMEZ, SMEZ-2)

Cleavage of bound IgG, inhibition of
opsonophagocytosis and killing by
polymorphonuclear leukocytes
Superantigens (aside from SpeB and
SpeA), mitogens (mediate polyclonal T
cell activation and division
Proteolysis of GAS and host
proteins. Strepadhesin, laminin-binding
and cysteine protease activity

Cysteine protease (SpeB)

(Åkesson et al., 1996,
Pence et al., 2010)
(Walker et al., 2007)
(Timmer et al., 2009,
Nizet et al., 2000)
(Hynes and Walton,
2000, Rivera Starr and
Engleberg, 2006)
(Kawabata et al., 2002,
Collin and Olsén, 2001)
(Commons et al., 2014)
(Hytönen et al., 2001,
Svensson et al., 2000,
Cole et al., 2006a)

The most important GAS virulence mechanism for the scope of this thesis is the
interaction of GAS with the Plg activation system of the host. This interaction with Plg
via the secretion of SK and expression of Plg binding proteins is critical for the
pathogenic potential of this organism and is a diverse multi-faceted relationship (Sun et
al., 2004, Khil et al., 2003, Walker et al., 2005, Irigoyen et al., 1999).
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1.6 The Plasminogen Activation System
The PAS is a highly regulated in vivo proteolytic system for degrading intravascular
fibrin clots, furthermore components of the PAS are involved in numerous
physiological processes, such as cell migration, angiogenesis, wound healing,
ovulation, remodeling and repair of both damaged and healthy tissue, trophoblast
implantation, and embryonic development (Andreasen et al., 1997, Coleman and
Benach, 1999, Plow et al., 1995b). However, subversion of the PAS components has
become an increasingly recognised mechanism that contributes to the course of an
infection directly through protease mediated degradation of tissue barriers or by
affecting the immune response generated by the host by pathogenic bacteria (Berge and
Sjobring, 1993, Sanderson-Smith et al., 2012, McArthur et al., 2012). Functionality of
the PAS requires the involvement of several proteins. These include, Plg (the zymogen
form of plasmin), specific mammalian Plg activators, urokinase (uPA) and tissue-type
Plg activator (tPA), as well as Plg-activator inhibitors 1 and 2 (PAI-1/PAI-2) and
plasmin specific inhibitors α2-antiplasmin (α2-AP) and α2-macroglobulin (α2-MG)
(Figure 1.1) (Andreasen et al., 2000).

1.6.1 Plasminogen
Plg, in its native form, is a 92 kDa, single chain glycoprotein zymogen of the broad
spectrum serine protease plasmin (Berge and Sjobring, 1993, Ponting et al., 1992).
Synthesised in the liver and found in plasma and most extracellular fluids, Plg is
maintained at a stable plasma concentration of approximately 2 µM (Ponting et al.,
1992). Plg consists of two polypeptide chains joined by disulphide bonds and the
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functional Arg561-Val562 peptide bond (Figure 1.2).The cleavage of the peptide bond

Figure 1.1: Schematic of the mammalian plasminogen activation system. The
activation of plasminogen (Plg) to plasmin occurs via urokinase (uPA) or tissue-type
Plg activators (tPA) and is inhibited by Plg activator inhibitors 1 and 2 (PAI-1/PAI-2).
Plasmin can degrade fibrin or other extracellular membrane proteins and this process is
inhibited by α2-antiplasmin (α2-AP) and α2-macroglobulin (α2-MG). Figure adapted
from Andreasen, (2000).

between Arg560 and Val561 of Plg by Plg activators (uPA and tPA), results in the
formation of broad serine protease plasmin (Nilsen et al., 1999). The light 25 kDa
polypeptide C-terminal chain B contains the serine active site, with His603, Asp646 and
Ser741 forming the catalytic triad, which is characteristic of serine proteases. The heavy
65 kDa polypeptide N-terminal chain A contains five homologous repeated ‘kringle’
domains (Figure 1.2) (Nilsen et al., 1999). The kringle domains contain lysine binding
sites that are responsible for interactions with fibrin and other lysine residues of tissue,
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cell surfaces receptors and target molecules (Nilsen et al., 1999, Ponting et al., 1992,
Law et al., 2012). In particular kringles 1, 2, 4, and 5 contain lysine-binding sites
comprised of a hydrophobic cleft formed by aromatic residues that most commonly
bind C-terminal lysine residues and internal lysine residues of receptors (Marti et al.,
1997). Upon conversion to plasmin the heavy and light chains of the molecule remain
connected by the two disulphide bonds. These bonds are important as they maintain the
conformation of the serine activation loop that is responsible for the proteolytic activity
of plasmin (Lahteenmaki et al., 2001).

Figure 1.2: Schematic structure of Glu-Plg and Glu-Plasmin. Glu-Plg contains a
preactivation peptide (PAP) that spans from Glu1 to Lys77, followed by 5 homologous
kringle domains (K1–K5), followed by a peptidase S1 domain (SPD). PAP is generated
by plasmin cleavage between Lys77- Lys78 giving rise to Lys-Plg. The conversion of
Glu-Plg or Lys-Plg to their respective plasmin forms occurs by hydrolysis of the Arg561Val562 peptide bond by either uPA or tPA. This yields chain A and the smaller chain B,
which remain covalently associated by interchain disulfide bonds. Kringles 1, 2, 4, and
5 contain lysine-binding sites with affinity for free lysine and lysine-like compounds
such as ω-aminocarboxylic ligands, cell surface receptors and fibrin in the in the
following order of binding affinity K1 > K4 > K5 > K2. Kringle 3 shows no detectable
binding to Lys or Lys-like compounds, due to sequence variation in the lysine binding
site. SK (not shown) binds in a 1:1 complex with the SPD to generate an activator
complex. Figure adapted from Sanderson-Smith et al. (2012)
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Plg normally circulates as the full-length 791 amino acid native form termed Glu-Plg
(Figure 1.2). Intramolecular binding between lysine residues and the lysine binding
sites of these kringles maintains circulating Glu-Plg in a compact and internally rigid
‘closed’ conformation that is highly resistant to activation. Upon binding to specific cell
surface receptors or ligands, such as fibrin, Glu-Plg adopts an ‘open’ conformation that
becomes more susceptible to activation (Figure 1.3) (Castellino and Ploplis, 2005, Law
et al., 2012, Xue et al., 2012). Additionally, the pre-activation peptide of Glu-Plg can
be removed through plasmin mediated N-terminal cleavage between the residues Arg67
-Met68, Lys76 -Lys77, or Lys77 -Val78, resulting in the production of Lys-Plg
(Lahteenmaki et al., 2001). Lys-Plg assumes the ‘open’ Plg conformation in circulation,
which is internally flexible and displays distinct physiochemical and functional
characteristics that enable stronger interactions with receptor and target molecules and
enhanced activation (Figure 1.3) (McCance and Castellino, 1995, Claeys and
Vermylen, 1974, Lahteenmaki et al., 2001).

The primary in vivo function of plasmin(ogen) is to regulate vascular patency by
degrading fibrin-containing thrombi, which form as both a reparative factor to tissue
damage and a protective factor in reaction to inflammation caused by an immune
response against an invading pathogen (Lewis et al., 1984). However, the identification
of Plg/plasmin receptors and the ability of plasmin to degrade matrix proteins other than
fibrin, has implicated plasmin in other functions involving localised degradation of
protein barriers and cell migration (Castellino and Ploplis, 2005). Diverse cell types
promote plasmin generation through their expression of uPA, tPA and cell surface
receptors (Cesarman-Maus and Hajjar, 2005). Endothelial cells, monocytes,
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macrophages, neutrophils and some tumour cells, all bind Plg, as well as tPA and/or
uPA. These receptors localise cell surface ﬁbrinolytic activity and provide specialised
environments that are protected from circulating inhibitors (Ellis and Whawell, 1997,
Plow et al., 1995b, Ponting et al., 1992). The primary role of tPA is in the generation of
plasmin for fibrinolysis in blood vessels and is known to be a poor Plg activator in the
absence of fibrin (Andreasen et al., 2000). While, uPA is generally agreed to be the
enzyme primarily associated in tissue remodelling, wound healing and cell mediated
degradation during inflammation (Andreasen et al., 2000, Andreasen et al., 1997).

Figure 1.3: Diagrammatic representation of the closed and open conformations of
plasminogen. (A) The circulating form of plasminogen is the closed conformation. The
heavy chain consisting of five kringle domains and the light chain containing the
catalytic domain are entwined. (B) When plasminogen binds to cells expressing
plasminogen receptors or other cell surface proteins, the activation susceptible open
conformation is induced. Physiological plasminogen activators cleave a peptide bond at
the cleavage site that is more susceptible to cleavage in the open form, to yield plasmin.
Figure from (Lahteenmaki et al., 2001).
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Due to the broad substrate specificity and proteolytic power of plasmin, the fibrinolytic
system is tightly regulated and plasmin generation under normal physiological
circumstances is generally restricted to specific foci. Failure to regulate the fibrinolytic
system can result in excessive thrombi formation (via insufficient activation of the
thrombolytic system or excessive inhibitors) or an increased bleeding tendency (via
over stimulation of the thrombolytic system and deficiency of inhibitors) depending on
the factor that is not regulated appropriately (El-Gengaihy et al., 2007). Endothelial
cells secrete PAI-1 and PAI-2, which circulate in plasma at a low concentration. PAI1/PAI-2 inactivates uPA constitutively and acts on tPA when it is not in the presence of
fibrin. In plasma, tPA and uPA also only have remarkably short half-lives of 5-8 min
and 7-20 min respectively (Khan and Gowda, 2003, Fedan, 2004, Andreasen et al.,
2000). Circulating plasmin is inhibited by physiological serine protease inhibitors (α2AP and α2-MG) that irreversibly bind and inactivate plasmin (Fedan, 2004). α2-AP and
α2-MG have binding regions that interact specifically with the lysine binding sites of
plasmin(ogen). This in the same region that makes the molecule specific for fibrin,
thereby acting as competitive inhibitors (Aoki et al., 1993). In addition to being
resistant to α2-AP and α2-MG inhibition at the site of fibrin loci, plasmin(ogen) bound
to the cell surface via these lysine residues are also resistant to inhibition (Wang et al.,
1995a).

1.6.2 Group A Streptococcus and the Plasminogen Activation System

The exploitation of host components to increase the chance of survival and spread
within the human host is an essential pathogenic mechanism of GAS. Human Plg is
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often used by invasive bacteria as a virulence factor and this process has been
recognised as a critical step in GAS invasion. GAS can interact with PAS components
via several mechanisms to produce extracellular proteolytic activity or acquire
proteolytic activity at the cell surface (Cole et al., 2006a, Walker et al., 2005, D'Costa
and Boyle, 1998). GAS can either bind host plasmin(ogen) directly to the cell surface,
or indirectly by binding a tri-molecular complex consisting of Plg, SK and fibrinogen
(Boyle and Lottenberg, 1997, McKay et al., 2004, Wang et al., 1995b). Currently three
plasmin(ogen) cell surface receptors on GAS have been characterised; 1) Plg-binding
GAS M-like proteins (PAM or Prp) (Berge and Sjobring, 1993, Sanderson-Smith et al.,
2007), 2) glyceraldehyde-3-phosphate dehydrogenase (GAPDH), also known as
streptococcal surface dehydrogenase (SDH) or Plg receptor (Plr) (Lottenberg et al.,
1992a, Pancholi and Fischetti, 1992) and 3) streptococcal surface enolase (SEN)
(Pancholi and Fischetti, 1998). Plg bound to the bacterial cell surface may also be
converted into plasmin through the action of the host derived Plg activators uPA and
tPA, or by SK (Lahteenmaki et al., 2001).

1.6.3 GAS Plasmin(ogen) Cell Surface Receptors

1.6.3.1 Plg-binding Group A Streptococcal M-like Proteins (PAM and Prp)
PAM is a 43 kDa member of the M-like protein superfamily, encoded by emm-like
genes (Berge and Sjobring, 1993). M-like proteins display an extensive array of binding
activities for tissue and plasma proteins of the human host, which play a role in antiphagocytic functions (Svensson et al., 1999). PAM binds both Plg and plasmin with
high affinity via a domain of 30 amino acids within the variable N-terminal region. This
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domain consists of two lysine-containing thirteen amino acid repeated sequences,
designated A1 and A2 (Wistedt et al., 1998). These repeat sequences are identical in
nine of the thirteen amino acid residues; non-identical residues possessing the same
charge and polarity interact with the lysine-binding 2nd kringle domain of Plg (Wistedt
et al., 1998, Ringdahl and Sjobring, 2000). The conformational structure of Plg when
bound to PAM is ordered in such a way that its catalytic domain is free to bind to
endogenous SK and host Plg activators meaning that after this interaction, the
streptococcal-bound Plg can be readily converted to plasmin (Ringdahl et al., 1998,
Wistedt et al., 1998).

1.6.3.2 Streptococcal Surface Enolase (SEN)
SEN is a 45 kDa GAS surface protein found on most GAS serotypes (Pancholi and
Fischetti, 1998). The contribution of two lysine residues (Lys434 and Lys435) at the SEN
C-terminus allow for high affinity binding to Lys-Plg and stabilise the conformation of
Plg binding sites in SEN (Derbise et al., 2004). SEN is functionally and structurally
different to other GAS Plg binding proteins (SK, GAPDH or PAM), as it has
significantly higher binding affinity for Plg than plasmin and binds to Lys-Plg with
almost three times more affinity than to Glu-Plg (Derbise et al., 2004, Lottenberg et al.,
1992b). The ubiquitous presence of SEN on the surface of almost all M types suggests
that SEN may play a major role in the strong direct Lys-Plg-binding activity of GAS,
including those serotypes that have been shown to bind Glu-Plg (Derbise et al., 2004).
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1.6.3.3 Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH)
GAPDH is a 41 kDa glycolytic enzyme that has been found to be present on the GAS
cell surface of all isolates (Pancholi and Fischetti, 1992). GAPDH was first identified as
a streptococcal receptor for plasmin and found to bind Glu-Plg very weakly. The
localisation of GAPDH on the cell surface of GAS has been demonstrated by
immunological and enzymatic methods (Pancholi and Fischetti, 1992, D'Costa and
Boyle, 1998, Winram and Lottenberg, 1998). GAPDH preferentially binds to Lys-Plg
and plasmin via interaction with the C-terminal Lys334. GAPDH will also bind Glu-Plg,
but at a relatively low affinity compared to SEN and PAM (Lottenberg et al., 1987).
GAPDH has also been shown to interact with fibronectin, lysozyme and other
cytoskeletal proteins, and it is supposed that these additional interactions may play a
role in GAS adherence to host tissue (Pancholi and Fischetti, 1992).

1.6.3.4 Indirect Interaction of GAS with Plg
In addition to the direct binding of plasmin(ogen), GAS can acquire plasmin activity on
the bacterial cell surface via a second, more complex pathway. This pathway involves
interactions between two host proteins, fibrinogen and Plg and two bacterial proteins,
the secreted Plg activator SK and a surface expressed Plg or fibrinogen receptor
(D'Costa and Boyle, 1998). The SK-Plg activator complex can bind to fibrinogen
forming a tri-molecular complex, which maintains un-regulated plasmin activity and
binds to the GAS cell surface via fibrinogen or Plg receptors (Wang et al., 1995a).
While the indirect pathway has not been shown to be related to invasive potential of
GAS (Wang et al., 1995b, Chibber et al., 1985, Christner et al., 1997), this pathway has
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been proposed as a mechanism for PAM negative GAS isolates to acquire cell surface
plasmin activity (Walker et al., 2005).

1.7 Streptokinase

1.7.1 Mechanism and Structure
SK is a Plg activating protein secreted by group A, C and G streptococci (Marcum and
Kline, 1983). The most studied forms of SK consist of 414 amino acids, are produced
by streptococcal strains isolated from human hosts and display a high degree of
homology (>85% identity at the amino acid level). While, Plg activators produced by
group C and G isolates from animal hosts and Streptococcus uberis are smaller in size
and display less homology with each other and human associated SK (20-40% identity
at the amino acid level) (Ward and Leigh, 2002). GAS is a human specific pathogen
and the SK secreted by GAS isolates is highly specific for human Plg and displays
inefficient activation of Plg from other species. This also suggests that SK proteins have
co-evolved with specific hosts and may contribute to the species-restricted infection
(Marcum and Kline, 1983, Wohl et al., 1983). Classical SK is composed of three
distinct domains termed α, β and γ (Huang et al., 1989). The three domains of SK are
separated by two coiled-coils, and small regions at the N- and C- termini of the protein
have disordered flexible structures (Wang et al., 1998). As a 26 residue leader peptide
is cleaved off the SK protein during secretion, the amino acid sequence positions of the
domains span residues 27 – 173 for the α domain, residues 174 – 317 for the β domain
and spans residues 318 – 440 for the γ domain (Kalia and Bessen, 2004, Parrado et al.,
1996, Wang et al., 1998).
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Crystallographic studies of SK bound to the catalytic domain of plasmin have deduced
the three domains of SK appear in a complex of homologous folding. Domains α and β
each contain a major β sheet of five mixed β strands and an α-helix, while the γ domain
has only four β strands and contains a long coiled-coil region rather than an α-helix
(Figure 1.4) (Wang et al., 1998).

Figure 1.4: Crystal structure of streptokinase (A) The solved 3D model of SKc from
Wang et al. (1998). (B) A 3D model for SKALAB49 was constructed using an automated
comparative protein modelling server, Swiss Model Workspace. (C) An overlay of
(solved) SKc model and (predicted) SKALAB49 model to highlight homology in the 3D
model structures of group C SK and group A SK were deduced by comparison of
protein residues to the crystallography data of SKc complexed with microplasmin by
Wang et al. (1998). SK is composed of three distinct domains termed α, β and γ which
are highlighted in the figure
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SK has no intrinsic enzymatic activity and unlike other Plg activators, such as host uPA
and tPA, it is not a protease (McClintock and Bell, 1971). Where host Plg activators
activate Plg by limited proteolytic cleavage, SK binds via lysine dependant interactions
between SK and the kringle/catalytic domains of Plg inducing conformational changes
in the molecule that result in the formation of an active site and the production of an
active complex, termed SK-Plg* (known as the ‘Conformational Activation Pathway’
or ‘Pathway I’) (Figures 1.5 and 1.6). The conformationally activated SK-Plg* complex
can then sequester substrate molecules of Plg and proteolytically convert those to the
broad serine protease plasmin via cleavage at the Arg561-Val562 peptide bond (Boxrud et
al., 2000, Boxrud et al., 2004). Plasmin, which has a higher affinity for SK than Plg,
rapidly displaces Plg in the SK-Plg* complex to produce an activated SK-plasmin
complex that is the main catalyst responsible for the full conversion of Plg to plasmin
(known as ‘Direct Proteolytic Activation Pathway’ or ‘Pathway II’) (Figures 1.5 and
1.6) (Boxrud et al., 2000, Boxrud et al., 2004, McClintock and Bell, 1971, Reddy and
Markus, 1972, Schick and Castellino, 1974)

.
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Figure 1.5: Schematic representation of the steps involved in the activation of Plg by SK. SK forms an equimolar complex with Glu-Plg (Plg)
that leads to the generation of an active centre in the complex (SK.Plg*) without cleavage of Arg561-Val562 scissile peptide bond in the ‘partner’
Glu-Plg (Pathway I). The SK-Plg complex recruits free Plg as substrate and proteolytically activates it to plasmin (Pln). Plasmin that is generated
rapidly exchanges the Plg from SK.Plg* complex due to a much higher affinity for SK in comparison to Glu-Plg. Alternatively, SK can directly
combine with Pln to form the mature SK.Pln activator complex (Pathway II). The SK-Pln activator complex catalytically acts on ‘substrate’ Plg
molecules and converts them into Pln. Schmatic information adapted from Aneja et al. (2009)
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Figure 1.6: Mechanism for coupling of conformational and proteolytic activation of
plasminogen by SK. A unified hypothesis for the mechanism of SK-induced conformational
and proteolytic activation of Plg is illustrated. Free Plg is represented as the five kringle
domains and the proteinase domain in blue. This has been done to simplify the scheme and is
not meant to be restricted to this form of Glu-Plg but to represent both conformational forms
of Glu-Plg and Lys-Plg. The reaction proceeds through the indicated complexes. Proteolytic
activation catalytic cycle (Pathway I) is initiated by SK binding to Plg and conformational
activation to generate SK.Plg* (light blue). This complex interacts with substrate Plg forming
the ternary Michaelis complex, SK-Plg*.Plg, which result in the generation of plasmin (Pln)
(orange) by proteolysis of the Arg561-Val562 scissile peptide. Pln generated by SK.Plg* can
displace Plg from the SK-Plg* complex or interact with free SK, forming SK.Pln (yellow).
The tightly bound SK.Pln complex initiates the lower catalytic cycle of direct proteolytic
activation (Pathway II), binding free substrate Plg to form SK.Pln,Plg, from which free Pln is
generated. Figure adapted from Boxrud and Bock (2004)
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1.7.4 Roles of α, β and γ Domains of Streptokinase in Plg Activation
The exact manner that each domain contributes to the high rates of Plg activation by full
length SK remains to be identified. However, the incredibly high catalytic turnover by
the SK.plasmin(ogen) activator complex has been attributed to the three-domain
architecture of SK. Selective deletions of α, β and γ domains, or parts thereof, result in a
drastic reduction in Plg activation activity, indicating that all three domains of SK are
essential in the functioning of the molecule (Parrado et al., 1996, Loy et al., 2001,
Conjero-Lara et al., 1998, Chaudhary et al., 1999). When individually isolated, each
domain retains significant amounts of native-like structure and significant capability to
bind with Glu-Plg, but cannot activate Plg (Parrado et al., 1996, Loy et al., 2001,
Conjero-Lara et al., 1998). While it is clear that the three domains are required to
function in concert for full activity, the exact inter-domain mechanism responsible for
interactions with partner plasmin(ogen), the formed SK-plasmin(ogen) activator
complex with substrate Plg and those responsible for post-docking and/or post-cleavage
steps such as product expulsion, are little understood at present (Yadav and Sahni,
2010).

Considering the large surfaces involved in the protein–protein interactions between SK
and plasmin(ogen), it seems very likely that there are a number of sites in the SK
molecule participate in the catalytic process. The crystal structure of SK alone, or in
complex with Glu-Plg is yet to be solved, however, the crystal structure of the catalytic
domain of human plasmin (sans kringle domains) complexed with SK, gives an
indication to the extent of interactions displayed by each SK domain. The level of these
interactions descends in order from α, γ, to β (Wang et al., 1998). In the current solved
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structure, the α domain binds to plasmin mainly through interactions between the αβ1
and αβ2 strands of SK and a loop region (residues 713 to 721) and also interacts with
catalytic domain near the catalytic triad residues His603 and Asp646. The γ domain binds
near the activation cleavage site of Plg in the “calcium-binding loop” (residues 622 to
628) and the “autolysis loop” (residues 692 to 695), via extensive charged and
hydrophobic interactions with the major coiled coil region and the strands αβ1 and αβ2 of
the domain. Lastly, the interaction β domain with the catalytic domain of plasmin
appears to be relatively limited (Wang et al., 1998).

Without structural data for SK interaction with native Glu-Plg, the focus for the
elucidation of the rest of the binding determinants and key residues in the molecular
mechanism of SK mediated Plg activation has been shifted to amino acid deletion,
domain truncation, site directed mutagenesis and molecular modelling approaches.
Subsequently, while not interacting with the catalytic domain, binding of the β domain
to the 5th kringle domain of Plg has been predicted. A distinct hairpin loop structure
(residues 250-264) links the two β sheets of the domain and in this region, residues
Lys256 and Lys257 are critical for Plg identification and subsequent high affinity binding,
however, this interaction alone is incapable of causing Plg activation (Chaudhary et al.,
1999, Wang et al., 1999b, Lin et al., 1996). Thus, it appears from the current data that
the α and γ domains provide most of the substrate recognition sites with the
plasmin(ogen) moiety and exhibit a synergistic effect of plasmin activation by full
length SK (Wang et al., 1998). While, the β domain provides no direct contact site with
the plasmin active site, it is required to bind to Plg and instigates the conformation
change of the Plg molecule (Chaudhary et al., 1999, Lizano and Johnston, 2005). This
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initial interaction of the β domain of SK with circulating native Glu-Plg results in the
conversion of Plg from the physiological ‘closed’ conformation to the more flexible
‘open’ conformation (Figure 1.6) (Boxrud et al., 2000). When in the ‘open’
conformation, Plg is more internally flexible, and exposes other lysine residues present
in the kringle domains making them available for further interactions with the α and γ
domains (Conjero-Lara et al., 1998, Loy et al., 2001).

1.7.2 Conjecture in the Molecular Mechanism that Streptokinase employs to
Activate Plg
Plg is usually activated by the proteolysis of the Arg561 - Val562 peptide bond. This new
N-terminal amino group (Val562) is believed to form a salt-bridge with the Plg
carboxylate group (Asp740) (Wang et al., 2000). This is analogous to the conversion of
trypsinogen to trypsin, a serine protease found in the digestive system of mammals,
where Ile16 forms a salt-bridge with Asp194 to induce active site development.
Formation of this salt bridge, in both cases, triggers a conformational change that
generates active protease (Wang et al., 2000, Wang et al., 1999a). However, SK binds
to Plg and causes it to assume an active conformation. As this occurs without the
regular cleavage of the activation peptide bond, the salt-bridge between Val562-Asp740
cannot form in the SK:Plg complex. It is therefore likely that a residue within the SK
moiety is able to provide a counter-ion for Asp740, however this process is poorly
defined and two hypotheses have been proposed (Wang et al., 2000).

The first mechanism proposed, termed ‘molecular sexuality hypothesis’, involves the
insertion of the N-terminus of SK (Ile1-Asp2-Gly3) into the activation pocket of Plg,
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facilitating the formation of a salt bridge between Ile1 and Asp740 of Plg (Bode and
Huber, 1976, Parrado et al., 1996, Wang et al., 1999a). The mutation or removal of this
Ile1 residue from SK by Wang et al., (2000) decreased the formation of the active site in
the SK:Plg complex by 100 fold. However, none of the N-terminal mutations that have
been conducted (Ile1 to Ala1, Gly1, Val1, Trp1 or Lys1) perturb the binding affinity of
SK to Plg, which suggest that Ile1 is not essential for the formation of the SK:Plg
complex, but is required for the formation of the active site in the molecule (Loy et al.,
2001, Mundada et al., 2003). Furthermore, removal of the N-terminal Ile1-Lys59 peptide
alters the mechanism of SK mediated Plg activation, resulting in a fibrin-dependent
mode of action, similar to that of tPA. Whereby, SK cannot activate circulating
substrate Glu-Plg and requires Plg to be in an ‘open’ conformation bound to fibrin or
the presence of plasmin to generate proteolytic activity (discussed further in the
introduction to Chapter 5) (Reed et al., 1999).

An alternative to the ‘molecular sexuality’ theory involves the hypothesised interaction
of the γ domain of SK in the formation of the active SK:Plg complex (Wang et al.,
1998, Young et al., 1998, Wu et al., 1990, Zhai et al., 2002). Known as ‘contact
activation’ (Zhai et al., 2002) or ‘binding activation’ (Wu et al., 2001), this theory
suggests that the γ domain binds to Plg inducing a conformational change in the Plg
molecule that exposing Lys698 to Asp740 of Plg. Lys698 acts as the important counter-ion
to form the crucial salt-bridge, triggering the conformational change of the Plg moiety
to its active state (Wu et al., 2001). By analysing the crystallography data presented by
Wang et al., (1998) it can be seen, as previously mentioned, that the SK γ domain binds
in close proximity to the activation cleavage site of micro-plasmin. Extensive charged
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and hydrophobic interactions are seen between the ‘serine active loop’ (residues 558 566) and the ‘calcium-binding loop’ (residues 622-628) of Plg and the coiled-coil
region of the SK γ domain (Wang et al., 1998). It is the coiled-coil region of the SK γ
domain (residues 314 - 342), specifically amino acid residues Arg324, Asp325, Lys332 and
Lys334 that are potentially critical for formation of the activator complex and
conformational modification of Plg (Wu et al., 2001).

Whilst there is evidence to support both theories, most conflict is inferred as to which
residue acts as the crucial counter-ion for Asp740. Experiments conducted by Wang et
al., (1999, 2000) have used mutational characterisation studies to test these two
hypotheses. They found that mutation of the Ile1 residue blocked formation of the active
SK:Plg complex but had no effect on the affinity of SK for Plg, while, mutation of
Lys698 impaired the initial formation of the activator complex and the affinity of SK for
Plg (Wang et al., 2000). In light of this, it is perhaps more likely, as suggested by Loy
et al., 2001, that active site formation occurs via two simultaneous interactions of SK α
and γ domains with Plg that are synergistic to the generation of an active site in the
molceule (Loy et al., 2001). In summary, whilst the exact function of each SK domain
in Plg activation is not fully defined, it is possible to conclude that complex formation
is initiated by the rapid and requisite binding of the SK β domain to the 5th kringle of
Plg (Wang et al., 1999a). This interaction triggers a conformational change in Plg from
the ‘closed’ to ‘open’ conformation, followed by the binding of all three domains of SK
to the catalytic domain of Plg (Loy et al., 2001). Active site formation is cooperatively
induced by the SK α and γ domains, while substrate Plg is recognised by the activator
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complex through interactions predominately mediated by the SK α domain (Loy et al.,
2001).

1.7.3 Variability of Streptokinase from GAS
Although S. pyogenes is restricted to a singular human host, SK alleles from distinct
clinical isolates exhibit considerable genetic diversity and variability of SK occurs
across all three domains (Kapur et al., 1995). The α and γ domains show 23% and 17%
amino acid divergence, respectively, while 54% amino acid divergence occurs in the β
domain. (Figure 1.4) (Kalia and Bessen, 2004). Through phylogenetic analysis of the β
domain from the 80 ska variants, two distinct phylogenetic lineages have been
identified, termed cluster type-1 and cluster type-2, with further evidence of sub clusters
in type 2 (cluster type-2a and 2b) (Figure 1.7) (Johnson et al., 1992, Kalia and Bessen,
2004).

SK variation has been linked to strains associated with acute post streptococcal
glomerulonephritis (Malke, 1993, Peake et al., 1991) and to strains that exhibit skin
tissue tropism (Kalia and Bessen, 2004). However, the full biological significance of SK
polymorphism in streptococcal pathogenesis has not been determined. It has recently
been shown that variant SK proteins produced by distinct clinical S. pyogenes isolates
display differing Plg activation capacities (McArthur et al., 2008). SK encoded by
cluster 1 ska alleles readily formed an active complex with soluble Plg while cluster 2
SK required the formation of a tri-molecular complex with Plg and fibrinogen to display
Plg-activating capability (McArthur et al., 2008). The phenotypic differences displayed
by SK variants suggest that these proteins may have differing roles in streptococcal
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pathogenesis. Despite such phenotypic differences, mechanisms have been proposed by
which all S. pyogenes strains with differing ska alleles can acquire plasmin activity onto
the cell surface. Plg receptors interact with different regions of the Plg protein. PAM
binds

to

Plg

via

interaction

with

K2

(Wistedt

et

al.,

1998),

whereas

Figure 1.7: Phylogenetic tree for a 423 bp variable region encoding the β -domain
of streptokinase. Bootstrap values of >90% (500 replicates) are indicated. Scale bar =
0.05 substitution per site. ska alleles used in this study as representative SK molecules
for each cluster type are highlighted in colour. Figure adapted from McArthur et al.,
2008.
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fibrinogen and other streptococcal Plg receptors (SEN and GAPDH) are believed to
bind via lysine-dependent interactions with K1, K4, and K5 (Ponting et al., 1992).
Therefore, in strains that express cluster 2 type SK, the active tri-molecular complex can
only be bound to the cell surface via PAM or fibrinogen-binding receptors (FgR) such

Figure 1.8 Schematic diagram summarising the hypothesised pathways of cell
surface plasmin acquisition by GAS strains expressing different alleles of SK. A)
Cluster type-2b SK must combine with Plg and fibrinogen to form a trimolecular
complex that exhibits plasmin activity. The trimolecular complex is bound to the cell
surface via the interaction between PAM and kringle 2 of Plg. Other GAS Plg-binding
proteins such as SEN cannot bind this trimolecular complex, because the domains K1,
K4, and K5 required for interaction are involved in the interaction with fibrinogen. B)
Cluster type-2a SK is believed to require Plg and fibrinogen to form a trimolecular
complex that exhibits plasmin activity. The trimolecular complex is bound to the cell
surface via the interaction between fibrinogen-binding receptors (FgR) such as M1
protein and fibrinogen. Fibrinogen can also initially bind to FgR and recruit SK-Plg
complexed to the cell surface to form the tri-molecular complex C) Cluster type-1 SK
will combine with Plg to form a complex with plasmin activity. This complex can be
bound directly to the bacterial cell surface via Plg receptors (PLRs) or through an
interaction with fibrinogen and fibrinogen receptors. Figure from McArthur et al., 2008.
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as Ml (Figure 1.8). Alternatively, strains that express cluster 1 type SK can bind the
activator complex directly to the bacterial cell surface via Plg receptors (PLRs) or
through an interaction with fibrinogen and FgR (Figure 1.8) (McArthur et al., 2008).

Interestingly, a sub-cluster of highly related ska alleles is found in strong linkage
disequilibrium with the pam gene, which clusters amongst the skin-tropic emm pattern
D isolates (Kalia and Bessen, 2004, Svensson et al., 1999). PAM and SK cooperate in
GAS plasmin acquisition in vitro, and both genes are required for full virulence in an in
vivo model of impetigo (Ringdahl et al., 1998, Svensson et al., 2002). Together, these
data support an involvement of ska allelic subtypes in tissue tropism at the skin (Kalia
and Bessen, 2004). Further analyses of the cluster groups have determined that cluster-1
ska alleles are identifiable from all three different disease related emm pattern groups
(pattern A-C, pattern D and pattern E). Interestingly all type-1 SK D pattern isolates
lack PAM (Kalia and Bessen, 2004). Isolates containing type-2a SK were determined to
come from emm pattern groups A-C and D. Type-2a SK isolates also lack PAM (Kalia
and Bessen, 2004). Variants from sub-cluster type-2b harbour D emm patterns, and are
PAM positive. These results have led to the hypothesis that type-2b ska alleles and pam
have been co-inherited and that PAM may play a vital role in harnessing plasmin
activity to the bacterial cell surface and disease manifestation GAS isolates containing a
cluster type-2b SK allele (Kalia and Bessen, 2004). Further research investigating the
biological significance of ska gene polymorphisms is required.
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1.8 Streptokinase as a Thrombolytic Therapeutic
1.8.1 Overview
Occlusion of blood vessels by thrombus (blood clot) is an essential function of
haemostasis. Under healthy conditions thrombus formation is suppressed, but reacts
extensively in the event of vascular injury to prevent blood loss. Thrombus formation is
limited to the site of vessel injury and is regulated to prevent clot dissemination through
normal healthy vessels. In the event of pathological conditions and/or failure to
maintain haemostasis, several cardiovascular disease states can arise and are divided
into three main categories: atherosclerotic heart disease (acute myocardial infarction),
cerebrovascular disease (stroke) and venous thromboembolism (deep-vein thrombosis
and pulmonary embolism) (Collen et al., 1988, Collen, 1990, Francis and Marder,
1991). Cardiovascular disease has increased significantly over the past few years and is
a major cause of disability and is the most common cause of mortality, accounting for
approximately 50% of deaths in individuals over the age of 50 (Lloyd-Jones et al.,
2009, Collen et al., 1988).

Pathological thrombosis formation is currently treated using thrombolytic therapy to
dissolve clots, resulting in reperfusion of the occluded blood vessels and improved
outcomes from resulting disease states (Collen et al., 1988). Thrombolytic therapy
involves intravenous infusion of Plg activators and has been in practice for almost 50
years (Fletcher et al., 1958, El-Gengaihy et al., 2007). The relatively recent realisation
that early administration (under 3 h) of thrombolytics can distinctly reduce mortality
rates, along with the rise of recombinant DNA technology has rekindled interest in
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thrombolytic therapy as a preventative measure against the burden of cardiovascular
disease (Banerjee et al., 2004). Consequently, tPA and SK became established as a
lifesaving treatment against acute myocardial infarction and were approved by the US
Food and Drug Administration (FDA) in the mid-1980s (Collen et al., 1988, ElGengaihy et al., 2007).

1.8.2 Comparison of Plg Activators Used in Thrombolytic Therapy
There is currently several existing thrombolytic therapeutics that are approved for use in
clinical settings. However, each agent differs in efficacy of thrombolysis, fibrin
specificity, half-life, activation potential, immunogenicity and associated bleeding
complications; as such, preference has not been assigned to one kind. The relatively
non-fibrin-specific agents include SK, anistreplase (anisoylated Plg SK activator
complex, APSAC), and uPA. The newer (or second-generation) Plg activators include
tPA (alteplase), staphylokinase and several variants of tissue-type Plg activator:
reteplase (r-PA), tenecteplase (TNK-tPA), and lanoteplase (n-PA). However, the
limitations of current Plg activators used as therapeutics continue to drive research for
improved agents.

SK is the least expensive fibrinolytic agent and is the most widely used thrombolytic
therapeutic, particularly in developing countries. Studies comparing thrombolytic agents
have shown that SK to be as good as that of tPA in terms of both efficacy and safety
(Boland et al., 2003, Dundar et al., 2003). However, the use of SK as a therapeutic has
been limited by immunogenicity, short half-life and lack of fibrin specificity. These
drawbacks have seen a decline in the use of SK in most developed nations (Sikri and
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Bardia, 2007). Short half-life and higher incidence of clinically significant
haemorrhagic complications associated with other Plg activator use has also driven the
continuation of therapeutic SK use over other thrombolytics. SK is the least expensive,
but most immunogenic Plg activator and is not fibrin specific. Fibrin bound plasmin
generated by the SK-Plg complex causes direct fibrinolysis of thrombus, however, the
explosive generation of unbound plasmin away from the site of thrombus leads to
systemic fibrinolysis and a hypocoagulable state, which in turn, can lead to non-specific
bleeding events. This is due to depletion of circulating fibrinogen, Plg and factors V and
VIII and an increase in bradykinin production (which lowers blood pressure) (Blann et
al., 2002, Khan and Gowda, 2003, Ohman et al., 2001). SK is eliminated from the body
via the liver and can be inactivated in part by anti-streptococcal antibodies resulting
from previous streptococcal infection or SK therapy (Bruserud et al., 1992). Plasmin
produced by SK-mediated activation of Plg also degrades SK. Consequently, SK has
two half-lives: rapid (11-13 mins) due to circulating antibodies and slow (23-29 mins)
due to loss of activity by plasmin degradation (Fedan, 2004, Wu et al., 1998).

Both uPA and tPA are trypsin like serine proteases which activate Plg directly and are
non-immunogenic (Table 1.4). uPA activates both circulating and fibrin bound Plg, but
does not bind to fibrin itself. uPA has a half-life of 15-20 min which results in less
systemic fibrinolysis when compared to SK (Fedan, 2004). In developed countries, tPA
is the most common fibrinolytic agent used for treatment of coronary artery thrombosis,
pulmnary embolism and acute stroke (El-Gengaihy et al., 2007). tPA is a fibrin specific
Plg activator which means plasmin production is confined to the area of thrombus.
Circulating tPA is rapidly cleared from plasma (initial half-life of 4-10 min) resulting in
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high rates of re-thrombosis (Khan and Gowda, 2003). As a result, for greatest efficacy
tPA administration is via an initial bolus injection, followed by short continuous
infusion (Khan and Gowda, 2003). Such large doses can produce systemic fibrinolysis
and unwanted bleeding episodes, side effects similar to those seen with SK treatment.
Therefore, much research has been aimed at improving the efficacy of current Plg
activators or identifying novel activators with more favourable Plg activation
characteristics, some of which have been summarised in Table 1.4.

1.8.3 Enhancing Streptokinase for use as a Therapeutic
SK is an immunogenic protein and as humans are frequently exposed to streptococcal
infections, the presence of circulating anti-SK antibodies can be detected in most
individuals (Tillett et al., 1934). Upon exposure to purified SK protein during
thrombolytic therapy, high titres of anti-SK antibodies are generated and can be long
lasting (up to 54 months) (Lee et al., 1993). High levels of circulating anti-SK
antibodies reduce the effectiveness of repeat SK therapy by rapidly neutralising SK
upon administration or by causing numerous allergic complications (Jalihal and Morris,
1990, Mcgrath and Patterson, 1984) A number of antigenic regions have been identified
within the SK protein by using murine monoclonal antibodies or patient sera (ParhamiSeren et al., 2003, Reed et al., 1993, Torrens et al., 1999, Coffey et al., 2001). Targeting
these regions with deletion or site directed mutagenesis has been proposed as possible
mechanisms by which the immunogenicity of SK can be reduced. An obvious
requirement with this approach is to retain the Plg activating properties of native SK.
Parhami-Seren et al. (2003) used naturally occurring variants of SK from different
strains of group G and group A streptococcus to determine how amino acid sequence
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Table 1.4: Comparison of thrombolytic agents that currently approved or being developed for human use.

Streptokinase*
Molecular Weight (kDa)

Source

Antistreplase
(APSAC)*

uPA*

Pro-uPA

rtPA

TNK-PA

(Alteplase)*

(Reteplase)*

(Tenecteplase)*

nPA

Staphylokinase

47

131

32/55

49

68

39.5

65

53.5

16.5

Streptococcus

Streptococcus

Recombinant,

Recombinant,

Recombinant,

Recombinant,

Recombinant

Recombinant

Staphyloccocus

equisimilis

equisimilis,

human fetal,

E. coli or,

human

human

plus mutation

plus

aureus

plasminogen

kidney

mammalian

melanoma

mutant tPA

cells

cell line

anisoylated
Plasminogen Activation

tPA

mutation

Indirect

Indirect

Direct

Direct

Direct

Direct

Direct

Direct

Indirect

Half-life (min)

20

100

<5

9

5

14

25

57

6

Fibrin Specificity

No

No

No

Yes

Yes

Yes

Yes

Yes

Yes

PAI-1 Resistance

N/A

N/A

No

No

No

No

Yes

No

N/A

Hepatic

Hepatic

Renal

Hepatic

Hepatic

Renal

Renal

Hepatic

Hepatic

Yes

Yes

No

No

No

No

No

No

Yes

Bolus, 1 hr

Bolus, 90

infusion

min infusion

Double bolus

Single bolus

Single bolus

>$2,000

$2,200

$2,200

$2,200

$2,200

Elimination
Antigenic
Dosing (AMI treatment)
Hospital Cost/Dose ($US)

1 h infusion
$300

10 min single
bolus
$1,800

1 h infusion
$2,000

Double bolus
over 30 min

Abbreviations: kDa = KiloDalton, PAI-1 = Plasminogen Activator Inhibitor-1, uPA = urokinase, tPA = tissue type plasminogen activator, N/A = Data Not Available,
AMI = acute myocardial infarction, * = FDA approved. (Ross, 1999, Banerjee et al., 2004, Baruah et al., 2006, Fedan, 2004, El-Gengaihy et al., 2007, Ohman et al.,
2001, Khan and Gowda, 2003)
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variation in previously identified antigenic epitope regions affected antibody binding
and SK function.

In this study, variant SK proteins which contained a Ser138Lys substitution were not
recognised by an anti-SK monoclonal antibody but displayed normal Plg activation
activity. When this amino acid change was introduced into therapeutic SK, the mutant
protein displayed unchanged Plg activation activity but was not bound by the anti-SK
mAb (Parhami-Seren et al., 2003). SK variation in GAS has evolved through the
interaction of this pathogen with the human fibrinolytic and immune systems.
Therefore, careful analysis of novel variants in future studies will assist in identifying
regions that can be mutated for immunogenic purposes without disrupting Plg activation
function.

Attempts to increase the in vivo half-life of SK have utilised chemical modifications and
site directed mutagenesis. Plasmin will initially cleave SK at Lys59 and Lys386 producing
a 37 kDa intermediate which retains only 16% of the Plg activation activity of native
SK (Shi et al., 1994). A Lys59Glu SK mutant maintained Plg activation activity that was
comparable to native SK but displayed increased resistance to plasmin proteolysis
indicating that this variant may have a longer functional half-life in therapeutic
applications (Wu et al., 1998). Similarly, PEGylated SK proteins also maintain good
activator function but are protected from proteolytic degradation and display decreased
antigenicity due to increased steric interference (Koide et al., 1982, Rajagopalan et al.,
1985). Currently, the only modified SK approved for human use is acylated Plg-SK
activator complex (APSAC) (Khan and Gowda, 2003). This therapeutic consists of an

41

Chapter 1

Literature Review

inactive complex of SK and Lys-Plg containing an acylated catalytic centre. Upon
injection, APSAC undergoes a controlled deacylation before displaying thrombolytic
activity which serves to increase the half-life of this therapeutic (Crabbe et al., 1990).
This allows APSAC to be administered as a rapid, bolus injection which is more
favourable when compared with the long infusions required with native SK. However,
the higher costs associated with this therapy has limited the use of APSAC in clinical
settings (Khan and Gowda, 2003) (Table 1.4)

Modifying the Plg activation characteristics of SK has also been attempted to improve
the therapeutic potential of this molecule. Fibrin-independent Plg activation by the SKPlg activator complex is thought to be due to the insensitivity of the activator complex
to α2-AP inhibition and due to the ability of the activator complex to activate circulating
Glu-Plg in the absence of fibrin (Sazonova et al., 2009). Critical for these characteristics
is the a-domain of SK. SK mutants harbouring an N-terminal, 59 amino acid deletion
(SKΔ59) of the α-domain will only form an activator complex with plasmin which is
susceptible to α2-AP inhibition and is a poor activator of circulating Glu-Plg (Reed et
al., 1999, Sazonova et al., 2004). However, the SKΔ59-plasmin complex will readily
activate unfolded forms of Plg such as Glu-Plg in the presence of fibrin (Reed et al.,
1999).When compared to tPA, this mutated form of SK displays less fibrinogen
degradation in human plasma and\has a greater capacity to degrade blood clots in vivo
using a murine model of human thrombosis (Sazonova et al., 2009).

SK from GAS are polymorphic and these variants posses differing Plg activation
characteristics. These differences are a result of divergence of GAS SK away from
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group C SK during a long co-evolution with the human host. This divergence could
naturally confer some of the characteristics that have been introduced previously into
the group C SK alleles via recombinant DNA technologies. Sequence modifications
have been the focus of attempts at increasing half-life, reducing or eliminating
immunogenicity and generally improving the activation potential of SK. However, the
genetic diversity displayed by ska alleles from GAS isolates represent an existing
reservoir of SK proteins that have become attuned to evading the host immune system
and interacting with the human fibrinolytic system.

1.9 Summary and Aims of the Current Research
The increasing incidence of invasive GAS infection over the past two decades has
re-ignited interest in the study of the invasive pathogenesis of the bacterium,
Streptococcus pyogenes. The subversion of the host Plg activation system by GAS
facilitates the capture of cell-surface proteolytic activity which is used by the bacterium
for invasion into normally sterile areas of the host. SK has been identified as one of the
key factors in PAS subversion. Allelic variants of SK produced by GAS isolates display
unique Plg activation properties, however the biological significance of SK
polymorphism among GAS isolates is yet to be elucidated. Therefore, the underlying
hypothesis of this project is that phenotypic differences resulting from ska
polymorphism have an effect on the pathogenesis of this organism. In this project, we
propose to undertake part of the first comprehensive phenotypic study of SK variants
produced by GAS by characterising the structural, functional and biochemical
differences displayed by SK variants. Investigating the role of SK polymorphism and
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effect on GAS virulence will further our understanding of PAS specific pathogenic
mechanisms employed by GAS and will assist in the rational design of recombinant SK
molecules that can be used as second generation thrombolytic therapeutics with
improved efficacy and safety, as well as potentially assisting in the development of
novel strategies to treat invasive disease caused by S. pyogenes..

Specific aims
(i)

Develop a system to express and purify recombinant forms of SK variants
from GAS.

(ii)

Undertake structural, functional and biochemical characterisation of
recombinant SK variants

(iii)

Investigate the effect of host and bacterial plasminogen co-factors on SK
mediated activation of Plg

(iv)

Assess the effect of phenotypic differences displayed by SK on GAS
pathogenesis.
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Preface
Current SK expression protocols have been developed to produce large quantities of
SK for therapeutic purposes, however many of these protocols produce SK protein of
poor quality or low yield of full length active SK. Thus, to examine the subtle
structural and functional differences displayed by GAS SK variants, a recombinant
expression system that results in the production of pure, full-length active protein was
crucial. The work in this chapter highlights the development of a SK expression
system which produced high quality protein that could be used in numerous
downstream characterisation processes to elucidate the molecular basis for the
phenotypic differences displayed by GAS SK variants.

Publication: Cook, S. M., Walker, M. J. and McArthur, J. D., (2014) “Cloning and
expression of streptokinase variants from Streptococcus pyogenes to assist in the
characterisation of streptokinase mediated plasminogen activation.” (Manuscript
prepared).
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2.1 Abstract
Streptokinase (SK) is a bacterial plasminogen activator, secreted by β-hemolytic group
A, C and G strains of the genus Streptococcus. Among group A streptococcal (GAS)
isolates, SK gene sequences (ska) are polymorphic and can be grouped into two distinct
sequence clusters (termed cluster type-1 and cluster type-2) with cluster type-2 being
further divided into sub-clusters type-2a and type-2b. In this study, SK from 5 different
GAS isolates, which represented examples from the three known phylogenetic sequence
clusters of SK were purified. SK from the group C streptococcal strain H46A was also
expressed for use as a control, as it is the most widely studied SK variant due to its use
as a thrombolytic therapeutic. Polymerase chain reaction with ska variant specific 5’
and 3’ primers was used on template Streptococcus spp. genomic DNA. This resulted in
the amplification of DNA fragments of ~1250 bp, which correlated to the expected size
of ska (without the region encoding the 26-amino acid signal peptide) with restriction
enzyme (5’ and 3’ ends) and Factor Xa protease recognition sequences (5’ end)
incorporated. These fragments were cloned into pQE-30 for expression as N-terminal
poly-histidine fusion proteins which could be purified via nickel affinity
chromatography. SK fusion proteins had an estimated molecular mass of ~49 kDa
which correlates to the theoretical molecular weight (49028 Da) and were regularly
purified at yields between 25 and 35 mg.L-1 of culture. The poly-histidine tag was
removed from purified SK proteins using Factor Xa digestion which also produced an
unwanted cleavage event at Arg401-Tyr402 in the C-terminus of the protein. Anion
exchange chromatography was used to separate full length SK from the truncated
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protein fragments and from Factor Xa. Recombinant SK proteins were subsequently
used in further structural and biochemical analyses as detailed in chapters 3, 4 and 5.
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2.2 Introduction

Streptokinase (SK) is a potent plasminogen (Plg) activator of bacterial origin, secreted
by β-haemolytic Streptococcal A, C and G isolates. SK consists of 414 amino acid and
is composed of three distinct domains; α (aa 1-150), β (aa 151-287) and γ (aa 288-414)
(Wang et al., 1998). The three domains of SK are separated by two coiled-coil regions
while the N- and C- termini of the protein have disordered flexible structures (Wang et
al., 1998). Despite extensive research, the exact role each domain plays in the activation
of human Glu-Plg is not completely understood, nor is the molecular mechanism of SK
mediated Plg activation (Boxrud and Bock, 2004).

SK from the group C streptococcal isolate H46A is the most frequently characterised
SK variant (Christensen, 1945). To date, the majority of expression, purification,
structural and functional characterisation studies have been conducted on group C SK
due to its extensive use as a thrombolytic therapeutic (McArthur et al., 2012). Group A
streptococcus (GAS; Streptococcus pyogenes) secrete SK as a virulence determinant to
generate soluble protease activity and to assist in the acquisition of plasmin activity to
the bacterial cell surface, allowing invasion into normally sterile tissue of the host
(McArthur et al., 2012). While SK from group C streptococcal isolates display minimal
genetic diversity, SK from human specific GAS isolates display considerable genetic
variability (Kalia and Bessen, 2004, McArthur et al., 2008, Kapur et al., 1995, Zhang et
al., 2012, Cook et al., 2012). Phylogenetic studies of the most divergent ska sequences
have revealed two main sequence clusters (cluster type-1 and 2) with evidence of
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smaller sub-clusters observed in cluster type-2 sequences (cluster type-2a and 2b) (Kalia
and Bessen, 2004, McArthur et al., 2008). To examine the specific phenotypic
differences displayed by SK variants, a recombinant expression system that results in
the retrieval of pure, full-length active protein is crucial. Current SK expression
protocols are designed to produce large amounts of SK for therapeutic purposes,
however many of these protocols produce SK protein of poor quality (Longstaff et al.,
2005). Common contaminants present in recombinant SK preparations include proteins
containing unwanted N-terminal methionine residues or proteins containing C-terminal
truncations. Both modifications are known to reduce the ability of SK to activate GluPlg (Wang et al., 1999a, Zhai et al., 2002). In this study, we developed a protocol to
produce full-length recombinant SK protein (1-414 amino acids), possessing a
functional Ile1 residue, which is separated from C-terminal truncation products and
other contaminating protein. This technique was used to produce phylogenetically
distinct recombinant SK proteins to assess the phenotypic differences displayed by these
variants (Cook et al., 2012, Russell and Facklam, 1975).

The ska alleles used in this study were amplified from genomic DNA from five different
GAS isolates of both Australian and International origins that represented type-1, type2a and type-2b ska (highlighted in Figure 1.7). These clinical strains were isolated from
patients suffering from a range of disease states encompassing invasive, superficial skin
and throat infections as well as a patient presenting with a case of GAS induced nonsuppurative sequelae. Type-1 SK came from strain NZ131 which was isolated from a
case of acute post streptococcal glomerulonephritis; type-2a SK representatives came
from strains 5448 and NS696 which were isolated from patients with invasive
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(necrotising fasciitis) and uncomplicated (throat) infections, respectively; and type-2b
SK representatives came from strains ALAB49 and NS88.2 which were isolated from
an impetigo lesion and from the blood blood of infected patients respectively (Simon
and Ferretti, 1991, Svensson et al., 2000, McKay et al., 2004, Aziz et al., 2004). SK
from human associated isolate of group C streptococcus (H46A) was also expressed for
use as a control (Christensen, 1945).

The cloning, expression and purification system developed in this chapter produced
high quality recombinant SK proteins that were used in subsequent experiments
elucidating the molecular basis for the phenotypic differences displayed by these
variants.
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2.3 Materials and Methods

2.3.1 Bacterial strain, culture conditions and reagents
GAS isolates NZ131 (Simon and Ferretti, 1991), ALAB49 (Svensson et al., 2000),
NS88.2 (McKay et al., 2004), NS696 (McKay et al., 2004), 5448 (Aziz et al., 2004) and
S. dysgalactiae subsp. equisimilis strain H46A (Christensen, 1945) were used in this
study. Streptococci strains were routinely cultured at 37°C on horse-blood agar
(Biomerieux, Sydney, NSW, Australia) or in static liquid cultures of Todd-Hewitt broth
(BD, Sydney, NSW, Australia) supplemented with 1% (w/v) yeast extract (Oxoid,
Adelaide, SA, Australia) (THY medium). E. coli strains JM109 and M15[pREP4], were
used as hosts for plasmid construction and protein expression respectively, and were
cultured at 37°C in Luria-Bertani broth (Sambrook et al., 1989). Where appropriate,
antibiotics were used for selection at the following concentrations: chloramphenicol,
100 μg.mL-1; kanamycin, 50 μg.mL-1; and ampicillin, 100 μg.mL-1. Factor Xa was
purchased from Sigma-Aldrich, Sydney, NSW, Australia.

2.3.2 DNA cloning strategy for ska variants
Genomic DNA from each GAS strain was extracted using a Wizard® Genomic DNA
Purification Kit as per manufactures instructions (Promega, Madison, WI, USA). The
SK encoding gene (ska) from each GAS strain without the 26-amino acid signal peptide,
was amplified from genomic DNA by polymerase chain reaction (PCR). PCR primers
were designed to incorporate BamHI and PstI restriction sites at the 5’ and 3’ ends of
the fragment respectively. This allowed cloning into pQE-30 (Qiagen, Valencia, CA,
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USA) for expression of recombinant SK as a poly-histidine tagged fusion protein. A
Factor Xa recognition site was incorporated at the 5’ end of sense primers to facilitate
removal of the poly-histidine tag after purification and expose the functional Ile1 Nterminal residue of SK. The primers used for amplification ska are as follows, a solid
underline indicates a BamHI recogntion sequence, double underline indicates a PstI
recognition sequence and a dashed underline indicates the sequence coding for the
Factor Xa recognition sequence: Type-1, type-2a and type-2b ska sense (5’GTGGATCCATCGAGGGAAGGATTGCTGGGTATGAATGGCTG-3’). H46A ska
sense
Type-1,

(5’-GTGGATCCATCGAGGGAAGGATTGCTGGACCTGAGTGGCTG-3’).
type-2a

and

type-2b

(NS88.2)

ska

antisense

(5’-TGCTGCAG

TTATTTGTCTTTAGGGTTATC-3’). H46A and type-2b (ALAB49) ska antisense (5’TGCTGCAGTTATTTGTCGTTAGGGTTATC-3’) (Sigma-Aldrich, Sydney, NSW,
Australia). Each PCR mix contained 0.25 μL of PfuUltra II DNA polymerase (Agilent
Technoligies, Santa Clara, CA, USA), in 1X Pfu reaction buffer, 1 μL of a 1:40 dilution
of GAS cDNA as template, forward and reverser primers (1 μM) (Sigma-Aldrich,
Sydney, NSW, Australia), 200 μM dNTPs (Bioline, NSW, Australia) and dH2O to a
total reaction volume of 20 μL. PCR were performed in a Thermocycler (Eppendorf,
Hamburg, Germany) using 1 cycle of 95°C for 1 min, 35 cycles of 95°C for 20 s, 55°C
for 30 s and 72°C for 1 min, followed by a final extension period of 10 min at 72°C.
Once completed reactions were assessed for DNA amplification by agarose gel
electrophoresis, before restriction digestion and ligation into linearised pQE-30 vector.
Each ligation mixture was electo-transformed into E. coli JM109 and positive clones
screened by either colony PCR using the same PCR parameters as above with Taq
polymerase (Bioline, Sydney, NSW, Australia) and/or crude alkaline lysis. Positive
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clones were confirmed by repeat restriction digestion to release the ska gene (~1200 bp)
from the linearised vector (~3400 bp). Upon completion of restriction digestion analysis
suspected positive clones were confirmed by DNA sequence analysis.

2.3.3 Restriction enzyme digestion
Restriction enzyme digestion of DNA was performed using BamH1 and PstI
(Fermentas, Pittsburgh, PA, USA). To prepare pQE-30 and full length ska for cloning,
purified plasmid or insert ska DNA (~1 μg) was double digested with 20 U of PstI
(Fermentas, USA) and 10 U of BamH1 (Fermentas, Pittsburgh, PA, USA) in a 20 μL
reaction volume containing 1X BamH1 buffer (Fermentas, Pittsburgh, PA, USA).
Digestions were incubated at 37ºC for 2 h and restriction enzymes were heat deactivated
by incubation at 80°C for 20 min. Agarose gel electrophoresis (see section 2.3.5) was
used to visualise and separate the digested DNA fragments, which were subsequently
extracted from the gel via Wizard® SV Gel and PCR Clean-up System (Promega,
Madison, WI, USA) according to manufacturer specifications.

2.3.4 Ligation of recombinant plasmids
Ligations were performed using T4 ligase (Fermentas, Pittsburgh, PA, USA). Each
ligation contained ~100 ng of digested plasmid DNA, ~500 ng of insert DNA and 20 U
of T4 ligase (Fermentas, Pittsburgh, PA, USA) in a final reaction volume of 30 μL
containing 1X T4 ligase buffer (Fermentas, Pittsburgh, PA, USA). Ligations were
incubated at 15°C over-night, followed by T4 ligase inactivation by incubation at 65°C
for 15 min. Ligations were purified for transformation via Wizard® SV Gel and PCR
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Clean-up System (Promega, Madison, WI, USA) according to manufacturer
specifications.

2.3.5 Agarose gel electrophoresis
Agarose gel electrophoresis was performed with a 0.85% agarose gels in 1X TAE
buffer. Electrophoresis was conducted at 90 V for 1 h in a MiniSub Cell GT
electrophoresis tank (BioRad, Hercules, CA, USA). DNA was visualised using a
Novaline Gel Documentation System (Novex, St Lucia, QLD, Australia) under
ultraviolet light (UVP, Upland, CA, USA) after staining in ethidium bromide solution
(1 μg.mL-1) for 20 min and de-staining in dH20 for 10 min. Approximate DNA fragment
size and concentration was determined by comparison to the migration of GeneRuler™
1kb DNA Ladder (Fermentas, Pittsburgh, PA, USA) (Appendix 8).

2.3.6 Preparation of electro-competent E. coli JM109 and M15/pREP4
To prepare electro-competent E. coli JM109 and M15/pREP4 for transformation with
recombinant plasmid DNA, a single colony of each bacterial strain was grown in 3 mL
of LB broth overnight at 37°C with shaking. The culture was used to inoculate 400 mL
of LB broth and grown at 37°C with shaking to an optical density (OD600) of 0.6. The
culture was chilled on ice for 20 min before centrifugation at 4,000 x g for 15 min at
4°C to harvest the cells. The cells were re-suspended in 400 mL of cold MilliQ water
(Millipore, Sydney, NSW, Australia) and re-centrifuged. The pellet was washed by resuspension in 200 mL of cold MilliQ water (Millipore, Sydney, NSW, Australia) and
centrifuged again. Cells were re-suspended in 4 mL of chilled 10% glycerol and
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centrifuged under the same conditions, before final re-suspension in 600 μL of chilled
10% glycerol. Cells were distributed into 40 μL aliquots for storage at -80°C.

2.3.7 Electro-transformation of electro-competent E. coli JM109 and M15/pREP4
Transformation of E. coli JM109 or M15/pREP4 was performed by adding 1 μL (~200
ng) of plasmid DNA to a 40 μL aliquot of electro-competent cells. The transformation
mixture was transferred to a cold 1 mL, 2 mm gap, electro-transformation cuvette
(Eppendorf, Hamburg, Germany) and transformed using MircoPulser™ (Bio-Rad,
Hercules, CA, USA) using settings defined by the manufacturer for bacterial
electroporation (2.5 μF capacitance, 2.5 kV single pulse, 20 Ω in series, 200 Ω in
parallel). Following transformation, 500 μL of LB broth was added to the
transformation mixture which was then transferred to a 1.5 mL microcentrifuge tube for
incubation at 37°C for 1 h. To select for successfully transformed bacteria, dilution
series of the transformation culture were plated onto LB agar containing appropriate
antibiotics and incubated over-night at 37°C.

2.3.8 DNA sequence analysis of pQE-30::ska variant constructs
DNA sequencing to confirm the construction of hybrid ska alleles was conducted using
the Big Dye Terminator v3.1 Cycle Sequencing Kit (Perkin-Elmer, USA). Each
sequencing reaction contained 0.5 μL of Big Dye Terminator Ready Reaction Mix (RR100) (Perkin-Elmer, USA), in 1X Sequencing Buffer, ~500 ng (5 μL) of template DNA,
3.2 pmol sequencing primer (2 μL) (Table 2.1) and 0.5 μL of dH20 to a total reaction
volume of 10 μL. Sequencing reactions were performed using a Thermocycler
(Eppendorf, Hamburg, Germany) over 25 cycles of 96°C for 10 sec, 50°C for 5 sec and
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60°C for 4 min followed by a final extension period of 10 min at 60°C. Following
sequencing PCR reactions, DNA was purified via ethanol precipitation by adding 3 μL
of 2 M sodium acetate (pH 4.5) and 35 μL of cold 95% (v/v) ethanol to the reaction
mix. The solution was incubated on ice for 10 min and centrifuged at 14,000 x g for 20
min to precipitate the DNA. The supernatant was removed and the DNA pellet resuspended in 250 μL of cold 70% (v/v) ethanol. The re-suspended pellet was
centrifuged at 14,000 x g for 20 min and the supernatant removed. The pellet was
allowed to air dry away from light and stored at -20°C until sequencing analysis was
performed. DNA sequencing was performed by Margret Phillips (Biological Sciences,
University of Wollongong, Australia) using a 3130xl Genetic Analyzer (Applied
Biosystems, USA), as per the manufacturer’s instructions.

Table 2.1: Oligonucleotides used for DNA sequencing of chimeric ska alleles.
A forward and reverse sequence was produced for each gene to make consensus
sequences and confirm domain switching. For sequencing of the mature SK encoding
region a combination of primers listed in this table were used depending on ska variant
type
Primer
pQEF
pQER
skaseqFOR
skaseqREV1
skaseqREV2

Primer Sequence (5’- 3’)
CGGATAACAATTTCACACAG
GTTCTGAGGTCATTACTGG
GATCCCTTTGATCGCAGTCAC
TATGAAGTGAGCTTTGTCTCC
ATATACTGTACAGTTTACTCC
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2.3.9 Expression and purification of recombinant SK protein
Recombinant SK protein expression in transformed M15[pREP4] was induced by
addition of isopropyl-1-thio-b-D-galactopyranoside to log-phase cells at a final
concentration of 1 mM. Three hours later, cells were harvested by centrifugation,
resuspended in native lysis buffer (1 mg.mL-1 Lysozyme, 0.1 mM PMSF, 10 mM
MgCl2, 5 μg.mL-1 DNase I, 0.1% (v/v) Triton X-100, 10 mM Imidazole, 50 mM
NaH2P04, 300 mM NaCl, pH 7.4), lysed using an EmulsiFlex-C5 (Avestin Inc., Ottawa,
ON, Canada) and purified under native conditions using nickel-nitriloacetic acid affinity
chromatography. Purification of protein from cleared lysate was performed using an
ÄKTAprime plus fast protein liquid chromatography (FPLC) system (GE Healthcare
Life Sciences, Piscataway,NJ, USA) with two 1 mL HisTrap HP columns in series (QE
Scientific, USA). The resin was equilibrated with 10 column volumes of binding buffer
(50 mM NaH2P04, 300 mM NaCl, 10 mM Imidazole, pH 8) and once equilibrated, 50
mL of 0.22 μm syringe filtered lysate was loaded onto the column. The column was
washed with binding buffer until the A280 trace returned to a constant pre-sample
injection baseline. The column was then washed with 10 column volumes of washing
buffer (50 mM NaH2P04, 300 mM NaCl, 20 mM Imidazole, pH 8) to remove nonspecifically bound contaminants. Column bound recombinant SK was eluted from the
column by flowing 20 column volumes of elution buffer (50 mM NaH2P04, 300 mM
NaCl, 250 mM Imidazole, pH 8) over the column resin and collected in 1mL elution
fractions. The native recombinant SK proteins were cleaved from the poly-histidine tag
by buffer exchange into QB cleavage buffer (50 mM Tris-HCl, 50 mM NaCl, 1 mM
CaCl2, pH 6.5) and incubation with 2U.mg-1 SK of Factor Xa (Sigma-Aldrich, Sydney,
NSW, Australia) for 12-36 h at 4°C (Figure 2.1). Post Factor Xa treatment a secondary
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truncation product was observed for all SK preparations during sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) analysis.

Figure 2.1: Exposure of the functional Ile1 residue by limited proteolysis with
Factor Xa. A schematic outlining the process by which recombinant poly-histidine
tagged SK variants were cleaved with Factor Xa to expose the functional Ile1 residue.
Recombinant SK was incubated with Factor Xa which cleaves at the C-terminal side of
the recognition sequence, as indicated, resulting in the removal of poly-histidine tags
from full-length SK

2.3.10 Electrospray ionisation mass spectrometry (ESI-MS)
A positive ion mass spectrum of expressed and purified SKALAB49 and SKNZ131 was
acquired on a quadrupole time of flight spectrometer (Q-TOF-MS) (Micromass Q-TOF
Ultima, Waters, Elstree, HRT, UK) fitted with a Z-spray ionisation source. SKALAB49
and SKNZ131 were exchanged into 10 mM ammonium acetate buffer (pH 6.8) containing
0.1% formic acid and made up to a final concentration of 10 μM. The protein was then
injected into the Q-TOF Ultima mass spectrometer (20 μL) and the mass spectrum
acquired with a capillary voltage of 2.6 kV, cone voltage of 50 V, source block
temperature of 40°C, and a resolution power of 5000 Hz. Ceasium iodide was used for
external calibration. The mass spectrum data is presented as raw data, on an m/z scale.
Mass was calculated using MassLynx MS software (Waters, Elstree, HRT, UK).
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2.3.11 Anion-exchange fast protein liquid chromatography (FPLC)
To separate full-length recombinant SK from truncation products, a secondary
purification step using anion exchange chromatography was undertaken using a Mono
Q 5/50 GL column attached to an ÄKTA explorer FPLC (GE Healthcare and
Lifesciences, Piscataway, NJ, USA). The resin was pre-equilibrated with 10 column
volumes of exchange buffer A (20 mM Bis-Tris, pH 6.5) and each protein mixture (~5
mg) was subsequently loaded onto the column at a flow rate of 0.5 mL.min-1, after being
dialysed into exchange buffer A to remove salt and impart a net negative charge on each
of the protein species. The bound protein was washed with ~10 column volumes of
exchange buffer A to maintain a constant A280 trace baseline before a NaCl elution
gradient up to 25% of exchange buffer B (20 mM Bis-Tris, 1 M NaCl, pH 6.5) was
applied to the resin over 35 column volumes, at a flow rate of 0.4 mL.min -1. These
conditions resulted in optimal separation resolution between each protein species.
Fractions of each A280 peak were collected in 500 µL aliquots and analysed by SDSPAGE.

2.3.12 Gel electrophoresis and Western blotting
Expression and purification of SK was monitored by SDS-PAGE and Western blotting.
Aliquots of the SK purification procedure were added to SDS-PAGE sample buffer
containing 1% SDS and 5% β-mercaptoethanol at 100°C. Samples were separated using
10% SDS-PAGE before being transferred to PVDF membrane (Millipore, Sydney,
NSW, Australia) via Western transfer. For detection of polyhistine tagged SK PVDF
membranes were blotted using Ni2+-NTA-HRP conjugate (Qiagen, Valencia, CA,
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USA). To directly detect SK a polyclonal rabbit-anti-SK antibody (Jason McArthur,
University of Wollongong, Wollongong, AUS) was used in combination with a
secondary goat-anti-rabbit-HRP antibody conjugate (Pierce Biotechnology, Rockford,
IL, USA). To visualise target proteins, 3,3’-diaminobenzidine at 0.05% (w/v) and
hydrogen peroxide at 15% (v/v) diluted in 100 mM Tris, pH 7.4 was applied to the
membrane.
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2.4 Results
2.4.1 Amplification and cloning of ska alleles
To construct plasmid vectors for the expression of recombinant SK variants, ska was
amplified from streptococcal genomic DNA using the primers described in section
2.3.2. The reaction product was analysed by agarose gel electrophoresis to determine if
amplification was successful (Figure 2.2). A single band at approximately 1250 base
pairs was observed corresponding to the expected size of ska with restriction enzyme
and N-terminal Factor Xa protease recognition sequences incorporated (Appendix 1).
The DNA fragments were purified from the gel, restriction digested with BamHI and
PstI and ligated into pQE-30 with T4 ligase.

Figure 2.2: PCR amplification of ska from group A streptococcal cDNA. ska was
amplified using primers that incorporated a Factor Xa recognition site and BamHI
restriction digestion recognition sequence at the 5’ end and a PstI restriction digestion
recognition sequence at the 3’ end. Full length ska variants appear as a DNA band at
~1250 bp in a 0.85% agarose gel skaH46A (lane 1), skaNZ131 (lane 2), skaNS696 (lane 3),
ska5448 (lane 5), skaALAB49 (lane 6) and skaNS696 (lane 6).
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The ligation reactions were transformed into E. coli JM109 and screened by colony
PCR and/or alkaline lysis (Sambrook et al., 1989) (data not shown). Successful plasmid
constructs for each variant were confirmed by extracting plasmid DNA from E. coli
JM109 transformants and subsequent restriction enzyme analysis with BamHI and PstI.
DNA fragments of ~3400 and ~1250 bp were observed for all constructs, which
corresponds to the predicted sizes of pQE-30 (~3400 bp) and full length ska (~1250 bp)
(Figure 2.3).

Figure 2.3: Restriction digestion of pQE-ska constructs. Composite figure of insert
positive pQE-30 constructs identified via colony PCR or crude alkaline lysis that were
extracted using a Wizard® Plus Mini-prep DNA purification system and digested with
10U of BamH1 and 20U of PstI for 2 hours at 37°C. pQE-30::ska constructs were
deemed positive if a DNA band was released at ~1250 bp from the linearised pQE-30
vector (~3400 bp) on 0.85% agarose gel. Positive constructs were DNA sequenced to
confirm the correct ska sequence was present in the correct coding frame with no errors.
pQE-SKH46A (lane 1), pQE-SKNZ131 (lane 2), pQE-SKNS696 (lane 3), pQE-SK5448 (lane
4), pQE-SKALAB49 (lane 5) and pQE-SKNS696 (lane 6).

2.4.2 Expression and purification of recombinant SK variants
Recombinant SK proteins were expressed as N-terminal, poly-histidine fusion proteins
and were purified via Ni2+-NTA affinity chromatography using an ÄKTAprime plus
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FPLC (GE Healthcare Life Sciences, Piscataway, NJ, USA) (Figure 2.4A). SDS-PAGE
analysis indicated the purified recombinant protein had a molecular mass of ~49 kDa
(Figure 2.4B), which corresponds closely to the theoretical molecular weight of fusion
tagged SK (49028 Da). Additionally, the recombinant protein also reacted with rabbit
polyclonal antisera specific for SK from group C streptococcus (McArthur et al., 2008)
(data not shown). The expression and purification of recombinant SK proteins using this
method regularly achieved yields between 25 and 35 mg.L-1 of culture. The purification
of SKALAB49 is given as a representative, while all other SK variant expression profiles
appear in Appendix 2.

N-terminal poly-histidine tags were removed from SK fusion proteins via proteolytic
cleavage with Factor Xa. This treatment effectively removed all vector encoded
histidine amino acid residues producing a recombinant SK protein possessing an Nterminal Ile1 residue. The Ile1 is present on the secreted wild type form of SK and is
critical for the proper functioning of this protein (Wang et al., 2000). Cleavage of polyhistidine tags from recombinant SK protein was assessed by SDS-PAGE and Western
blot analysis using a Ni2+-NTA-HRP conjugate that specifically binds to poly-histidine
tags. A representative of this process is given for SKALAB49 (Figure 2.5). Digestion of
SKALAB49 with Factor Xa resulted in the production of two truncated protein species
with a molecular mass of 47 kDa and 45.9 kDa respectively (Figure 2.5A; lane 3). This
cleavage pattern is the result of the action of Factor Xa, as SKALAB49 incubated under the
same reaction conditions, but in the absence of Factor Xa, maintained an intact
molecular mass of 49 kDa (Figure 2.5A; lane 2). Western blot analysis using the Ni2+NTA-HRP conjugate indicated that Factor Xa digestion was successful in the removal
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of the poly-histidine tag residues from the recombinant fusion protein (Figure 2.5B; lane
3).

Figure 2.4: Expression and purification of native recombinant poly-histidine
tagged fusion protein SKALAB49 via FPLC Ni2+-NTA affinity chromatography. (A)
Elution profile from ÄKTAprime plus FPLC showing A280 trace (solid line) and
percentage elution buffer (dashed line) for SKALAB49. Point i represents injection of
cleared lysate. Point ii represents injection of binding buffer. Point iii represents
injection of wash buffer and point iv represents injection of elution buffer. (B)
Coomassie stained 10% SDS-PAGE of SKALAB49 purification process. Un-induced E.
coli whole cell lysate (lane 1), 2 h post induction E. coli whole cell lysate (lane 2) native
lysis pellet containing insoluble protein (lane 3), lysate (lane 4) Ni2+-NTA column flow
through (lane 5), wash buffer Ni2+-NTA column flow through (lane 6) and Ni2+-NTA
column elution fractions (lanes 7-12). Figures relating to the expression and purification
of all other SK variants used in this study are given in Appendix 2.1.

65

Chapter 2

Cloning and Expression of Streptokinase Variants

Figure 2.5: Factor Xa cleavage of recombinant poly-histidine tagged SKALAB49
fusion protein (A) Coomassie stained 10% SDS-PAGE of SKALAB49 cleavage.
SKALAB49 T = 0 h (lane 1), SKALAB49 T = 36 h without Factor Xa (lane 2) and SKALAB49
T = 36 h Factor Xa added (lane 3) (B) Western blot of the duplicate samples using Ni2+NTA-HRP conjugate to detect poly-histidine tags. Figures relating to Factor Xa
cleavage of all other SK variants used in this study are given in Appendix 2.2.

2.4.3 Nano-electrospray ionisation mass spectrometry (Nano-ESI-MS)
Nano-ESI-MS was used to determine the composition of SK truncation products in the
sample after treatment with Factor Xa. The representative Nano-ESI-MS spectrum of
SKALAB49 (Figure 2.6) shows a pattern of multiply charged ions in the m/z range of 950–
1170 consistent for the 47 kDa species (Figure 2.6B). The calculated molecular weight
of 47469.75 Da was in agreement with the theoretical average molecular weight of
47465.21 Da (Figure 2.5A). In addition, two further charge states from m/z 1,500 –
1,600 representing a product of 45946.97 Da were detected (Figure 2.5A and B). This
lower molecular weight product was the result of a second proteolytic cleavage
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occurring at Arg401-Tyr402 in the C-terminus of the recombinant SK (theoretical average
molecular weight of 45943.60 Da) (Figure 2.6A).

Figure 2.6: A positive ion Nano-ESI-mass spectrum of purified SKALAB49 in 10 mM
ammonium acetate (pH 6.8) containing 0.1% formic acid after Factor Xa cleavage.
(A) The two SK species observed during MS analysis were calculated to be 47469.75
Da and 45946.97 Da SK. (B) The m/z spectrum shows a pattern of multiply charged
ions in the range of 950–1170 consistent for 47469.75 Da the and two further charge
states from m/z 1,500 – 1,600 representing the 45946.97 Da SK truncation product.
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2.4.4 Anion exchange chromatography
To separate full-length recombinant SK from the C-terminal Arg401 truncation product,
a secondary purification step using anion exchange chromatography was undertaken.
The theoretical pI of full length SK and C-terminal truncated SK were determined to be
5.41 and 5.48, respectively. This allowed a difference in negative charge to be imparted
on the SK species at pH 6.5. Chromatography was conducted using an ÄKTA explorer
FPLC (GE Healthcare Life Sciences, Piscataway, NJ, USA) and monitored by
measuring relative change in A280. The A280 profile for the purification of SKALAB49 is
given as a representative (Figure 2.7). The first peak of ~49 mA280 units on the trace
correlates to the elution of a ~45.9 kDa protein, which is the expected molecular weight
of the SK C-terminal Arg401 truncation product (Figure 2.7A and B, i). Peak ii of the
A280 trace (~86 mA

280

units) was determined to be a protein of ~47 kDa (Figure 2.7A

and B, ii), which correlates to the expected molecular weight of full length SK.
Following this a small ~ 11 mA280 unit co-elution of full length and truncated SK is
exhibited in peak iii of the trace (Figure. 2.7A and B, iii). Fractions corresponding to
peak ii containing full length SK protein free from all other contaminating protein were
pooled for use in subsequent experiments.
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Figure 2.7: Anion-exchange fast protein liquid chromatography of SKALAB49. (A)
Elution profile from an ÄKTA explorer FPLC showing A280 trace (solid line) and
percentage of Buffer B (0 -1 M NaCl) (dashed line). Three peaks were resolved in the
A280 trace correlating to truncated SKALAB49 (peak i), full length 47 kDa SK (peak ii) and
a co-elution of both species (peak iii). (B) Coomassie stained 10% SDS-PAGE of anion
exchange elution peaks. Elution peak I (lanes 1-7) correlated to truncated SKALAB49,
elution peak ii (lanes 8-12) correlated to full length ~47 kDa SK and elution peak iii
(lanes 13-22) appeared to be a co-elution of both species. Each lane corresponds to an
elution volume of 0.5 mL. Figures relating to anion exchange chromatography of all
other SK variants used in this study are given in Appendix 2.3, each SDS-PAGE has
been truncated due to the absence of other protein species.
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2.5 Discussion
In 1984, ska from Streptococcus equisimilis H46A was first cloned and expressed in E.
coli (Malke and Ferretti, 1984). Since then, several methods of recovery and
purification of SK have been described for this therapeutically important protein. These
include purification of SK from the parental wild-type streptococcus strain H46A, as
well as numerous recombinant SK production systems utilising several Gram-negative
and Gram-positive bacterial hosts (Yazdani and Mukherjee, 1998, Zhang et al., 1999,
Estrada et al., 1992, Avilan et al., 1997, Perez et al., 1998, Yazdani and Mukherjee,
2002, Babu et al., 2008, Reed et al., 1995, Gladysheva et al., 2007, Mundada et al.,
2003, Dhar et al., 2002, Chaudhary et al., 1999, Yadav and Sahni, 2010, Wu et al.,
2001, Malke and Ferretti, 1984, Malke et al., 1984).

Mature wild type SK is naturally secreted by streptococcal species. After cleavage of
the signal sequence during secretion, the mature protein contains an N-terminal Ile1
residue that is critical for the proper functioning of this protein as it forms a salt bridge
with Asp740 of Glu-Plg during active site formation (Wang et al., 2000). Therefore, it is
essential that mature 414 amino acid recombinant SK proteins also possess an Nterminal Ile1 residue. To achieve this, recombinant SK (1- 414 amino acid) proteins in
this study were produced as fusion proteins containing an N-terminal poly-histidine tag
followed by a Factor Xa protease recognition sequence for affinity tag removal and Ile1.
One difficulty encountered using this strategy was the generation of an unwanted Cterminal truncation product during Factor Xa digestion of SK-fusion proteins. Analysis
of this truncation product found it to be the result of proteolytic cleavage between
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Arg401 and Tyr402 in the C-terminal region of SK. This highly flexible region is known
to be susceptible to proteolytic activity and similar truncation products have been
observed for recombinant group C SK expression systems (Figure 2.6) (Shi et al., 1994,
Zhai et al., 2002). SK proteins with C-terminal truncations have been shown to display
reduced biological activity, therefore it is important to remove this common truncated
species from protein preparations prior to subsequent experimentation (Zhai et al.,
2002). To remove these contaminating species we employed a secondary purification
system utilising anion exchange chromatography, which was successful in allowing the
retrieval of full length SK of high quality and purity (Figure 2.7 and Figure A2.2.2).

Several groups have attempted to produce large quantities of recombinant SKc using E.
coli as a host (Yazdani and Mukherjee, 1998, Zhang et al., 1999, Estrada et al., 1992,
Avilan et al., 1997, Perez et al., 1998, Yazdani and Mukherjee, 2002, Babu et al.,
2008). In E. coli, the N-terminal methionine residue is removed from many proteins by
endogenous methionine aminopeptidase enzymes (Ben-Bassat et al., 1987). Therefore it
may be possible to produce Ile1-SK in E. coli without the need to remove N-terminal
residues using exogenous proteases such as Factor Xa. However, previous studies
investigating this strategy have found the N-terminal Met residue is removed from
recombinant SK expressed in E. coli with only low efficiency. This may be due to the
large side chain residing on the penultimate Ile residue inhibiting the activity of
methionine aminopeptidase (Walker et al., 2014, Jones et al., 1991). Due to the
importance of the N-terminal Ile1 residue and a non-truncated C-terminus biochemical
and functional data generated in studies that have failed to purify SK proteins that are
free from N-terminal affinity tags, methionine residues and contaminating proteins
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cannot be used in direct comparison with data generated using full length protein (Dhar
et al., 2002, Chaudhary et al., 1999, Yadav and Sahni, 2010, Wu et al., 2001).

Other studies utilising SK expression strategies have employed several combinations of
affinity tags and cleavage proteases to ensure recombinant SK proteins contain the Nterminal Ile1 residue. However, it is not made clear if these expression and purification
systems were hindered by similar unwanted proteolytic events (Reed et al., 1995,
Gladysheva et al., 2007, Mundada et al., 2003, Zhang et al., 2012). Here it was
observed that GAS SK is more susceptible to C-terminal truncation than SKc and the
extent of C-terminal degradation differed between these variants (Figure 2.7, Figure
A2.3). The reason for this phenomenon was not elucidated, but the system we employed
here ensures the retrieval of full length SK at a purity that is suitable for comparative
biochemical analyses and can be applied to all SK variants. Nevertheless, the
observation of variant specific differences in C-terminal degradation suggests GAS SK
variants may exhibit structural differences when not bound to Plg.

Here, we successfully implemented a method to purify full-length recombinant SK in
E. coli. Further biochemical characterisation of these proteins will increase our
understanding of the phenotypic differences displayed by these novel SK variants
from GAS.
.
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Chapter 3:

Streptokinase Variants from
Streptococcus pyogenes Isolates Display
Altered Plasminogen Activation
Characteristics – Implications for
Pathogenesis.
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Preface
The subversion of the human plasminogen activation system by GAS is critical for the
pathogenesis of this organism. The work in this chapter aimed to characterise the
functional differences displayed by allelic variants of SK secreted by S. pyogenes, with
a view to assess the implications of the observed biochemical and functional differences
on pathogenesis. Our findings clearly demonstrate that variation in the molecular
mechanism of SK-mediated Plg activation influences the pathogenesis of S. pyogenes
and may contribute to the varied disease spectrum associated with this pathogen.

Publication: Cook, S. M., A. Skora, C. M. Gillen, M. J. Walker and J. D. McArthur,
(2012) “Streptokinase variants from Streptococcus pyogenes isolates display altered
plasminogen activation characteristics - implications for pathogenesis.” Molecular
Microbiology 86: 1052-1062.
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3.1 Abstract
Streptococcus pyogenes (group A streptococcus, GAS) secretes streptokinase (SK), a
potent Plg activating protein. Among GAS isolates, SK gene sequences (ska) are
polymorphic and can be grouped into two distinct sequence clusters (termed cluster
type-1 and cluster type-2) with cluster type-2 being further divided into sub-clusters
type-2a and type-2b. In this study, far-UV circular dichroism spectroscopy indicated
that purified SK variants of each type displayed similar secondary structure. Type-2b
SK variants could not generate an active site in Glu-Plg through non-proteolytic
mechanisms while all other variants had this capability. Furthermore, when compared to
other SK variants, type-2b variants displayed a 29-35 fold reduction in affinity for GluPlg. All SK variants could activate Glu-Plg when an activator complex was preformed
with plasmin; however type-2b and type-1 complexes were inhibited by α2-antiplasmin.
Exchanging skatype-2a in the M1T1 GAS strain 5448 with skatype-2b caused a reduction in
virulence while exchanging skatype-2a with skatype-1 into 5448 produced an increase in
virulence when using a mouse model of invasive disease. These findings suggest that
SK variants produced by GAS isolates utilise distinct Plg activation pathways which
directly affects the pathogenesis of this organism.
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3.2 Introduction
Group A streptococcus (GAS; Streptococcus pyogenes) is a human specific pathogen
responsible for a diverse range of diseases which have a major impact on global
morbidity and mortality rates (Carapetis et al., 2005). GAS readily colonise skin and
pharyngeal tissue producing mild superficial infections such as pyoderma, impetigo and
pharyngitis. However, GAS may also produce life-threatening systemic (streptococcal
toxic shock syndrome) and invasive infections (necrotising fasciitis). Additionally, postinfection sequelae can occur, which include post streptococcal glomerulonephritis and
acute rheumatic fever (Walker et al., 2014).

To cause this diverse range of diseases, GAS employ a broad range of virulence factors
that facilitate bacterial colonisation, evasion of the immune response and systemic
dissemination (Tart et al., 2007, Musser and Shelburne, 2009, Olsen et al., 2010, Cole
et al., 2011). Virulence factor expression is exquisitely controlled by 13 two-component
regulatory systems and 30 transcriptional regulators allowing GAS to adapt to the
dynamic

physiological

conditions

encountered

during

the

infection

process

(Kreikemeyer et al., 2003, Sumby et al., 2006). Many of the virulence factors produced
by GAS interact specifically with human plasma proteins including fibrinogen,
plasmin(ogen), IgG, α2-macroglobulin, albumin and numerous complement factors
(Cunningham, 2000, Walker et al., 2005). GAS can encounter plasma proteins during
invasive systemic dissemination through the vasculature, but may also be exposed to
plasma constituents at the site of infection through vascular leakage produced during the
inflammatory response induced in the host (Herwald et al., 2004).
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The interaction of GAS with the Plg activation system of the host is a virulence
mechanism critical for the invasive pathogenesis of this organism (Sun et al., 2004, Khil
et al., 2003, Walker et al., 2005, Irigoyen et al., 1999). Plasminogen (Plg), a singlechain glycoprotein zymogen of the serine protease plasmin, is a key component of the
fibrinolytic system and is found in plasma and extracellular fluids. GAS can bind
plasmin(ogen) to the cell surface via numerous cell wall associated proteins such as M
proteins (PAM, Prp), glyceraldehyde-3-phosphate (GAPDH) and streptococcal enolase
(SEN) (Lahteenmaki et al., 2001, Walker et al., 2005, Castellino and Ploplis, 2005).
GAS also secrete a Plg activating protein, designated streptokinase (SK), which
facilitates the production of both soluble and cell-bound plasmin activity. The
generation of plasmin activity at the site of infection may result in the activation of host
matrix metalloproteinases, degradation of extracellular matrix and/or tissue barriers and
degradation of fibrin networks produced by the host to confine the initial infection
(Walker et al., 2005). These processes allow bacteria to spread to other, normally
sterile, sites of the body.

Unlike mammalian Plg activators that activate Plg by limited proteolytic cleavage, SK
binds to Plg inducing conformational changes in the molecule that results in the
formation of an active site and the production of an enzymatically active complex,
termed SK-Plg* (known as the ‘Conformational Activation Pathway’ or ‘Pathway I’).
The conformationally activated SK-Plg* complex can then sequester substrate
molecules of Plg and proteolytically convert those to plasmin (Boxrud et al., 2000,
Boxrud et al., 2004). Plasmin (which has a higher affinity for SK than Plg) rapidly
displaces Plg in the SK-Plg* complex to produce an irreversibly activated SK-plasmin
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complex that is the main catalyst responsible for the full conversion of Plg to plasmin.
(known as ‘Direct Proteolytic Activation Pathway’ or ‘Pathway II’) (Boxrud et al.,
2000, Boxrud et al., 2004). These SK-plasmin activator complexes are also resistant to
inhibition by host plasma inhibitors (α2-antiplasmin (α2-AP) and α2-macroglobulin),
thereby allowing complexes to sequester and activate substrate Plg while bypassing host
protease regulation mechanisms (Parry et al., 2000).

SK is a single chain, 414 amino acid protein, composed of three distinct domains; α (aa
1-150), β (aa 151-287) and γ (aa 288-414) (Wang et al., 1998). The three domains of
SK are separated by two coiled-coil regions while the N- and C- termini of the protein
have disordered flexible structures (Wang et al., 1998). Despite extensive research, the
exact role each domain plays in the activation of human Glu-plasminogen (Glu-Plg) is
still not completely understood. While the majority of structural and functional studies
conducted to date have used the therapeutic form of SK (originally isolated from the
group C streptococcal isolate H46A) (Christensen, 1945), SK proteins from group A
streptococcal isolates display considerable variability and have not been well
characterised (Kalia and Bessen, 2004, McArthur et al., 2008, Kapur et al., 1995).
Phylogenetic studies of the most divergent ska sequences have revealed two main
sequence clusters (cluster type-1 and 2) with evidence of smaller sub-clusters observed
in cluster type-2 sequences (cluster type-2a and 2b) (Kalia and Bessen, 2004, McArthur
et al., 2008). While some phenotypic differences displayed by GAS type-1 and type-2
SK variants have been identified (McArthur et al., 2008), further research is required to
determine if these variants play differing roles in pathogenesis. In this study, we found
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that SK variants produced by GAS isolates display different mechanisms of Plg
activation and that this process directly affects GAS pathogenesis.
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3.3 Materials and Methods
3.3.4 Far-UV circular dichroism (CD) spectroscopy
CD spectroscopy was performed using a J-810 spectropolarimeter (Jasco, Tokyo, Japan)
at room temperature. Samples were prepared in 10 mM phosphate buffer (pH 7.4) to a
final concentration of 100-300 µg mL-1. Spectra representing the average of six scans
were collected from 190 nm to 250 nm at 1 nm intervals, with a path length of 1 mm.
Molar residue ellipticity (Ө) was calculated using the following formula: [Ө] = Ө x 100
x molecular weight (kDa)/concentration (mg mL-1) x path length x number of amino
acids.

3.3.5 Non-proteolytic active site generation in Glu-Plg
Non-proteolytic active site generation in Glu-Plg by SK variants was examined using
the fluorescent active site titrant 4-methylumbelliferyl p-guanidinobenzoate (MUGB)
(Marker Gene Technologies, Inc., Eugene, OR, USA) in a POLARstar Omega
fluorescence spectrophotometer (BMG LABTECH, Ortenberg, HE, GER). Glu-Plg
(Haematologic Technologies, Essex Junction, VT, USA ) (200 nM) was added to a
black 96-well micro-plate containing MUGB (1 µM) in assay buffer (50 mM Tris-HCl,
100 mM NaCl, pH 7.4) at 37 °C. To initiate the reaction, SK was added to a final
concentration of 400 nM in a total volume of 100 µL and the development of
fluorescence was monitored continuously with excitation at 355 nm and emission at 460
nm. Data was normalised by subtracting a control reaction of 200 nM Glu-Plg and 1 µM
MUGB. This accounted for intrinsic fluorescence associated with buffer and protein
species, as well as non-specific hydrolysis of MUGB over the course of reactions.
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3.3.6 Surface plasmon resonance
Binding of SK variants to Glu-Plg and plasmin were examined via Biacore T200
(Biacore AB, Uppsala, Sweden) at 25ºC. Ligand Glu-Plg and plasmin were immobilised
on a Series S Sensor Chip CM4 (Biacore AB, Uppsala, Sweden) via primary amino
acids using an amine coupling kit according to the manufacturer's instructions (Biacore
AB, Uppsala, Sweden). Briefly, the chip was activated with a 1:1 mixture of 0.2 M Nethyl-N'-(3-dimethylaminopropyl)carbodiimide and 0.05 M N-hydroxysuccimide. GluPlg and plasmin were coated onto the chip at 40 µg mL-1 in 10 mM sodium acetate (pH
4) to a level of ~1500 and ~250 response units respectively. Unoccupied binding sites
were blocked using 1 M ethanolamine, pH 8.5. A blank immobilised CM4 cell was used
as a reference. Analytes were diluted into running buffer (10 mM HEPES, 150 mM
NaCl, 0.005% P-20, pH 7.4) and kinetic assays were performed by injecting
recombinant SK proteins at varying concentrations (0-1600 nM), for 200-300 s at a flow
rate of 20 μL min-1 with a 600 s dissociation period. Regeneration of the ligand surface
was achieved with 6 M urea in running buffer for 15 s at 20 μL min-1. To test ligand
binding efficacy and reproducibility on the sensor chip, control group C SK was
injected at a known concentration and response was monitored. The response to SKc
binding post burst 6M urea treatment was the same on all flow cells (tested over several
sensor chips) indicating that Glu-Plg was folding correctly. Glu-Plg interaction
biosensorgram data were prepared for analysis using Scrubber2 (BioLogic Software,
Campbell, ACT, Australia) and data was analysed manually using a two-component
heterogeneous surface model with data curves fit using GraphPad Prism 5 (GraphPad
Software, La Jolla, CA, USA). For Glu-Plg interactions with each SK variant, one

81

Chapter 3

Streptokinase variation affects pathogenesis

binding component accounting for ~30-90% of the total response showed relatively fast
association rate constants (ka values) and dissociation rate constants (kd values), with ka
showing a linear dependence on [SK], while the other showed slow on and off rates
independent of [SK]; we chose to ignore this second non-specific component and
determined equilibrium binding constants (KD) from the ratio of kd and ka for the
specific binding component. For plasmin interactions, ka, kd and KD were calculated
from sensorgrams by non-linear fitting of the association and dissociation curves
according to a 1:1 Langmuir binding model using the Biacore T200 evaluation software
supplied by the manufacturer (Biacore AB, Uppsala, Sweden).

3.3.7 Glu-Plg activation assays
The Plg activation potential of SK variants were studied by the addition of
stoichiometric SK-plasmin activator complexes (final concentration 5 nM) that had
been preformed for 5 min at 37°C, to assay buffer (10 mM HEPES, 150 mM NaCl,
0.01% Tween-20, pH 7.4) containing Glu-Plg (500 nM) and S-2251 (Chromogenix,
Mölndal, Sweden) (500 µM) in a total volume of 100 µL. The exponential generation of
plasmin was monitored by change in absorbance at 405 nm and measured for 30 min
using a SpectraMax Plus 384 spectrophotometer (Molecular Devices, Sunnyvale, CA,
USA) at 37°C.

3.3.8 Inhibition of amidolysis by α2-antiplasmin
Stoichiometric complexes of SK-plasmin were formed by mixing SK (400 nM) and
plasmin (Haematologic Technologies, Essex Junction, VT, USA) (200 nM) for 5min at
37°C. Complexes were diluted to 20 nM in assay buffer in the presence of increasing
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α2-AP (Haematologic Technologies, Essex Junction, VT, USA) concentration (0-400
nM) and incubated at 37°C for 15 min. The reactions were initiated by the addition of S2251 (final concentration 500 µM) and change in absorbance at 405 nm was measured
at 37°C. IC50 values were determined by plotting percentage of residual activity (Vmax)
versus log α2-AP concentration and fit to a sigmoidal dose response curve using
GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA)

3.3.9 Allelic exchange mutagenesis
Isogenic mutants of GAS strain 5448 were produced by replacing the parental ska5448
with either skaALAB49, skaNZ131 or with the chloramphenicol acetyltransferase (cat) gene
via precise, allelic replacement using a modified protocol to Buchanan et al. (2006). To
construct plasmids for allelic exchange, skaALAB49 and skaNZ131 were amplified from
genomic

DNA

by

PCR

using

sense

primer:

(5’-TTCTTCC

TGTCTGTTTATGTACCCGCAGCTACTTGATACC-3’) and antisense primer: (5’TTGTCCTCTTCTGTTTTGGCTACCAAGAACGCTTGATTG-3’)

(Sigma-Aldrich,

Sydney, NSW, Australia), to include GAS chromosomal flanking regions 834 bp
upstream and 853 bp downstream of ska, in addition to regions homologous to the
temperature sensitive, erythromycin resistant shuttle vector pHY304-LIC {Buchanan,
2006 #518}. For knockout plasmid construct p5448∆ska, upstream (369 bp) and
downstream (538 bp) ska DNA fragments containing regions homologous to pHY304LIC

and

cat

were

amplified

using

sense

primer

(5’-

TTCTTCCTGTCTGTTTAGATGAGGGCCTACTTGCATC-3’) and antisense (5’GTGGCTTTTTTCTCCATACGGTCTGGTAGCCATCCAT-3’)
homology

region

and

sense

primer

for

the

upstream

(5’-GTGGCTGGGCGG
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GGCGTAAAAGCTTACAGCTACCTGCGT-3’)

and

antisense

(5’-TTGTC

CTCTTCTGTTTCGGACCAATGGCTAAGAAAG-3’) for the downstream homology
region.

The

cat

gene

was

amplified

using

(5’-GGAGAAAAAAGCCACTGGATATACCACC-3’)

and

(5’-ACGCCCCGCCCAGCCACTCATCGCAATACTGTT-3’).

the

sense

primer

antisense

primer

Single-strand

overhangs were created on all PCR products and PmeI pHY304-LIC shuttle vector by
T4 DNA polymerase treatment at 22°C for 30 min. Treated pHY304-LIC was combined
with equal concentrations of ska upstream/downstream regions and the cat gene to
create the Δska knock-out construct, or with either skaALAB49 or skaNZ131 gene fragments
to create allelic exchange constructs (Figure 3.1). Complementary sequences were
allowed to anneal on ice for 30 min before transformation into chemically competent E.
coli. The purified plasmid constructs were confirmed by DNA sequencing analysis and
transformed into GAS strain 5448. Erythromycin resistant transformants were grown at
the permissive temperature for plasmid replication (30°C). Single-crossover
chromosomal insertions were selected by shifting to the non-permissive temperature
(37°C) while maintaining erythromycin selection. Single-crossover mutants were
incubated overnight at 30°C to allow for looping out of the inserted plasmid and then
patched onto both THY agar and THY agar containing erythromycin and incubated at
37°C. This allowed selection of double crossover mutants encoding in-frame allelic
exchanges and was confirmed using DNA sequence analysis (Figure 3.1). The allelic
exchange mutant strains were designated 5448::skaALAB49, 5448::skaNZ131 and
5448Δska.
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Figure 3.1: Schematic example of allelic exchange mutagenesis to create GAS
strain 5448 isogenic mutants by replacement of the parental ska5448 with skaALAB49.
Isogenic mutants were constructed via precise allelic replacement using a modified
protocol to Buchanan et al. (2006).
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3.3.10 Growth comparison of S. pyogenes strains
Overnight cultures of S. pyogenes were diluted 1:10 in fresh THY media and grown to
stationary phase. Optical density (OD) of the strains at 600 nm (OD600) was documented
at 30 min increments to determine relative growth.

3.3.11 Hyaluronic acid capsule determination
Overnight cultures of S. pyogenes were diluted 1:10 in fresh THY media and grown to
an OD600 of 0.5– 0.6. The hyaluronic acid capsule was extracted and quantified by the
stains-all method as described previously (Cole et al., 2006a).

3.3.12 GAS strain streptokinase expression
For analysis of SK expression, aliquots of overnight GAS cultures were washed twice
by centrifugation, followed by subsequent resuspension with equal volumes of fresh
THY before being used to inoculate new cultures. When GAS cultures had reached
midlog phase (OD600 = 0.6), supernatants were harvested by centrifugation, filtered
using a 0.2 µm polyvinylidene difluoride (PVDF) syringe filter (Millipore, Sydney,
NSW, Australia). GAS culture supernatants were then concentrated 18-fold by 10%
trichloroacetic acid precipitation before SDS-PAGE and western transfer to PVDF
membrane (Millipore, Sydney, NSW, Australia). For detection of SK, the membranes
were immunoblotted using rabbit immune serum raised against commercial group C SK
(Sigma-Aldrich, Sydney, NSW, Australia) as described previously (Cole et al., 2006a).

86

Chapter 3

Streptokinase variation affects pathogenesis

3.3.13 Transgenic murine infection model
Humanised Plg transgenic AlbPLG1 mice, heterozygous for the human Plg gene (Sun et
al., 2004), were used as the animal model for determining GAS invasive potential as
previously described (Walker et al., 2007). Briefly, GAS isolates were grown in THY
medium at 37°C to logarithmic phase (OD600 = 0.6), washed with sterile 0.7% (w/v)
NaCl and appropriately diluted to prepare the inoculum. Cohorts of 9-10 mice were
infected with a 100 µL intradermal injection containing 5448 (Maamary et al., 2010)
(3.9 x 107 CFU/dose), 5448::Δska (3.7 x 107 CFU/dose), 5448::skaALAB49 (4.6 x 107
CFU/dose), or 5448::skaNZ131 (3.7 x 107 CFU/dose) and mortality was recorded over a
10-day period.

3.3.14 Statistical analyses
Differences in survival of humanised Plg transgenic mice infected with GAS strains
5448, 5448::Δska, 5448::skaALAB49, or 5448::skaNZ131 were determined by the log-rank
test. Differences were considered statistically significant at P < 0.05. All statistical tests
were performed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA).

3.3.15 Ethics permissions
Permission to undertake animal experiments was obtained from the University of
Wollongong Animal Ethics Committee.
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3.3.16 Accession numbers
The nucleotide sequences of the ska genes used in this study are deposited in the
GenBank database and shown in Appenidix A1.2: H46A: K02986.1, NZ131:
CP000829.1, 5448: JQ650489, NS696: JQ650488, ALAB49: AY234134.1 and NS88.2:
JQ650490.

Details

of

data

submission

can

be

found

at:

GenBank:

www.ncbi.nlm.nih.gov.
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3.4 Results

3.4.1 Expression and secondary structural analysis of recombinant SK proteins
To characterise the phenotypic differences displayed by SK proteins from different
group A streptococcal isolates, a cluster type-1 ska allele (SKNZ131), two cluster type-2a
ska allele (SK5448 and SKNS696) and two cluster type-2b ska allele (SKALAB49 and
SKNS88.2) were cloned, sequenced and expressed as recombinant proteins. SK from the
group C streptococcal isolate H46A (SKc) was also produced as a recombinant protein
using the same methodology for use as a positive control. From the alignment of the
deduced amino acid sequences (Figure 3.2), the type-1 SK protein had the most
divergent β domain sequence (66% identity to SKc). The β domains from type-2b SK
proteins and type-2a SK were more conserved displaying 85% and 91% identity
respectively. The type-1 SK protein also had the most conserved α and γ domains (94%
and 97% identity) while these domains in type-2a and type-2b proteins were less
conserved with identities ranging from 83% to 87% for α domains and 88% to 90% for
γ domains.

Recombinant SK proteins were analysed for size and purity by SDS-PAGE (Figure.
3.3A). Proteins ranged in size from 44 to 49 kDa, which is similar to the sizes observed
for native SK proteins present in GAS culture supernatants (McArthur et al., 2008). All
protein preparations were free from contaminating proteins. Far-UV circular dichroism
spectroscopy was utilised to compare the secondary structure of all recombinant SK
proteins. Despite significant differences in amino acid composition, variant SK proteins
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had similar molar residue ellipticity spectra across the full range of wavelengths
measured. The output spectra observed was typical of that expected for an
amalgamation of α helical (minima at ~ 210 nm maxima at ~190 nm) and anti-parallel β
sheet (minima at ~215 nm and maxima at ~195 nm) spectra indicative of the known
structure of SK (Wang et al., 1998) (Figure 3.3B).

Figure 3.2: ClustalW Multiple alignment of deduced amino acid sequences of the
SK protein variants used in this study. Amino acid residues identical to those in
SKH46A (SKc) are indicated with a dot while amino acid changes have been indicated.
Non-conserved amino acid changes are highlighted in grey. The SK sequence positions
of the three domains span residues 1 – 147 for the α domain, residues 148 – 291 for the
β domain and spans residues 292 – 414 for the γ domain (Kalia and Bessen, 2004,
Parrado et al., 1996, Wang et al., 1998)
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Figure 3.3: SDS-PAGE and Far-UV circular dichroism spectroscopy analysis of
recombinant SK proteins used in this study. (A) Variant SKc (lane 1), SKNZ131 (lane
2), SK5448 (lane 3), SKNS696 (lane 4), SKALAB49 (lane 5) and SKNS88.2 (lane 6) were
separated by 10% SDS-PAGE under reducing conditions. Molecular weight standards
in kDa are indicated. (B) All SK variants have similar molar residue ellipticity values
and CD out-put spectrum structure across the full range of wavelengths indicating no
differences in secondary structure.

3.4.2 Non-proteolytic active site generation in Glu-Plg by variant SK
Active site generation in Glu-Plg by SK variants (SK-Plg*) was examined using the
fluorescent active site titrant 4-methylumbelliferyl p-guanidinobenzoate (MUGB). This
allowed generation of SK-Plg* (conformational activation, Pathway I) to be measured
directly. SKNZ131 (Type 1) displayed the fastest rate of conformational activation of GluPlg, followed by SKc (group C) (Figure 3.4A). SKNS696 and SK5448 (type-2a variants)
both displayed very slow rates of Glu-Plg activation while SKALAB49 and SKNS88.2 (type-
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2b variants) failed to induce an active site in Glu-Plg (Figure 3.4A). As SK mediated
Glu-Plg activation is known to be affected by the conformation of Plg, experiments
were conducted in the absence of Cl- ions to compare the effect of ‘open’ Plg
conformation on non-proteolytic active site generation (McCance and Castellino, 1995).
Under these conditions SKNZ131 and SKc displayed increased rates of active site
generation that were very similar (Figure 3.4B). The rate of active site generation by
type-2a variants (SKNS696 and SK5448) was also significantly enhanced, but was less than
that observed for SKNZ131 and SKc (Figure 3.4B). Interestingly, type-2b variants
(SKALAB49 and SKNS88.2) both failed to generate an active site in open Glu-Plg (Figure
3.4B). Taken together, these data indicate that type-2b SK variants cannot
conformationally induce an active site in open or closed forms of Glu-Plg.

Figure 3.4: Non-proteolytic active site generation in Glu-Plg by SK variants and
influence of Glu-Plg conformation on SK-Plg* generation. Glu-Plg (200 nM) was
added to 1 µM MUGB in (A) Cl- present assay buffer (50 mM Tris-HCl, 100 mM NaCl,
pH 7.4) or (B) chloride Cl- absent buffer (50 mM Tris pH 7.4) at 37 °C. To initiate the
reaction, SK was added to a final concentration of 400 nM in a total volume of 100 µL
and the development of fluorescence was monitored continuously with excitation at 355
nm and emission at 460 nm. Data shown represent minimum of two independent
experiments (n = 3). Error less than 10% are not shown for clarity of presentation.

92

Chapter 3

Streptokinase variation affects pathogenesis

3.4.3 Binding affinity of SK variants to human Glu-Plg and plasmin
To determine if SK variants display differences in affinity for human Glu-Plg and
plasmin, the binding of each SK variant to immobilised Plg and plasmin was assessed
using surface plasmon resonance (SPR) analysis (Appendix A4.2). Group C SK (SKc),
type-1 SK (SKNZ131) and type-2a SK (SK5448 and SKNS696) variants all displayed high
affinity for human Glu-Plg (KD ranging from 62 – 88 nM). In contrast, type-2b SK
variants had lower affinities for human Glu-Plg with SKALAB49 and SKNS88.2 displaying a
29 and 35-fold reduction respectively (Table 3.1). All SK variants had increased (69 347 fold) affinity for plasmin over Glu-Plg. Group C SK (SKc), type-1 SK (SKNZ131)
and type-2a SK (SK5448 and SKNS696) had KD ranging from 0.37 – 1.03 nM, while type2b (SKALAB49 and SKNS88.2) displayed slightly lower affinities for plasmin with KD
values of 11.5 nM and 6.2 nM respectively (Table 3.1).

3.3.4 Plasminogen activation by variant SK-plasmin activator complexes
The ability of variant SK-plasmin complexes to sequester and activate substrate Plg was
determined by mixing preformed, stoichiometric SK-plasmin activator complexes (5
nM) with an excess of substrate Glu-Plg and monitoring the generation of plasmin
activity using the chromogenic substrate, S-2251. All variant SK-plasmin complexes
examined in this study were capable of efficient substrate Plg activation (Figure 3.5A).
The plasmin activity displayed by the plasmin-SK activator complex is known to be
resistant to the major physiological plasmin inhibitor α2-AP (Cederholm-Williams,
1979). In this study, we observed that complexes of plasmin with SKc or type-2a SK
(SK5448 and SKNS696) variants were also resistant to inhibition by α2-AP (Figure 3.5B).
Interestingly, complexes of plasmin with type-2b SK variants (SKALAB49 and SKNS88.2)
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Table 3.1. Association (kon) and dissociation (koff) rate constants and apparent equilibrium dissociation (KD) constants for the
interaction of SK variants with immobilised Plg and plasmin by SPR.
Analyte
SK Variant Type

Ligand Plg

Ligand Plasmin

ka (M-1 s-1)

kd (s-1)

KD (nM)

ka (M-1 s-1)

kd (s-1)

KD (nM)

Group C

SKc

2.9 ± 0.5 x 104

1.8 ± 0.3 x 10-3

62 ± 19

8.6 ± 0.2 x 105

3.1 ± 0.5 x 10-4

0.37 ± 0.04

Type-1

SKNZ131

2.8 ± 0.7 x 103

2.5 ± 0.6 x 10-4

88 ± 12

1.1 ± 0.8 x 106

1.1 ± 0.4 x 10-3

0.76 ± 0.09

Type-2a

SK5448

1.1 ± 0.2 x 106

72.6 ± 1.4 x 10-3

66 ± 7

1.0 ± 0.6 x 106

8.3 ± 0.7 x 10-4

0.96 ± 0.39

SKNS696

1.2 ± 0.2 x 106

84.1 ± 3.4 x 10-3

70 ± 17

1.2 ± 0.8 x 106

9.4 ± 0.1 x 10-4

1.03 ± 0.47

SKALAB49

4.6 ± 0.4 x 104

81.3 ± 0.8 x 10-3

1767 ± 199

4.2 ± 0.4 x 105

4.3 ± 0.3 x 10-3

11.55 ± 3.03

SKNS88.2

7.9 ± 0.5 x 104

170.0 ± 3.0 x10-3

2153 ± 512

4.4 ± 0.3 x 105

2.2 ± 0.6 x 10-3

6.22 ± 2.70

Type-2b

Glu- Plg binding data was prepared for analysis using Srubber2 (BioLogic Software, Campbell, ACT, Australia) and analysed by
fitting data to a heterogeneous ligand population model using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) as described
under ‘Experimental Procedures’. Values represent the mean ± SD. Plasmin binding data were calculated by non-linear fitting of the
association and dissociation curves according to a 1:1 Langmuir binding model using the Biacore T200 evaluation software (Biacore
AB, Uppsala, Sweden)
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or type-1 SK (SKNZ131) were susceptible to inhibition by α2-AP, displaying IC50 values
of 20 nM, 35 nM and 7 nM respectively (Figure 3.5B).

Figure 3.5: Plg activation by SK-plasmin variant activator complexes and
inhibition of variant SK-plasmin complexes by α2-antiplasmin. (A) SK was
preformed with plasmin for 5 min at 37°C (5 nM), then added to assay buffer (10 mM
HEPES, 150 mM NaCl, 0.01% Tween-20, pH 7.4) containing Glu-Plg (500 nM) and S2251 (500 µM). The generation of Plg activation activity was monitored at an
absorbance of 405 nm. (B) Stoichiometric complexes of SK-plasmin (20 nM) were
preformed for 5 min at 37°C in assay buffer (10 mM HEPES, 150 mM NaCl, 0.01 %
Tween-20, pH 7.4) and subsequently incubated for 15 min at 37°C with α2-antiplasmin
(final concentration 0 – 400 nM). The reactions were initiated by addition of S-2251
(500 µM) to complex mixtures and the percentage of residual activity of the SK-plasmin
complexes was determined by measuring the absorbance at 405 nm.

3.3.5 Role of SK variation in GAS pathogenesis
In vitro characterisation of the isogenic mutants 5448Δska, 5448::skaALAB49 and
5448::skaNZ131 indicated all strains maintained similar growth rates and expressed
similar amounts of hyaluronic capsule (Figure 3.6A-B). Additionally, 5448Δska did not
produce SK while 5448::skaALAB49 and 5448::skaNZ131 both secreted the exchanged
variant of SK (Figure 3.6C). Utilising the humanised Plg transgenic mouse line
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AlbPLG1, the virulence of the wild-type 5448 and the isogenic mutant GAS strains,
5448Δska, 5448::skaALAB49 and 5448::skaNZ131 was assessed. The virulence of GAS
strain 5448 has been well characterised and has previously been shown to be virulent

Figure 3.6: In vitro characterisation of wild type GAS strain 5448 and isogenic mutant
strains 5448Δska, 5448::skaALAB49 and 5448::skaNZ131 (A) 5448 and the isogenic mutants
display comparative growth at 37°C in THY medium. (B) 5448 and the isogenic
mutants express capsular hyaluronic acid (mean ± SD) and (C) Composite anti-SK
probed Western blot showing SK expression by wild type GAS strains 5448, ALAB49,
NZ131 (Lanes 1-3) and similar expression by isogenic mutants 5448::skaALAB49 and
5448::skaNZ131 (Lanes 5-6), while 5448Δska does not express SK (Lane 4).

in this mouse model (Figure 3.7) (Maamary et al., 2010, Walker et al., 2007). In
comparison to the wild-type 5448 strain, the virulence of 5448Δska and 5448::skaALAB49
was significantly reduced (P < 0.05; 50% vs. 10% mortality) (Figure 3.7). Conversely,
the virulence of 5448::skaNZ131, is increased when compared to the wild-type 5448
strain, although these data were not statistically significant (P > 0.05; 100% vs. 50%
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mortality) (Figure 3.7). Taken together, these data suggest that the unique Plg activation
kinetics/properties displayed by the different SK variants affect the pathogenesis of
GAS.

Figure 3.7: Survival curves after subcutaneous infection of humanised Plg
transgenic AlbPLG1 mice with GAS strain 5448 and isogenic mutants. 5448 (3.9 x
107 CFU/dose; n = 10) (Maamary et al., 2010), 5448::skaALAB49 (4.6 x 107 CFU/dose; n
= 10), 5448Δska (3.7 x 107 CFU/dose; n = 10) or 5448::skaNZ131 (3.7 x 107 CFU/dose; n
= 9). Differences in survival of humanised Plg transgenic mice infected with GAS
strains 5448, 5448::Δska, 5448::skaALAB49, or 5448::skaNZ131 were determined by the
log-rank test. Differences were considered statistically significant at P < 0.05. Virulence
of strains 5448Δska and 5448::skaALAB49 were significantly reduced (P < 0.05) vs 5548.
Conversely, the virulence of 5448::skaNZ131, was increased when compared to the wildtype 5448 strain, although these data were not statistically significant (P > 0.05; 100%
vs. 50% mortality) All statistical tests were performed using GraphPad Prism 5
(GraphPad Software, La Jolla, CA, USA).
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3.5 Discussion

GAS is a versatile human pathogen capable of causing a wide range of human diseases.
The broad pathogenicity of GAS is underpinned by the genetic diversity displayed by
clinical isolates of the species. There is a large amount of evidence in the literature
describing how the absence or presence of virulence genes or changes in the complex
regulatory mechanisms controlling the expression of these genes can alter the
pathogenicity of a particular GAS isolate (Sumby et al., 2006, Walker et al., 2007,
Kreikemeyer et al., 2003, Musser and Shelburne, 2009, Castellino and Ploplis, 2005).
Similarly, allelic variation of specific virulence genes may also influence the
pathogenicity of GAS isolates however, these changes may be more subtle and therefore
more difficult to characterise.

Allelic variation of the ska gene has been well characterised (Kalia and Bessen, 2004,
Kapur et al., 1995, McArthur et al., 2008). Bioinformatical analyses of predicted SK
protein sequences suggested that SK variants maintain similar secondary structure
despite differences in the amino acid sequences (Kapur et al., 1995). In this study, the
six SK proteins were specifically chosen as representatives of divergent sequence
clusters and despite significant amino acid sequence differences, all recombinant SK
proteins displayed similar secondary structures as indicated by individual CD spectra.
This data further supports the hypothesis that selection pressure may be placing
structural constraints on SK molecules (Kapur et al., 1995). However, biochemical
analysis of the SK variants presented in this study clearly demonstrates that these

98

Chapter 3

Streptokinase variation affects pathogenesis

variants do display a number of different phenotypic properties, which alter the ability
of these molecules to interact with and activate human Glu-Plg.

GAS SK variants display significant differences in ability to non-proteolytically
generate an active site in Glu-Plg. Type-2b SK variants could not induce the formation
of an active site in Glu-Plg. Additionally, type-2b SK variants have a 25 fold less
affinity for Glu-Plg when compared to other SK variants which all displayed similar
high affinities (Table 3.1). Therefore, the inability of type-2b SK variants to produce an
active site in Glu-Plg may be the result of the type-2b variants failing to interact with
Glu-Plg. However, type-1 SK, group-C SK and type-2a SK molecules which all bind to
Glu-Plg with similar, high affinity, also displayed different rates of active site formation
in Glu-Plg. These data suggest that while the formation of the nascent SK-Plg complex
plays a role in the generation of a conformationally re-arranged active site in Glu-Plg,
other protein specific changes may also be affecting this process.

SKc mutants with deletions or site directed amino acid changes within the α domain,
also form complexes with Glu-Plg that display delays in the generation of amidolytic
activity (Fay and Bokka, 1998, Wang et al., 1999a, Rodríguez et al., 1995, Young et al.,
1995). In particular, residues 1-59 of the SK α domain have been shown to be critical
for SK mediated Plg activation (Young et al., 1995, Mundada et al., 2003, Reed et al.,
1999). SK mutants (such as α domain truncation mutants and numerous amino terminal
site directed mutants) also display reduced amidolytic activity, reduced Plg affinity and
increased susceptibility to α2-AP inhibition (Fay and Bokka, 1998, Sazonova et al.,
2004, Rodríguez et al., 1995, Boxrud et al., 2000, Mundada et al., 2003). Upon mixing
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of SK and Glu-Plg, SK is rapidly cleaved at the Lys59-Ser60 peptide bond once bound to
Plg (Shi et al., 1994). The N-terminal peptide remains associated (non-covalently) with
the SK-Plg complex and is required for non-proteolytic active site induction and
stabilisation of the activator complex (Parrado et al., 1996, Young et al., 1995, Wang et
al., 1999a, Mundada et al., 2003). For SK to induce an active site in Plg, the SK Ile1
residue must be positioned within the Plg molecule so that it can form a salt bridge with
Asp740 of Plg (Wang et al., 1999a). SK mutants lacking this residue cannot induce an
active site in Plg through non-proteolytic mechanisms (Wang et al., 1999a, Mundada et
al., 2003). While all SK variants examined in this study had an N-terminal Ile residue,
cluster type-2b SK proteins contain two specific amino acid changes (Q86R and
E134Q) in the α domain regions that come in direct contact with the Plg moiety (Law et
al., 2012)(Figure 3.2). These changes (or potentially others within the β and γ domains)
may slow the initial interaction of SK with Glu-Plg and also possibly prevent the correct
positioning of the N-terminal fragment within the SK-Plg complex thereby preventing
(or slowing) non-proteolytic active site formation in Glu-Plg.

The physiological inhibitor of plasmin, α2-AP, is a member of the serpin family and
tightly regulates the activity of plasmin in plasma (Aoki et al., 1993). When plasmin
reacts with α2-AP, the serpin is cleaved resulting in a covalently bound complex of
plasmin and α2-AP that is inactive (Shieh and Travis, 1987). Activator complexes
consisting of Plg/plasmin and therapeutic SK (SKc) are known to be resistant to α2-AP
inhibition (Cederholm-Williams, 1979). Similarly, we found complexes of plasmin and
type-2a SK (SK5448 and SKNS696) variants were also resistant to inhibition by α2-AP,
while complexes of plasmin and type-2b SK variants (SKALAB49 and SKNS88.2) or type-1
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SK (SKNZ131) were not (Figure 3.5B). The susceptibility of type-2b SK for inhibition by
α2-AP and inability of this variant to non-proteolytically generate in active site in GluPlg suggests that GAS isolates expressing a type-2b SK molecule have evolved novel
mechanisms to control SK mediated Plg activation. The apparent requirement of
plasmin for type-2b SK mediated activation of Plg also suggests that Plg activation may
be restricted to areas where there is free plasmin (i.e. at the sites of fibrinolysis).
Alternatively, SK variants may require additional cofactors (either host or bacterial in
origin) to facilitate successful Plg activation, such as: fibrinogen, SEN, GAPDH or
PAM (McArthur et al., 2008, Gaffney et al., 1988, Lahteenmaki et al., 2001).

Subversion of the host Plg activation system is a well-documented pathogenic
mechanism used by GAS and other bacterial pathogens to cause disease (Boyle and
Lottenberg, 1997, Coleman and Benach, 1999, Castellino and Ploplis, 2005). SK
mediated Plg activation has been shown to play a critical role in the invasive
pathogenesis of GAS (Sun et al., 2004, Castellino and Ploplis, 2005). M1T1 GAS
strains are considered a highly virulent clone capable of causing serve invasive disease
of humans. Consequently, the M1T1 GAS strain 5448 used in this study (which
contains a type-2a ska allele) is highly virulent for the human Plg transgenic mouse
strain that was used in these experiments (Cole et al., 2011, Maamary et al., 2010,
Walker et al., 2007). In this study, the acquisition of the type-1 ska allele increased
M1T1 virulence. Similarly, GAS strain NZ131 (type-1 SK) has previously been shown
to be virulent in other mouse models of GAS infection. (Kuo et al., 1998, Tsao et al.,
2001, Li et al., 2011). When the type-2a ska allele of the M1T1 strain 5448 is replaced
with a type-2b allele (skaALAB49), the invasive pathogenesis of this strain is reduced,
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similar to a level seen for the isogenic ska deletion mutant (5448Δska) (Figure 3.7).
Previous studies conducted in our laboratory have shown that wild-type ALAB49 is
avirulent in this mouse model (Maamary et al., 2010). This result indicates that type-2b
SK cannot reproduce the in vivo function of a type-2a SK in a M1T1 genetic
background and suggests the requirement of plasmin by type-2b SK to form an efficient
activator complex affects the invasive pathogenesis of GAS. Previous studies have
shown a strong association between cluster type-2b alleles and skin tropic emm pattern
D strains containing the high affinity Plg binding M-protein PAM (Kalia and Bessen,
2004). Taken together, these observations suggest that type-2b SK proteins require
bacterial co-factors present only in a subset of strains for efficient plasmin acquisition or
that reduced/restricted Plg activation kinetics produced by type-2b SK in vivo may be
beneficial for successful long term skin infections such as impetigo. Similarly, the Plg
activator staphylokinase from the ubiquitous skin coloniser, Staphylococcus aureus,
also requires plasmin for efficient Plg activation, which suggests this mechanism of Plg
activation may be advantageous for skin colonisation (Rampling and Gaffney, 1976).
Additionally, Plg acquisition and activation mechanisms have been documented for
commensal strains of oral streptococci, which also suggests this process may also be
involved in maintaining long term infections (Kinnby et al., 2008).

This study confirms the importance of SK mediated Plg activation in GAS pathogenesis
and highlights a mechanism whereby variability in this important virulence factor can
influence the pathogenesis of this organism. Characterising GAS SK variants represents
a novel approach to elucidate the mechanism of SK-mediated Plg activation. Therefore,
future comparative studies that characterise GAS SK variants in more detail will help to
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identify critical residues involved in SK function and could assist the rational design of
new drugs targeting this specific interaction which may be useful in treating GAS
infections.
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Chapter 4:

Site Restricted Plasminogen Activation
Mediated by Group A streptococcal
Streptokinase Variants
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Preface
The protease activity harnessed by group A streptococcus is critical for disease
progression in humans and influences pathogenic outcomes. Genetic variants of the
potent Plg activator protein, SK, which is secreted by group A streptococcal isolates,
display differences in the mechanism of Plg activation and have previously been shown
to influence invasive pathogenesis. Bacterial and host-derived Plg activation system
cofactors have been widely implicated in the subversion of the fibrinolytic system by
bacteria. Furthermore, plasmin(ogen) ligands naturally assist in regulating protease
activity to areas required in the healthy host. Here we examined the effect of these cofactors on SK variant interaction with the Plg activation system. We show these
interactions have a role in restricting protease activity to specific microenvironments for
some group A streptococcal isolates and SK variation may contribute to the broad
disease spectrum associated with this pathogen.

Publication: Cook, S. M., Skora, A., Walker, M. J., Sanderson-Smith M. L. and
McArthur, J. D., (2013) “Site restricted plasminogen activation mediated by
streptokinase variants from Streptococcus pyogenes.” Biochemical Journal Immediate
Publication, doi:10.1042/BJ20131305
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4.1 Abstract

Streptokinase (SK) is a secreted Plg activator and virulence factor of group A
streptococcus (GAS). Among GAS isolates, SK gene sequences are polymorphic and
are grouped into two sequence clusters (cluster type-1 and cluster type-2) with cluster
type-2 being further classified into sub-clusters (type-2a and type-2b). Here we examine
the role of bacterial and host-derived cofactors in SK mediated Plg activation. All SK
variants, apart from type-2b, can form an activator complex with Glu-Plg (Glu-Plg).
Specific ligand-binding induced conformational changes in Glu-Plg mediated by
fibrinogen, Plg-binding group A streptococcal M protein (PAM), fibrinogen fragment D
or fibrin, were required for type-2b SK to form a functional activator complex with GluPlg. In contrast with type-1 and type-2a SK, type-2b SK activator complexes were
inhibited by α2-antiplasmin unless bound to fibrin or to the GAS cell surface via PAM
in combination with fibrinogen. Taken together, these data suggest that type-2b SK Plg
activation may be restricted to specific micro-environments within the host such as
fibrin deposits or the bacterial cell surface through the action of α2-antiplasmin. We
conclude that phenotypic SK variation functionally underpins a pathogenic mechanism
whereby SK variants differentially focus Plg activation, leading to specific niche
adaption within the host.
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4.2 Introduction

Streptokinase (SK) is a plasminogen (Plg) activator secreted by β-haemolytic
streptococcal species. SK from Streptococcus equisimilis isolate H46A (SKc) is the
most characterised SK protein due to its widespread use as a thrombolytic therapeutic
since approval in 1977 (McArthur et al., 2012). Unlike host Plg activators that activate
Plg by limited proteolytic cleavage, SKc binds to Plg inducing conformational changes
in the protein that result in the formation of an active site and the production of an
enzymatically active complex, termed SK-Plg* (known as the ‘Conformational
Activation Pathway’ or ‘Pathway I’). The conformationally activated SK-Plg* complex
can then sequester substrate Plg and proteolytically convert these molecules to the
broad-spectrum serine protease plasmin via cleavage at the Arg561-Val562 peptide bond
(Boxrud et al., 2000, Boxrud et al., 2004). Plasmin, which has a higher affinity for SK
than Plg, rapidly displaces Plg in the SK-Plg* complex to produce an activated SKplasmin complex that is the main catalyst responsible for the full conversion of Plg to
plasmin (known as ‘Direct Proteolytic Activation Pathway’ or ‘Pathway II’) (Boxrud et
al., 2000, Boxrud et al., 2004).

The process of Plg activation in a healthy individual is strictly controlled. Multiple
regulatory mechanisms function in a co-ordinated manner to restrict Plg activation to
specific locations within the host where the potent protease activity of plasmin is
required. Plg activation is greatly influenced by the conformation of the Glu-Plg
molecule. Plg contains several structural domains, consisting of the N-terminal PAp
domain (also known as the NTP domain and PAN module domain), followed by five
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kringle domains (KI-K5) and the carboxy-terminal serine protease catalytic domain
(Ponting et al., 1992, Law et al., 2012, Xue et al., 2012, Brown et al., 2001, Brown et
al., 2003). Intramolecular binding between lysine residues and the lysine binding sites
of these kringles maintains circulating Glu-Plg in a ‘closed’ conformation that is highly
resistant to activation. Upon binding to specific cell surface receptors or ligands such as
fibrin, Glu-Plg adopts an ‘open’ conformation that becomes more susceptible to
activation (Castellino and Ploplis, 2005). While soluble plasmin is readily inhibited by
the circulating inhibitor α2-antiplasmin (α2-AP), plasmin that remains bound to
receptors/ligands may be resistant to inhibition, thereby restricting plasmin activity to
specific foci such as the cell surface or fibrin thrombi (Irigoyen et al., 1999).

Plg activation by SKc is not affected by these regulatory mechanisms as the closed
conformation of Glu-Plg does not prevent activation and because plasmin activation
activity displayed by the SKc-Plg* activator complex is not inhibited by α2-AP (Xue et
al., 2012, Cederholm-Williams, 1979). Thus, SKc-mediated Glu-Plg activation can
rapidly generate high levels of soluble plasmin activity as activator complexes sequester
and activate substrate Plg while bypassing host regulation mechanisms (Parry et al.,
2000). Based on these observations, it is now a widely held view that the human
specific pathogen, Streptococcus pyogenes (group A streptococcus, GAS) hijacks the
host Plg activation system by generating unregulated soluble and cell bound plasmin
activity that is used to overcome immune defences and break down tissue barriers to
facilitate dissemination (Walker et al., 2005, Sun et al., 2004, Khil et al., 2003).
However, recent research that has characterised SK variants from different GAS isolates
suggests these variants may play differing roles in the pathogenesis process (Cook et al.,
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2012, Zhang et al., 2012). SK produced by GAS displays considerable genetic and
phenotypic diversity (Kalia and Bessen, 2004, McArthur et al., 2008, Kapur et al.,
1995, Zhang et al., 2012, Cook et al., 2012). Phylogenetic studies of ska sequences
from GAS isolates have revealed two main sequence clusters (cluster type-1 and 2) with
cluster type-2 sequences being further subdivided (cluster type-2a and 2b) (Kalia and
Bessen, 2004, McArthur et al., 2008). Epidemiological studies have shown the type-2b
ska linage to be largely restricted to skin tropic, pam positive GAS isolates expressing
the high affinity plasminogen-binding group A streptococcal M protein PAM (Kalia and
Bessen, 2004).

Despite significant sequence variation, SKc, type-1 and type-2a SK variants display
several important phenotypic similarities, such as a high affinity for Glu-Plg and an
ability to conformationally activate Glu-Plg via ‘Pathway I’. Conversely, type-2b SK
variants have low affinity for Glu-Plg and cannot induce an active site in this protein
through conformational rearrangement (Cook et al., 2012, Zhang et al., 2012). In
addition, the exchange of ska allelic variants in a virulent M1T1 GAS isolate (strain
5448; cluster type-2a) alters pathogenesis in a murine model of invasive infection (Cook
et al., 2012). While these observations confirm the importance of Plg activation in GAS
pathogenesis, the rationale and mechanisms defining how SK variants influence
virulence are yet to be determined.

This study examines the role of bacterial and host-derived cofactors in Glu-Plg
activation mediated by different SK variants with a view to determine how these
interactions may influence GAS pathogenesis. Our data suggest Glu-Plg activation by

109

Chapter 4

Site restricted streptokinase mediated plasminogen activation

type-2b SK variants is restricted by ligand induced conformational changes in the GluPlg molecule and that soluble type 2b SK-Plg* activator complexes are inhibited by
α2-AP. Taken together, we propose the activation of Glu-Plg by type-2b SK variants is
restricted to specific microenvironments at the infection foci which may promote long
term skin colonisation.
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4.3 Materials and Methods

4.3.1 Bacterial strain, culture conditions and reagents
Escherichia coli strain M15 [pREP4] was used as a host for protein expression and was
cultured at 37°C in Luria-Bertani broth. GAS isolates ALAB49 (Svensson et al., 2000),
ALAB49Δpam, NS88.2 (McKay et al., 2004) and NS88.2prp (Sanderson-Smith et al.,
2008) were used in this study. All streptococcal strains were routinely cultured at 37°C
on horse-blood agar (Biomerieux, Sydney, NSW, Australia) or in static liquid cultures
of Todd-Hewitt broth (BD, Sydney, NSW, Australia) supplemented with 1% (w/v) yeast
extract (Oxoid, Adelaide, SA, Australia) (THY medium). Where appropriate, antibiotics
were used for selection at the following concentrations: kanamycin, 50 μg/mL and
ampicillin, 100 μg/mL. Glu-Plg, plasmin, Fg, FgD, FgE and α2-AP were purchased from
Haematologic Technologies, Essex Junction, VT, USA. The chromogenic substrate HD-Val-Leu-Lys-pNA·2HCl (S-2251) was obtained from Chromogenix, Mölndal,
Sweden. Thrombin from human plasma was purchased from Sigma-Aldrich, Sydney,
NSW, Australia and 4-methylumbelliferyl p-guanidinobenzoate (MUGB) was from
Marker Gene Technologies, Inc., Eugene, OR, USA.

4.3.2 Cloning, expression and purification of recombinant proteins
Recombinant SK variants, plasminogen-binding group A streptococcal M proteins
(PAM, Prp), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and streptococcal
enolase (SEN) were cloned, expressed in E. coli, purified, and characterised as
previously described (Sanderson-Smith et al., 2006, Cook et al., 2012, Derbise et al.,
2004, Cole et al., 2006b).
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4.3.3 Non-proteolytic active site generation in Glu-Plg

Non-proteolytic active site generation in Glu-Plg by SK variants was examined using
the

fluorescent

active

site

MUGB

in

a

POLARstar

Omega

fluorescence

spectrophotometer (BMG LABTECH, Ortenberg, HE, Germany). Glu-Plg (200 nM)
was added to a black 96-well microtitre plate containing 1 μM MUGB in assay buffer
(50 mM Tris-HCl, 100 mM NaCl, pH 7.4) at 37°C. To initiate the reaction, SK was
added to a final concentration of 400 nM in a total volume of 100 μL and the
development of fluorescence was monitored continuously with excitation at 355 nm and
emission at 460 nm. To test the effect of various Plg ligands and co-factors on nonproteolytic active site generation in Glu-Plg by SK variants, each of these molecules
were incubated in various combinations for 10 min at 37°C before addition of MUGB,
at the following concentrations: SEN (200 nM), GAPDH (200 nM), PAM (200 nM), Fg
(200 nM), Fg fragment D (FgD) (200 nM), Fg fragment E (FgE) (200 nM). For active
site experiments in the presence of plasma, SK was added to a 1:10 dilution of pooled
EDTA-treated human plasma and MUGB (1 μM). Data was normalised by subtracting a
control reaction of all protein species without the addition of SK and 1 μM MUGB. This
accounted for intrinsic fluorescence associated with buffer and protein species, as well
as non-specific hydrolysis of MUGB over the course of reactions. Fluorescence
measurements were expressed as the fractional change in the initial fluorescence (FobsFo)/Fo =ΔF/Fo. Values for rates of active site generation were calculated using the initial
linear portion of the reactions as (ΔF.Fo-1).min-1. This is subsequently referred to in the
simplified form as ΔFU/min. To calibrate relative fluorescence units and convert these
measurements to [SK-Plg*], standard curves of known concentrations of the fluorescent
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product 4-methylumbelliferone were constructed. The fluorescence measurements were
made in the assay buffer (50 mM Tris-HCl, 100 mM NaCl, pH 7.4) at 37°C containing
400 nM SK and 200 nM Glu-Plg, with the same instrument settings as MUGB
experiments. Values for rates of active site generation were calculated using the initial
linear portion of the reactions as pmol SK-Plg*.min-1. Initial rates of active site
generation were compared using a two-tailed unpaired students t-test using GraphPad
Prism 5 (GraphPad, San Diego, CA, USA).

4.3.4 Plasminogen activation by variant SK-Plg complexes
The capacity of variant SK-Plg complexes to activate substrate Glu-Plg was studied by
the addition of SK (final concentration 5 nM) to assay buffer (10 mM HEPES, 150 mM
NaCl, 0.01% Tween-20, pH 7.4) containing a large excess of Glu-Plg (500 nM) and S2251 (500 μM) in a total volume of 100 μL. The parabolic generation of plasmin was
monitored by change in absorbance at 405 nm and measured over 30 min at 37°C using
a SpectraMax Plus 384 spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).
To assess the role of co-factors and ligands, each was pre-incubated with Plg for 10 min
at 37°C at the following concentrations: Fg (500 nM), PAM (500 nM), α2-AP (50 nM).
For quantitative comparison of ligand effects, change in A405nm, which is a function of
S-2251 substrate cleavage by plasmin generated during the activation of Glu-Plg by SK,
was plotted against t2. The velocities of these reactions were then calculated from the
gradient of A405nm vs t2. All data transformation and linear regressions were performed
in GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA).

113

Chapter 4

Site restricted streptokinase mediated plasminogen activation

To examine the role of Plg binding to the GAS cell surface of type-2b expressing
strains, whole GAS cells were used as an exogenous source of the cell receptors
PAM/Prp to assess the effect on Plg activation, with PAM and Prp knock-out strains
used as controls. For these experiments a single colony of each strain (NS88.2,
NS88.2prp, ALAB49 and ALAB49Δpam) was inoculated in THY medium for growth
overnight at 37°C. The overnight culture (A600nm = 1.1–1.3) was diluted (10% v/v) in
pre-warmed THY medium and grown to an A600nm = 0.5. The cells were collected by
centrifugation (5,000 g for 10 min) and washed twice with sterile PBS (3.2 mM
Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, and 135mM NaCl, pH 7.4) followed by
resuspension of 1 x 108/CFU of each GAS strain per replicate in 90 μL assay buffer (10
mM HEPES, 150 mM NaCl, 0.01% Tween-20, pH 7.4) containing Glu-Plg (500 nM)
and repeated in the presence of absence of α2-AP (250 nM) and/or Fg (500 nM). Protein
mixtures were incubated for 10 min at 37°C in a 96-well plate to bind Plg to the cell
surface. To initiate Plg activation, SKALAB49 or SKNS88.2 and S-2251 were added to the
wells at 5 nM and 500 μM respectively, in a final volume of 100 μL. The exponential
generation of plasmin was monitored by change in absorbance at 405 nm was measured
over 30 min at 37°C using a SpectraMax Plus 384 spectrophotometer with shaking
between measurements (Molecular Devices, Sunnyvale, CA, USA).

4.3.5 Effect of fibrin on the amidolytic activity of variant SK-plasminogen
complexes
To study the amidolytic activity of SK-Plg complexes bound to insoluble fibrin
matrices, fibrin-coated micro-titre plate wells (96 wells/plate) were prepared by
incubating Fg (3 μM) and thrombin (0.8 NIH U/mL) in 50 μL of sample buffer (0.05 M
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Tris, 0.02 M CaCl2, 0.1% Tween-20, pH 7.75) at room temperature for 4 h. Wells were
blocked for 1 h with 3% bovine serum albumin and washed five times with washing
buffer (0.05 M Tris, 0.1% Tris-20, pH 7.75). Glu-Plg (20 nM) in 100 uL of assay buffer
(10 mM HEPES, 150 mM NaCl, 0.01% Tween-20, pH 7.4) was bound to the fibrin clots
for 1 h. Wells were washed 5 times with assay buffer. To measure the amidolytic
activity of complexes, each SK variant (40 nM) and S-2251 (500 μM) was added to
wells, in the presence or absence of α2-AP (250 nM) and change in absorbance at 405
nm was measured over 30 min at 37°C using a SpectraMax Plus 384 spectrophotometer
(Molecular Devices, Sunnyvale, CA, USA).

4.3.6 Plasma clot lysis assay
Cross-linked plasma clots were prepared using human plasma pooled from healthy
donors, which had been collected using K2EDTA BD vacutainers (BD, North Ryde,
NSW, Australia). Clotting was initiated by adding human thrombin (0.8 NIH U/mL)
and CaCl2 (20 mM) to plasma at room temperature. Immediately after mixing, 50 µL of
the polymerising plasma was transferred to a 96-well micro-titre plate. The plasma clots
were formed at room temperature for 2 h and washed once with 50 µL of plasma. Clot
lysis was performed by adding 50 µL of pooled plasma containing variant SK (50 nM)
to the clot at 37°C. The clot lysis process was monitored by change in turbidity at 340
nm using a SpectraMax Plus 384 spectrophotometer (Molecular Devices, Sunnyvale,
CA, USA). As a control, plasma clots were incubated with 50 µL of plasma without
addition of SK to monitor stability during the course of the assay.
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4.3.7 Plasma fibrinogen depletion by SK variant plasminogen activation
The level of plasma Fg depletion by each SK variant was determined by a modified
version of the sodium sulphite precipitation method (Rampling and Gaffney, 1976).
Briefly, SK variants (50 nM, final concentration) were added to 100 µL of pooled
EDTA-treated human plasma and incubated at 37°C for 30 min. Each aliquot was
immediately mixed with aprotinin (20 µM) to inhibit plasmin activity, and precipitated
with 900 µL of 10.5 % (w/v) sodium sulphite by incubation in a 37°C water bath for 15
min. Precipitant Fg was cleared from solution by centrifugation at 1,500 x g for 15 min.
The supernatant was carefully decanted and the cleared Fg washed with 500 µL of
10.5 % (w/v) sodium sulphite, re-centrifuged and the supernatant removed. To dissolve
the collected Fg, 1 mL of 4 M urea in 0.1 N NaOH was added to each tube and
incubated at 100°C for 15 min. Finally, the A280 of each solution was measured using a
NanoDrop 2000c spectrophotometer (Thermo Fischer Scientific, Scoresby, VIC,
Australia) and remaining Fg concentration determined by comparison to control plasma
aliquots prepared without addition of SK. Statistical data analysis was conducted via
one-way ANOVA with Tukey’s multiple-comparison test. Data sets were considered
significantly different at P < 0.05. All analysis was performed using GraphPad Prism 5
(GraphPad, San Diego, CA, USA).

4.3.8 Accession numbers
The nucleotide sequences of the ska genes used in this study are deposited in the
GenBank database: H46A: K02986.1, NZ131: CP000829.1, 5448: JQ650489, NS696:
JQ650488, ALAB49: AY234134.1 and NS88.2: JQ650490. Details of data submission
can be found at: GenBank: www.ncbi.nlm.nih.gov.
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4.3.9 Ethics approval:
Permission to collect human blood was obtained from the University of Wollongong
Human Ethics Committee (HE08/250). Blood was taken from healthy adult volunteers,
who provided informed, written consent.
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4.4 Results
4.4.1 Non-proteolytic active site generation in Glu-Plg by variant SK
Active site generation in Glu-Plg by SK variants (SK-Plg*) was examined using the
fluorescent active site titrant MUGB. This allowed generation of SK-Plg*
(conformational activation, Pathway I) to be measured directly. To calibrate relative
fluorescence units and convert these measurements to [SK-Plg*], standard curves of
known concentrations of the fluorescent product 4-methylumbelliferone were
constructed. The fluorescence measurements were made in the assay buffer (50 mM
Tris-HCl, 100 mM NaCl, pH 7.4) at 37°C containing 400 nM SK and 200 nM Glu-Plg,
with the same instrument settings as MUGB experiments. We concluded that 1.0 mol 4methylumbelliferone/mol SK-Glu-Plg* was formed. It was previously identified that
SKNZ131 (Type 1) displays the fastest rate (3.2 pmol SK-Plg*.min-1) of conformational
activation of Glu-Plg, followed by SKc (1.9 pmol SK-Plg*.min-1). SKNS696 and SK5448
(type-2a variants) both display very slow rates of active site generation (0.34 and 0.27
pmol SK-Plg*.min-1 respectively) while SKALAB49 and SKNS88.2 (type-2b variants) fail to
induce an active site in Glu-Plg (Figure 4.1A) (Cook et al., 2012). As SK mediated GluPlg activation is affected by the conformation of Glu-Plg, experiments were conducted
in the presence of Fg and Fg fragments D (FgD) and E (FgE) to the assess effect on
conformational rearrangement of Plg by these molecules. In the presence of Fg and Fg
fragment D, SKNZ131 (type-1) and SKc displayed increased rates of active site generation
(Fg = 0.35 and 0.33 pmol SK-Plg*.min-1 respectively and FgD = 0.36 and 0.33 pmol
SK-Plg*.min-1 respectively) (Figure 4.1B and C). The rate of active site generation by
type-2a variants (SKNS696 and SK5448) was also significantly enhanced (1.9-2.0 and 2.63.0 fold respectively), but the rates were less than those observed for SKNZ131 and SKc
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(Figure 4.1B and C). The type-2b variants (SKALAB49 and SKNS88.2) could generate an
active site in Glu-Plg when combined with Fg or FgD, however this occurred at a slow
rate of 0.12-0.19 pmol SK-Plg*.min-1 for both variants with each ligand (Figure 4.1B
and C). FgE had minimal effect on the rate of active site generation for the SK variants
and did not allow type-2b SK to generate an active site in Glu-Plg (Figure 4.1D). This
indicated that binding of Glu-Plg to Fg or FgD, but not FgE, results in a conformational
change in the Glu-Plg molecule that readily allows non-proteolytic active site
generation (Pathway I) by SK variants.

Figure 4.1: Effect of Fg and Fg fragments on non-proteolytic active site
generation in Glu-Plg and plasminogen activation by SK variants. Glu-Plg alone
(200 nM) (A) or in the presence of 200 nM Fg (B), FgD (C), or FgE (D) were added
to 1 µM MUGB in assay buffer (50 mM Tris-HCl, 100 mM NaCl, pH 7.4) at 37 °C to
preform for 10 min. To initiate the reaction, SK was added to a final concentration of
400 nM in a total volume of 100 µL and the development of fluorescence was
monitored continuously with excitation at 355 nm and emission at 460 nm. Panel (A)
appears in Cook et al. (2012) and is included for comparison. Data shown represent
minimum of two independent experiments (n = 3). Error less than 10% are not shown
for clarity of presentation.
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4.4.2 Effect of GAS cell surface Plg receptors on non-proteolytic active site
generation in Glu-Plg by variant SK
The binding of plasmin(ogen) to the bacterial cell surface via cell wall associated
proteins such as plasminogen-binding group A streptococcal M proteins (PAM, Prp),
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and streptococcal enolase (SEN)
has been well documented (Lahteenmaki et al., 2001, Walker et al., 2005, Castellino
and Ploplis, 2005). To assess the effect of these bacterial Plg receptors on SK-mediated

Figure 4.2: Effect of GAS cell surface Plg receptors on non-proteolytic active
site generation in Glu-Plg and plasminogen activation by SK variants. Glu-Plg
(200 nM) in the presence of 200 nM SEN (A), GAPDH (B), or PAM (C) were added
to 1 µM MUGB in assay buffer (50 mM Tris-HCl, 100 mM NaCl, pH 7.4) at 37 °C
to preform for 10 min. To initiate the reaction, SK was added to a final concentration
of 400 nM in a total volume of 100 µL and the development of fluorescence was
monitored continuously with excitation at 355 nm and emission at 460 nm. Data
shown represent minimum of two independent experiments (n = 3). Error less than
10% are not shown for clarity of presentation.

conformational activation of Glu-Plg, active site generation assays were performed in
the presence of recombinant GAPDH, SEN and PAM. Pre-binding Glu-Plg with either
SEN or GAPDH had no effect on active site generation in this molecule by any of the

120

Chapter 4

Site restricted streptokinase mediated plasminogen activation

SK variants (Figure 4.2A and B). Interestingly, when Glu-Plg was pre-bound with
PAM, type-2b variants (SKALAB49 and SKNS88.2), were able to non-proteolytically induce
an active site in Glu-Plg. Furthermore, the rate of active site generation mediated by
SKc, and type-2a variants (SKNS696 and SK5448) were all enhanced, producing activation
rates similar to type-1 SK (SKNZ131), which was not affected by any of the bacterial cofactors (Figure 4.2C).

4.4.3 Non-proteolytic active site generation in human plasma by variant SK
To assess Glu-Plg activation under conditions that are more physiologically relevant,
active site generation experiments were repeated in the presence of EDTA treated
human plasma pooled from several donors. When added directly to plasma, SKc
displayed the fastest rate of conformational activation of Glu-Plg, followed closely by
SKNZ131 (Type 1) (0.033 and 0.025 ΔFU/min respectively) (Figure 4.3A). SKNS696 and
SK5448 (type-2a variants) both displayed slow rates of Glu-Plg activation (0.004 and
0.002 ΔFU/min) while SKALAB49 and SKNS88.2 (type-2b variants) failed to induce an
active site in Glu-Plg (Fig. 3A). This result indicates that type-2b SK variants do not
form active complexes with Glu-Plg when circulating in plasma despite the presence of
Fg. When this experiment was repeated in the presence of PAM, type-2b variants
(SKALAB49 and SKNS88.2) were able to induce an active site in Glu-Plg (Figure 4.3B)
indicating that the presence of PAM is required for type-2b SK variants to generate
plasmin activity through conformational activation of Glu-Plg in plasma. Given that Fg
and α2-AP are present at significant concentrations in plasma, these results suggest that
active type-2b SK-Glu-Plg* complexes formed in the presence of plasma Fg are not
resistant to inhibition by α2-AP unless PAM is also available. Additionally, in the
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presence of PAM SKNS696 and SK5448 (type-2a variants) displayed 7 and 9.6 fold
increases (P < 0.01) in active site generation, while reaction rates produced by SKc and
type-1 SKNZ131 were not affected (Figure 4.3B). This suggests that interaction of GluPlg with PAM via kringle 2 produces a conformation that is favourable for activation by
cluster 2 SK variants.

Figure 4.3: Non-proteolytic active site generation in Glu-Plg and plasminogen
activation by SK variants in human plasma Pooled human plasma was added
(1:10 dilution) to 1 µM MUGB in assay buffer (50 mM Tris-HCl, 100 mM NaCl, pH
7.4) at 37 °C in the absence (A) or presence of 200 nM PAM (B). To initiate the
reaction, SK was added to a final concentration of 400 nM in a total volume of 100
µL and the development of fluorescence was monitored continuously with excitation
at 355 nm and emission at 460 nm. Data shown represent minimum of two
independent experiments (n = 3). Error less than 10% are not shown for clarity of
presentation.
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4.4.4 Regulation of soluble Plg activation activity of type-2b SK-Plg variants by
host α2-AP
To investigate how Plg ligands affect the inhibition of SK-Plg activator complexes by
α2-AP, a catalytic amount of SK (5 nM) was added to a 100 fold excess of substrate
Glu-Plg, with various combinations of Fg and PAM in the presence or absence of α2-AP
(Figure 4.4). As expected, SKc could efficiently activate substrate Glu-Plg (v = 6.9
mAB405nm.min-2) and the initial velocity for rate of activation was partially reduced by
the presence of α2-AP (2.1 mAB405nm.min-2) (Figure 4.4A). As type-2b SK variants
cannot generate an active site in Glu-Plg, no Plg activation activity was observed in the
reaction with SKALAB49 (Figure 4.4A). In the presence of either Fg or PAM, the initial
velocity of SKc mediated Plg activation was enhanced (2.2 and 2.6 fold respectively)
and was not inhibited by α2-AP (Figure 4.4B and C). As type-2b SK variants can nonproteolytically generate an active site in the presence of Fg (Figure 4.1B) and PAM
(Figure 4.2C), type-2b SK activator complexes could subsequently activate substrate
Glu-Plg in the presence of either of these ligands (v = 1.75 and 0.6 mAB405nm.min-2
respectively) (Figure 4.4B and C). However, the activity displayed by these activator
complexes was not resistant to inhibition by α2-AP (Figure 4.4B and C). When SK was
added in the presence of both PAM and Fg together, both SKc and type 2b SK
(SKALAB49) could efficiently activate substrate Plg at an initial velocity of 30
mAB405nm.min-2 and this activity was not inhibited by α2-AP (Figure 4.4D).

To determine if similar results would be observed on the bacterial cell surface, whole
GAS cells were used as an exogenous source of Plg receptors (PAM/Prp) in Glu-Plg
activation assays. In the presence of WT GAS cells (ALAB49 and NS88,2), type-2b SK
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Figure 4.4: Effect of Fg and PAM on inhibition of SK variant mediated Plg
activation ability by α2-AP SK (5 nM final concentration) was added to assay
buffer (10 mM HEPES, 150 mM NaCl, 0.01% Tween-20, pH 7.4) containing S2251 (500 µM) with combinations of (A) Glu-Plg (500 nM), (B) Glu-Plg (500 nM)
and equimolar Fg, (C) Glu-Plg (500 nM) and equimolar PAM, or (D) Glu-Plg (500
nM) with equimolar Fg and PAM. Panels A-D were tested for resistance to
inhibition with α2-AP (50 nM). Whole cell GAS experiments were conducted as
above with 1x108 cells added as a source of exogenous PAM/Prp with ΔPAM/Prp
strains used as controls. To these cells (E) Glu-Plg (500 nM) or (F) Glu-Plg (500
nM) and equimolar Fg were added. All combinations were tested in the presence or
absence of α2-AP (250 nM). The generation of Plg activation activity was monitored
at an absorbance of 405 nm at 37 °C. Data represent minimum of two independent
experiments in duplicate. Data represent mean +/- SEM.
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variants (SKALAB49 and SKNS88.2) could readily initiate substrate Glu-Plg activation. In
the presence of isogenic PAM/Prp knock-out strains (ALAB49Δpam and NS88.2prp),
type-2b SK variants could not initiate substrate Glu-Plg activation confirming the
essential role of PAM/Prp in type-2b SK-mediated Glu-Plg activation (Figure 4.4E).
α2-AP was able to inhibit Plg activation at the cell surface in these assays (Figure 4.4E).
As expected, in the presence of purified Fg, type-2b SK variants could initiate Glu-Plg
activation in the presence of both WT and knockout GAS strains (Figure 4.4F).
Additionally, in the presence of Fg and WT GAS cells, cell surface Plg activation
activity was not inhibited by α2-AP, whereas in the presence of Fg and ALAB49Δpam
and NS88.2Δprp cells, Glu-Plg activation activity was inhibited (Figure 4.4F). This data
demonstrates a critical role for both PAM/Prp and Fg as synergistic cofactors in the
generation of unregulated Plg activation activity on the surface of GAS strains
expressing type-2b SK.

4.4.5 The effect of fibrin on the activity of type-2b SK variants
Therapeutic SK is considered a fibrin-independent agent because it rapidly generates
plasmin in the blood at sites distant from fibrin clots. While type-2b SK variants do not
readily activate circulating Glu-Plg, we investigated if this SK variant could activate
conformationally modified Glu-Plg when bound to fibrin. Fibrin clots were produced in
vitro by the addition of thrombin and calcium chloride to purified human Fg. Glu-Plg
was then bound to fibrin and activated by the addition of SK variants (Figure 4.5). In the
absence or presence of fibrin, SKc could readily activate Glu-Plg, while type-2b
variants (SKALAB49 and SKNS88.2) could only activate Glu-Plg that was bound to fibrin
(Figure 4.5A and B)
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Figure 4.5: Generation of amidolytic activity and resistance to inhibition of
variant SK-Plg complexes formed in the absence or presence of a fibrin clot (A)
Complex formation was initiated by addition of variant SK (40 nM) to assay buffer (10
mM HEPES, 150 mM NaCl, 0.01% Tween-20, pH 7.4) containing Glu-Plg (20 nM)
and chromogenic substrate S-2251 (500 µM) then monitored at A405. (B) Fibrin clots
were formed for 4 h at RT in a 96-well plate by the addition of thrombin (0.8U/mL)
and CaCl2 (20 mM) to recombinant fibrinogen (3 µM). Plg (20 nM) was bound to the
fibrin clots for 1 h at 37°C. Bound Plg was washed before complex formation was
initiated and monitored at A405 by addition of variant SK (40 nM) to assay buffer (10
mM HEPES, 150 mM NaCl, 0.01% Tween-20, pH 7.4) chromogenic substrate S-2251
(500 µM) at 37°C. (C) The ability of SK-Plg complexed formed in the presence of
fibrin were also assessed for susceptibility to inhibition by α2-AP (200 nM). Data
represent three independent experiments (n = 3). Data represent mean +/- SEM

As type-2b SK variants were able to generate Plg activation activity in the presence of
fibrin, we compared the capacity of SKc and type-2b SK variants to lyse plasma clots
produced from human plasma. As expected SKc displayed efficient fibrinolytic activity
(Figure 4.6A). Both type-2b SK proteins (SKALAB49 and SKNS88.2) displayed fibrinolytic
activity with potency similar to that of SKc (Figure 4.6A). Additionally, plasma
fibrinogen depletion during these activation experiments in plasma was high in SKc
mediated lysis reactions (~99 %) but was significantly reduced in both SKALAB49 (P <
0.05) and SKNS88.2 (P < 0.01) mediated lysis reactions (~40% and ~19% respectively)
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(Figure 4.6B). Taken together, these data indicate the plasmin activity generated by
type-2b SK variants is restricted to the surface of the fibrin clot.

Figure 4.6: Induction of plasma clot lysis by SK variants and capacity to deplete
plasma Fg (A) Fibrin clots were formed in pooled EDTA treated human plasma by the
addition of thrombin (0.8U/mL) and CaCl2 (20 mM). Variant SK molecules were then
suspended in fresh plasma to a final concentration of 50 nM over the plasma clot and
lysis was monitored by measuring a reduction in turbidity at 340 nm at 37°C (B) Group
C SK or type-2b SK variants (each at a concentration of 5 or 50 nM) were added to
plasma for 30 min at 37°C. Plasmin activity was inhibited by the addition of aprotinin
(20 µM) and plasma fibrinogen concentration was measured by the sodium sulphite
precipitation method. Results are standardised to control reactions, which lacked SK.
Data represent three independent experiments in duplicate. Data represent mean +/SEM. Asterisks indicate statistical significance as determined by one-way ANOVA, P
< 0.05 (*) and P < 0.01 (**).
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4.5 Discussion

Plasmin is a potent protease with many important physiological functions including
fibrin clot dissolution, tissue repair/remodelling and cell migration (Plow et al., 1995a).
Regulation of the Plg activation system is essential for the maintenance of homeostatic
function and the conversion of Plg into plasmin (the critical first step involved in this
process) is a major regulatory target (Castellino and Ploplis, 2005). The conformation of
the Glu-Plg molecule greatly influences the regulation of Plg activation. Glu-Plg
conformation may be altered upon interaction with ligands, primarily through lysine
binding sites located within the kringle domains, and it is now well recognised that
these interactions play a central role in modulating key steps in Plg activation by host
and bacterial Plg activators (Castellino and Ploplis, 2005, Gladysheva et al., 2007,
Rijken and Lijnen, 2009).

Fg is known to enhance activation of human Plg by uPA, tPA and SK, however the
exact mechanism for this is not defined (Chibber et al., 1985, Cesarman-Maus and
Hajjar, 2005). While full length Fg is relatively inert in circulation, fibrin(ogen)
fragments that enhance Plg activation can be generated through numerous physiological
processes; Fg proteolysis by thrombin during fibrin deposition, fibrinolysis and direct
Fg proteolysis by SK-Plg activator complexes at the site of bacterial infection
(Yakovlev et al., 2000, Varadi and Patthy, 1983, Chibber et al., 1985, Medved and
Nieuwenhuizen, 2003). To differentiate the effect of full length Fg and Fg fragments on
Glu-Plg activation by SK variants, the plasmin inhibiting, flurogenic active site titrant
(MUGB) was used to measure SK-Plg* activator complex formation. Our results
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indicated that full length Fg and FgD accelerated the formation of SK-Plg* for all SK
variants and also permitted type-2b SK to generate an active site in Glu-Plg (Figure
4.1B and C and Figure 4.4B). While Glu-Plg and Fg molecules are normally relatively
inert in circulation, the interaction between SK, Glu-Plg and Fg must therefore permit a
series of conformational modifications that expose binding sites that are not present in
native Glu-Plg and Fg molecules. This supports the previously proposed hypothesis that
SK, Plg and Fg can interact to form a tri-molecular complex (McArthur et al., 2012,
Takada and Takada, 1989, Wang et al., 1995b).

Bacterial Plg receptors interact with plasmin(ogen) to acquire protease activity at the
cell surface (Lahteenmaki et al., 2001). However, the influence of bacterial ligands on
Glu-Plg conformation and the subsequent effect on activation kinetics by SK variants
has not been assessed. PAM binds to Glu-Plg via interaction with the Plg K2 but this
bacterial receptor is restricted to skin tropic, emm pattern D GAS strains (Svensson et
al., 1999). SEN and GAPDH are present in all GAS isolates and display weaker Glu-Plg
affinity binding to K1 and K5 through lysine-dependent interactions (Sanderson-Smith
et al., 2012). SEN and GAPDH do not affect the generation of the SK-Plg* activator
complex for any of the SK variants (Figure 4.2A and B). PAM significantly enhanced
active site generation in Glu-Plg by cluster 2 SK variants and more importantly allowed
the non-proteolytic generation of an active site in Glu-Plg by type-2b SK (Figure 4.2C
and Figure 4.4C). This suggests that differences in the conformational state adopted by
Glu-Plg upon interaction with different ligands effects the potential of these ligands to
enhance active site generation by SK. Therefore it is possible that some bacterial ligands
may play a role in Plg activation while others may only function to bind Plg or plasmin.
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Interestingly, Plg/plasmin bound to the bacterial cell surface has also been shown to
function as a bridging molecule facilitating bacterial adherence and internalisation of
bacteria into keratinocytes/epithelial cells (Siemens et al., 2011, Pancholi et al., 2003).
As this process occurs independently of protease activity, Plg receptors with no role in
Plg activation may be useful for such purposes.

While the conformation of Glu-Plg plays an important role in the regulation of plasmin
generation, the primary regulator of plasmin activity is α2-AP. The inhibitor α2-AP
binds to plasmin through an initial interaction with the lysine binding sites in the kringle
domains which is then followed by a slower irreversible covalent modification of the
active centre (Cederholm-Williams, 1979, Gerber et al., 2010). SKc induces an active
site in Glu-Plg by the insertion of Ile1 of SKc into the Glu-Plg amino-terminal binding
cleft, which forms a crucial salt linkage with Asp740, in place of Val562 of Plg (Wang et
al., 1999). SKc-Plg* activator complexes are resistant to α2-AP inhibition which is
thought to be the result of SKc occupying or blocking critical lysine binding sites in Plg
and/or through steric shielding of the active site (Cederholm-Williams, 1979). The
inability of type-2b SK to induce an active site in Glu-Plg and the fact that type-2b SKplasmin activator complexes are inhibited by α2-AP may suggest these variants fail to
block α2-AP binding to specific lysine binding sites in Plg or they are unable to
correctly position the N-terminal region of the type-2b SK molecule within Plg (Cook et
al., 2012). While type-2b SK-Plg* activator complexes formed in the presence of either
Fg or PAM separately can be inhibited by α2-AP, in the combined presence of PAM and
Fg, activator complexes were resistant to α2-AP inhibition (Figure 4.4D). This complex
of multiple ligands may shield the active site by restricting access for α2-AP and/or may
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occupy the lysine binding sites of Plg that are required for initial α2-AP binding,
functions that cannot be imparted by the presence of each ligand alone. As such, type-2b
SK variants require additional ligands to assist with the conformational rearrangement
of Glu-Plg to induce a proteolytically active site and further additional ligand
combinations are required to protect the newly formed active site from inhibition by α2AP. This work provides the first comprehensive demonstration of the functional
relationship between GAS SK variants, bacterial and host Plg binding ligands and α2AP.

It has long been hypothesised that SK-mediated Plg activation, and subsequent
recruitment of plasmin activity to the GAS cells surface, acts to prevent plasmin
inhibition by α2-AP. By characterising this delicate interplay between bacterial derived
SK variants and cell surface receptors such as SEN, GAPDH, M proteins (PAM and
Prp) and host proteins such as Fg, fibrin and α2-AP, we have been able to define a
possible mechanism for how these phenotypic variations influence the pathogenesis
GAS strains (see Figure 4.7). While type-1 and type-2a SK variants display Plg
activation/inhibition mechanisms that are similar to SKc, GAS strains expressing type2b SK have evolved a distinct and unique system for the interaction with the human Plg
activation system that limits soluble plasmin generation. Unlike other SK variants, type2b SK proteins cannot conformationally induce an active site in Glu-Plg when it has a
closed conformation. Type-2b SK can form an activator complex with plasmin and with
Plg-PAM or Plg-Fg complexes, however these complexes are readily inhibited by α2AP (Figure 4.7A, B, C and D). Type-2b SK will form an activator complex that is
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resistant to α2-AP inhibition when Glu-Plg is bound by a combination of both PAM and
Fg or when Glu-Plg is bound to fibrin (Figure 4.7E and F). As a result, Plg activation by

Figure 7. Schematic diagram summarising the site/surface restricted activation of
plasminogen by type-2b SK expressing GAS strains. Cluster type-2b SK cannot
induce an active site in Glu-Plg. Free complexes of cluster type-2b SK with plasmin (A)
or Plg/plasmin-Fg (B) are inhibited by α2-antiplasmin. Similarly complexes of cluster
type-2b SK with Plg/plasmin with PAM are also inhibited by α2-antiplasmin (C and D).
Cluster type-2b SK can only generate unregulated plasmin activity when a tri-molecular
complex of SK-Plg-fibrinogen is bound to the cell surface PAM (E) or Plg is bound to
fibrin (F). Therefore, plasmin activity generated by cluster type-2b SK in restricted to
the bacterial cell surface or to fibrin thrombi.

type-2b SK will be limited by the availability of cofactors and will restrict plasmin
activity to specific microenvironments such as the bacterial cell surface and to the fibrin
clot surface. This Plg activation mechanism displayed by type-2b SK has similarities to
the Plg activation activity of staphylokinase produced by Staphylococcus aureus. Both
activators fail to generate soluble plasmin activity, as fluid-phase activator complexes
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are readily inhibited by α2-AP. S. aureus is a ubiquitous skin coloniser. Similarly,
epidemiological studies have shown the type-2b ska linage to be largely restricted to
pam positive, emm pattern D GAS strains which have a strong tendency to cause skin
infections (Kalia and Bessen, 2004). Therefore, these characteristics could limit
systemic bacterial dissemination as there would be low activation of metalloproteases
and less degradation of extracellular matrix components (Lu et al., 2011). Plasmin
activity that is restricted to the cell surface could promote bacterial persistence in the
skin by facilitating evasion of innate immune defences, producing delayed wound
healing and allowing transmission to new hosts (Bessen and Tengra, 2010).

Bacterial activators with “fibrin specific” Plg activation activity such as staphylokinase
and a truncated form of SKc (SKΔ59) have been proposed as potential thrombolytic
therapeutics with improved fibrinolytic activity (Reed et al., 1999, Collen and Lijnen,
1994). The fibrin selectivity displayed by these activators results from 1) a requirement
of plasmin to generate a functional Plg activation complex and 2) free activator
complexes being inhibited by α2-AP, thereby restricting plasmin activity to the fibrin
clot environment. Similar to these activators, soluble type-2b SK activator complexes
are inhibited by α2-AP. However, unlike staphylokinase and SKΔ59, type-2b SK is not
reliant on trace plasmin present in low quantities at the clot surface to produce an
activator complex. Type-2b SK activators are capable of activating fibrin bound Glu-Plg
which is present in much higher quantities when compared to free plasmin. As the
fibrinolytic potency of type-2b SK variants was comparable to SKc (Figure 4.6A) but
with significantly reduced Fg depletion (Figure 4.6B), these variants could be useful for
thrombolytic therapeutic applications.
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Proteins from Streptococcus pyogenes
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Preface
Since the discovery of streptococcal fibrinolysis in the 1930s and subsequent
therapeutic potential of SK in the mid-1950s, a vast amount of research has focused on
elucidating the mechanism of SK activity. However, a definitive description of the
molecular mechanism of SK mediated Plg activation is still yet to be determined. This
is partially due to the lack of crystal structure data combined with the subtle
complexities involved in functionally characterising the activation of Glu-Plg by SK
using biochemical techniques. A recent shift in focus to examining the role of SK
polymorphism in GAS, has discovered that a myriad of phenotypic differences are
displayed by these SK variants and generated new approaches to pinpoint specific
amino acid residues involved in the mechanism of SK activity. The purpose of this
chapter was to highlight how chimeric versions of GAS SK variants with known
phenotype could be used a tool to determine the specific domains regions responsible
for the molecular basis of SK phenotypic differences and applied to the SK mechanism
in its entirety.

Publication: Cook, S. M., Walker, M. J. and McArthur, J. D., (2014) “Elucidating the
molecular mechanism of streptokinase function through the construction chimeric
proteins from Streptococcus pyogenes streptokinase variants” (Manuscript prepared)
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5.1 Abstract
Streptokinase (SK) is a bacterial plasminogen activator, secreted by β-hemolytic group
A, C and G strains of the genus Streptococcus. Among group A streptococcal isolates,
SK gene sequences (ska) are polymorphic and can be grouped into two distinct
sequence clusters (termed cluster type-1 and cluster type-2) with cluster type-2 being
further divided into sub-clusters type-2a and type-2b. GAS SK variants display distinct
phenotypic differences. Type-1 SK and type-2a SK variants generally display
similarities to the elucidated mechanism for SKc, while type-2b SK display a 29-35 fold
reduction in affinity for Glu-Plg, cannot activate Glu-Plg via conformational
rearrangement, are inhibited by α2-antiplasmin and require the presence of additional
ligands to generate activity. With the discovery of these differences it has now become
possible to utilise this information to identify regions of the molecule that are critical for
Plg activation function. To determine how specific SK domains contribute to
phenotypic differences, hybrid ska genes were constructed in which the α, β and γ
domain encoding regions of ska were exchanged between type-1 (skaNZ131) and type-2b
(skaALAB49) alleles. In this study, far-UV circular dichroism spectroscopy indicated that
wild-type SK variants (SKALAB49, SKNZ131 and SKc) and SK chimeras (SKβT1, SKβT2b,
SKγT1 and SKγT2b) have similar secondary structures. While, α domain swap chimeras
(SKαT1 and SKαT2b) displayed a significant increase in α-helicity when compared to
wild-type SK proteins. Preliminary characterisation of the role of the SK α domain
using the chimeric mutant containing the α domain from the active SKNZ131 molecule
combined with β and γ domains of SKALAB49 was conducted. This chimera (SKαT1) was
able to generate an active site in Glu-Plg and form an activator complex that could
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activate substrate Glu-Plg, albeit at a reduced rate compared to the parental type-1 SK
variant (9.4 fold slower rate of active site generation). Taken together these data
indicate that amino acid residues within the α domain affect the ability of SK variants to
generate an active site in Glu-Plg and also influence the overall structure of the protein.
Using variant SK proteins that display known phenotypic differences will allow the
identification of regions that are critical for function. This information will produce a
greater understanding of the molecular mechanism of SK mediated Plg activation.
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5.2 Introduction

SK from the group C streptococcal isolate H46A is the most frequently characterised
SK. To date, the majority of expression, purification, structural and functional
characterisation studies have been conducted on SK from group C streptococcus due to
its extensive use as a thrombolytic therapeutic (McArthur et al., 2012). Group A
streptococcus (GAS; Streptococcus pyogenes) secrete SK which generates soluble
plasmin activity and facilitates the acquisition of protease activity to the bacterial cell
surface (McArthur et al., 2012). While SK from group C streptococcal isolates display
minimal genetic diversity, SK from human specific GAS isolates display considerable
genetic variability (Kalia and Bessen, 2004, McArthur et al., 2008, Kapur et al., 1995,
Zhang et al., 2012, Cook et al., 2012).

Genetic variability in GAS confers distinct phenotypic differences between SK variants.
Type-1 and type-2a GAS SK variants generally display phenotypic similarity to the
therapeutic group C SK variant; these include a high affinity for native Glu-Plg, an
ability to form a functional activator complex with Glu-Plg independent of additional
cofactor ligands, and resistance to host inhibitory mechanisms such as α2-antiplasmin .
Conversely, type-2b SK variants display a 29-35 fold reduction in affinity for Glu-Plg,
cannot activate Glu-Plg via conformational rearrangement, are not resistant to inhibition
by α2-antiplasmin and require the presence of additional ligands such as fibrinogen (Fg)
or Plg-binding group A streptococcal M protein (PAM) to overcome host regulation
mechanisms and generate proteolytic activity. These phenotypic differences displayed
by GAS type-1 and type-2 SK variants have also been shown to affect GAS
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pathogenesis (McArthur et al., 2008, Cook et al., 2012, Zhang et al., 2012, Russell and
Facklam, 1975).
Nevertheless, further research on the specific structural and biochemical alterations
responsible for these phenotypic changes is required to increase our understanding of
the molecular basis for SK-mediated Glu-Plg activation. SK variants with known
phenotypic differences can be used to elucidate amino acid regions that are important
for function through the generation of chimeric SK proteins. In this study, α, β and γ
domains were exchanged between type-1 (SKNZ131) and type-2b (SKALAB49) SK variants
producing all six possible chimeric combinations. Structural and biochemical
characterisation of these chimeric proteins has revealed a role for inter-domain
interactions in co-ordinating native SK structure and highlights the α domain as a
critical region involved in the non-proteolytic generation of an active site in Glu-Plg.
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5.3 Materials and Methods

5.3.1 Bacterial strain, culture conditions and reagents
GAS isolates NZ131 (The New Zealand Reference Culture Collection, Institute of
Environmental Sciences and Research), ALAB49 (Svensson et al., 2000) and
S. dysgalactiae subsp. equisimilis strain H46A (Christensen, 1945) were used in this
study. Streptococcal strains were routinely cultured at 37°C on horse-blood agar
(Biomerieux, Sydney, NSW, Australia) or in static liquid cultures of Todd-Hewitt broth
(BD, Sydney, NSW, Australia) supplemented with 1% (w/v) yeast extract (Oxoid,
Adelaide, SA, Australia) (THY medium). E. coli strains JM109 and M15[pREP4], were
used as hosts for plasmid construction and protein expression respectively and were
cultured at 37°C in Luria-Bertani broth. Where appropriate, antibiotics were used for
selection at the following concentrations: chloramphenicol, 100 μg.mL-1; kanamycin, 50
μg.mL-1; and ampicillin, 100 μg.mL-1. Glu-Plg, plasmin, and α2-AP were purchased
from Haematologic Technologies, Essex Junction, VT, USA. The chromogenic
substrate H-D-Val-Leu-Lys-pNA·2HCl (S-2251) was obtained from Chromogenix,
Mölndal, Sweden and 4-methylumbelliferyl p-guanidinobenzoate (MUGB) was from
Marker Gene Technologies, Inc., Eugene, OR, USA.

5.3.2 Cloning strategy for construction of chrimeic ska allele
To fragment skaALAB49 and skaNZ131 and construct ska domain swap chimeras, wild-type
ska alleles were removed from the expression vector pQE-30 by restriction digestion
with BamHI and PstI and sub-cloned into pHSGXceIS1 which is a modified pHSG398
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generated in our laboratory produced by deleting a 250 bp fragment, which removed the
NspI restriction site from the plasmid backbone (Appendix 7). Once sub-cloned into
pHSGXceIS1, the region encoding domain could be removed from full length ska via
various combinations of restriction enzymes (Figure 5.1). DNA fragments were
separated by 0.85% agarose gel electrophoresis and gel purified using Wizard® SV Gel
and PCR Clean-up System (Promega, USA) according to manufacturer specifications.
Purified domain fragments were cloned into the corresponding purified DNA fragment
containing the two residual domains of the alternate gene in pHSGXceIS1 construction
vector (Appendix 7). Once each chimeric ska had been constructed, the full length
chimeric gene was sub-cloned into pQE-30 for DNA sequencing analysis and
subsequent protein expression

Figure 5.1: Strategy for fragmentation and construction of domain swap chimeras

between type-1 and type-2b variants of ska. The restriction sites labelled in this
schematic were used to release domains separately and clone each into the opposing ska
allele contained in pHSGXceIS1 for the construction of chimeras. After construction
chimeric ska alleles were sub-cloned into pQE-30 for recombinant protein expression.
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pska𝜷T2

pska𝜷T1

Figure 5.2: Schematic example of the cloning strategy used to create chimeric SK
proteins. In this example the ska β domain fragment is released from pSCSKNZ131 and
pSCSKALAB49 via restriction digestion with NspI and XmnI. This digest produces two
DNA fragments; an ~2788 bp fragment containing the plasmid vector and the α and γ
encoding regions of ska and a ~432 bp fragment which encodes the ska β domain. As
indicated by the arrows, the fragment encoding the β domain is ligated into the plasmid
containing the α and γ domains of the other allele. This strategy was employed to
construct all six chimeric conformations of type-1 and type-2b ska. This schematic
outlines the construction of the β domain chimeras. All other chimeras and relating
figures are shown in an additional publication (Cook, 2008).
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5.3.3 Expression and purification of recombinant SK protein
SK chimeric variants were cloned, expressed and purified as previously described
(Cook, 2008, Cook et al., 2012) SKαT1, SKβT2b, SKγT1 and SKγT2b were expressed and
purified under native conditions while SKαT2b and SKβT1 were insoluble and thus
expressed and purified under denaturing conditions (Appendix 2.4) (Cook, 2008). SK
variants further utilised in biochemical and functional analysis underwent secondary
purification, as outlined in Chapter 2. See Appendix 2.1 for an example purification of
chimera SKαT1.

5.3.4 Far-UV circular dichroism (CD) spectroscopy
CD spectroscopy was performed using a J-810 spectropolarimeter (Jasco, Tokyo, Japan)
at room temperature. Samples were prepared in 10 mM phosphate buffer (pH 7.4) to a
final concentration of 100-300 µg.mL-1. Spectra representing the average of six scans
were collected from 190 nm to 250 nm at 1 nm intervals, with a path length of 1 mm.
Molar residue ellipticity (Ө) was calculated using the following formula: [Ө] = Ө x 100
x molecular weight (kDa)/concentration (mg.mL-1) x path length x number of amino
acids.

5.3.5 Non-proteolytic active site generation in Glu-Plg
Non-proteolytic active site generation in Glu-Plg by SK variants was examined using
the

fluorescent

active

site

MUGB

in

a

POLARstar

Omega

fluorescence

spectrophotometer (BMG LABTECH, Ortenberg, HE, Germany). Glu-Plg (200 nM)
was added to a black 96-well microtitre plate containing 1 μM MUGB in assay buffer
(50 mM Tris-HCl, 100 mM NaCl, pH 7.4) at 37°C. To initiate the reaction, SK was
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added to a final concentration of 400 nM in a total volume of 100 μL and the
development of fluorescence was monitored continuously with excitation at 355 nm and
emission at 460 nm. Data was normalised by subtracting a control reaction of all protein
species without the addition of SK and 1 μM MUGB. This accounted for intrinsic
fluorescence associated with buffer and protein species, as well as non-specific
hydrolysis of MUGB over the course of reactions. To calibrate relative fluorescence
units and convert these measurements to [SK-Plg*], standard curves of known
concentrations of the fluorescent product 4-methylumbelliferone were constructed. The
fluorescence measurements were made in the assay buffer (50 mM Tris-HCl, 100 mM
NaCl, pH 7.4) at 37°C containing 400 nM SK and 200 nM Glu-Plg, with the same
instrument settings as MUGB experiments.

5.3.6 Plasminogen activation by variant SK-plasmin complexes
The capacity of variant SK-plasmin complexes to activate substrate Plg was assessed.
SK was pre-formed with plasmin at 37 °C for 5min. SK-Plasmin complexes (5 nM final
concentration) were diluted in assay buffer (10 mM HEPES, 150 mM NaCl, 0.01%
Tween-20, pH 7.4) containing a large excess of Glu-Plg (500 nM) and S-2251 (500 µM)
in a total volume of 100 µL. The exponential generation of plasmin was monitored by
change in absorbance at 405 nm and measured over 35 min at 37°C using a SpectraMax
Plus 384 spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).
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5.4 Results
To characterise the phenotypic differences displayed by SK proteins from different
GAS isolates, chimeric variants encompassing the six possible domain conformations of
a cluster type-1 ska (skaNZ131) combined with a cluster type-2b ska (skaALAB49) were
constructed and expressed as recombinant proteins. Recombinant chimeric SK proteins

Figure 5.3: SDS-PAGE analysis composite of expressed recombinant chimeric SK
proteins used in this study. SKαT1, SKβT2b, SKγT1 and SKγT2b were expressed and
purified under native conditions while SKαT2b and SKβT1 were insoluble and thus
expressed and purified under denaturing conditions (A) Variant SKαT1 (lane 1), SKαT2b
(lane 2), SKβT1 (lane 3), SKβT2b (lane 4), SKγT1 (lane 5) and SKγT2b (lane 6) were
separated by 10% SDS-PAGE under reducing conditions. Molecular weight standards
in kDa are indicated.

were analysed for size and purity by SDS-PAGE (Figure. 5.3). Proteins ranged in size
from 44 to 49 kDa, which is similar to the sizes observed for native SK proteins present
in GAS culture supernatants and recombinant wild-type proteins (McArthur et al., 2008,
Cook et al., 2012). However, it was observed during the expression and purification of
these chimeric proteins under native conditions, that SKαT2b and SKβT1 were insoluble.
Consequently, these proteins were effectively re-purified under denaturing conditions,
however all attempts to re-fold these proteins were unsuccessful (data not shown). Due
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to time constraints further secondary structural analysis was undertaken on the limited
soluble portion of these proteins from these re-folding attempts and further biochemical
analyses were limited to the type-1 SK α domain containing chimera SKαT1. For use as
positive controls SK from the group C streptococcal isolate H46A (SKc) and wild-type
parental GAS variants (SKNZ131 and SKALAB49) were also expressed and purified as
shown previously in Chapter 2.

5.4.1 Determination of secondary structure by far-UV circular dichroism (CD)
spectroscopy
Far-UV circular dichroism spectroscopy was utilised to compare the secondary
structural elements of wild type SK cluster type-1 (SKNZ131), cluster type-2b (SKALAB49)
and group C (SKc), as well as the domain swap chimeras. Despite significant
differences in amino acid composition, wild type and chimeric SKβT1, SKβT2b, SKγT1 and
SKγT2b variants had similar molar residue ellipticity spectra across the full range of
wavelengths measured (Figure 5.4) (Cook et al., 2012). The output spectra observed
was typical of that expected for an amalgamation of α helical (minima at ~ 210 nm
maxima at ~190 nm) and anti-parallel β sheet (minima at ~215 nm and maxima at 195
nm) spectra indicative of the known structure of SK (Wang et al., 1998). However,
when the type-1 (SKNZ131) α domain was incorporated with the β and γ domains of
cluster type-2b (SKALAB49) or the type-2 (SKALAB49) α domain was incorporated with the
β and γ domains of cluster type-1 (SKNZ131) these SK chimeras (SKαT1 and SKαT2b)
showed an increase in α-helicity when compared to the parental SK protein (Figure 2.5).
These data suggest that inter-domain interactions involving the α domain influence the
structure of the SK molecule.
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Figure 5.4: Far-UV circular dichroism spectroscopy analysis of recombinant SK
proteins used in this study. Wild-type SK variants (SKALAB49, SKNZ131 and SKc) and
SK chimeras (SKβT1, SKβT2b, SKγT1 and SKγT2b) have similar molar residue ellipticity
values and CD out-put spectrum structure across the full range of wavelengths
indicating no differences in secondary structure. While, α domain swap chimera (SKαT1
and SKαT2b) displayed structural changes with a significant increase in α-helicity when
compared to wild-type SK proteins

5.4.2 Non-proteolytic active site generation in Glu-Plg by variant SK
Active site generation (SK-Plg* formation) in Glu-Plg by SK variants and chimeras was
examined

using

the

fluorescent

active

site

titrant

4-methylumbelliferyl

p-

guanidinobenzoate (MUGB). This allowed generation of SK-Plg* to be measured
through Conformational activation (Pathway I), independent of direct proteolytic
activation encountered in the presence of plasmin (Pathway II) (Figure 1.5 and Figure
1.6)(Boxrud et al., 2004). SKNZ131 (type-1 variant) generated the greatest number of
active sites at the fastest rate (~5 min) followed by SKc (group C) (Figure 5.4). As
expected, SKALAB49 (type-2b variant) could not non-proteolytically generate an active
site in Glu-Plg (Figure 5.4) (Cook et al., 2012). These data indicate that type-2b SK
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variants rely on the presence of plasmin to generate activity via Pathway II (Cook et al.,
2012). Interestingly when the α domain from SKNZ131 was incorporated with the β and γ
domains of SKALAB49 to produce SKαT1, the chimera was able to generate an active site
in Glu-Plg through non-proteolytic mechanisms (Figure 5.4). This suggests that specific
residues within the α domain of SK are required for the generation an active site in GluPlg via non-proteolytic mechanisms (Pathway I).

[SK-Plg*] (nmol)

200

SKNZ131
SKc
SKT1

150

SKALAB49

100
50
0
0.0

2.5

5.0

7.5 10.0 12.5 15.0 17.5 20.0

Time (min)

Figure 5.5: Non-proteolytic active site generation in Glu-Plg by SK variants and
influence of Glu-Plg conformation on SK-Plg* generation. Glu-Plg (200 nM) was
added to 1 µM MUGB in assay buffer (50 mM Tris-HCl, 100 mM NaCl, pH 7.4) at
37 °C. To initiate the reaction, SK was added to a final concentration of 400 nM in a
total volume of 100 µL and the development of fluorescence was monitored
continuously with excitation at 355 nm and emission at 460 nm.

5.4.3 Plasminogen activation by variant SK-plasmin-plasmin activator complexes
The ability of variant SK-plasmin complexes to sequester and activate substrate Plg was
determined by mixing preformed, stoichiometric SK-plasmin activator complexes with
a large excess of substrate Glu-Plg and monitoring the generation of plasmin activity
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using the chromogenic substrate, S-2251. All variant SK-plasmin complexes examined
in this study were capable of efficient substrate Plg activation (Figure 5.5). The fastest
rates of substrate Plg activation activity were observed for group C SK (SKc) and type-1
SK (SKNZ131). Similar rates of Plg activation observed for type-2b SK (SKALAB49) and
the SK chimera (SKαT1) indicate that the chimeric protein is able to form an activator
complex with plasmin, and that substrate Plg recognition is not influenced by the
modified secondary structure of the chimera. Taken together, these data suggest
substrate Plg recognition/activation is largely mediated by interactions with the β and γ
domains of SK.
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Figure 5.6: Plasminogen activation by variant SK-plasmin activator complexes. SK
was pre-formed with plasmin at 37 °C for 5min. SK-Plasmin complexes were diluted to
5 nM final concentration in assay buffer (10 mM HEPES, 150 mM NaCl, 0.01%
Tween-20, pH 7.4) containing Glu-Plg (500 nM) and S-2251 (500 µM). The generation
of Plg activation activity was monitored at an absorbance of 405 nm at 37 °C.
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5.5 Discussion

GAS strains produce SK proteins with distinct genetic and phenotypic variability (Kalia
and Bessen, 2004, McArthur et al., 2008, Kapur et al., 1995, Zhang et al., 2012, Cook
et al., 2012). While type 1 and type 2a SK variants from GAS possess the hallmark
characteristic ability of being able to generate an active site in Glu-Plg through nonproteolytic conformational activation, recent research from our laboratory has shown
that type-2b SK variants display distinct phenotypic differences (Cook et al., 2012).
GAS SK variants with known phenotypic differences but limited amino acid sequence
diversity can be used to elucidate protein regions that are important for function through
the generation of chimeric SK proteins.

In this study, chimeric SK proteins were produced by exchanging α, β and γ domains
between two phenotypic distinct variants, type-1 (SKNZ131) and type-2b (SKALAB49).
When overexpressed as recombinant proteins in E. coli, four chimeric variants (SKαT1,
SKβT2b, SKγT2b and SKγT1) were soluble and were readily purified while SKαT2b and
SKβT1 (both containing the SKALAB49 α domain linked to the β of SKNZ131), were
insoluble and could only be purified under denaturing conditions. This suggests the
arrangement of a type-2b α domain being followed by a type-1 β domain produces a
structural change that affects the solubility of these chimeric proteins. The β domains of
type-1 SK (SKNZ131) and type-2b SK (SKALAB49) share only 63% sequence identity.
Therefore it is possible that non-conserved amino acid changes (>25) in the β domain of
SKNZ131 are preventing interactions with SKALAB49 α domain that are required to

150

Chapter 5

Role of the ska α domain in type-1 and type-2b SK phenotype in GAS

maintain the structural stability of the SK protein. However, no crystal structure data is
currently available for SK in an unbound native conformation and therefore the residues
involved in stabilising native domain folding, or potential inter-domain interactions
cannot be confirmed.

Interestingly, these results are in contrast to those generated by Zhang et al., 2013 who
produced similar chimeric proteins using a type-1 SK variant (SKNS931) and a type-2b
SK variant (SKNS88.2). Under the conditions used in their experiments, all recombinant
chimeric proteins were soluble and displayed similar secondary structure. It is therefore
possible that the amino acid differences between the allelic variants used by Zhang et
al., (2013) and those used in this study may be residues influencing the native structure
of SK. Comparison of amino acid sequences for these variants shows that type-1
SKNS931 displays 93.7% amino acid sequence identity to SKNZ131 of which 17 of the 21
total amino acid sequence variations are non-conserved. Type-2b SK variants (SKNS88.2
and SKALAB49) display a greater level of homology (97.6% amino acid sequence
identity), however non-conserved changes within this amino acid variation can also be
observed (8 of 9) (Figure 3.1). While there are numerous non-conserved amino acid
variations between these different SK proteins, these changes do not produce detectable
functional differences in these proteins (Cook et al., 2012, Zhang et al., 2012).
Therefore, these specific residues may have a role in maintaining the structure of free
SK. These data further indicate that inter-domain interactions potentially co-ordinate the
overall structure of the SK molecule when not bound to Plg. This is an interesting
hypothesis as the domains of SKc have been thought to be independently folded within
the native molecule and additionally this supports the proposition that selection pressure

151

Chapter 5

Role of the ska α domain in type-1 and type-2b SK phenotype in GAS

may be placing structural constraints on SK (Conejero-Lara et al., 1996, Kapur et al.,
1995). More research is required in support of this and such studies could reveal
important structural information on the free SK protein.

The α domain of SK has a critical role in SK function and is involved in non-proteolytic
generation of the active site in Glu-Plg, substrate Plg activation activity, SK affinity for
Plg and susceptibility to α2-AP inhibition (Fay and Bokka, 1998, Wang et al., 1999a,
Rodríguez et al., 1995, Young et al., 1995, Sazonova et al., 2004, Boxrud et al., 2000,
Mundada et al., 2003, Sundram et al., 2003, Kim et al., 2002). For SK to induce an
active site in Glu-Plg, the SK Ile1 residue must be positioned within the Glu-Plg
molecule so that it can form a salt bridge with Asp740 of Glu-Plg (Wang et al., 1999a).
Amino acid changes in the 1-59 region (or any other region that elicits structural
modifications) may prevent the correct positioning of the N-terminal fragment within
the SK-Plg complex, thereby preventing (or slowing) non-proteolytic active site
formation in Glu-Plg. Confirming this, site directed mutagenesis studies conducted on
these regions in SKc have revealed that mutations in the αβ1 strand (residues 17–26) of
the α domain markedly reduces the formation of an active complex with Glu-Plg and
also renders the mutant SK-Plg/plasmin complexes severely defective in activating
substrate Plg (Lee et al., 1997, Kim et al., 2000, Mundada et al., 2003, Fay and Bokka,
1998). Therefore, the type-2b specific, non-conserved amino acid differences in this
region of SKNS88.2 and SKALAB49 (e.g. Ile/Thr20, Asp/Asn30, Lys/Gln31, Lys/Asp32,
Phe/Ser34 and Asn/Lys36) could be responsible for the inability of these type-2b SK
proteins to induce an active site in Glu-Plg (Figure 3.1). Additional non conserved
amino acid changes in these proteins (such as Gln/Arg45, Pro/Ser71 and Arg/Gln86) may
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also influence the type-2b SK phenotype. Site directed mutagenesis studies in SKc have
shown that amino acid changes within or near the mobile loop region (residues 45–70)
impede the substrate Plg activation activity of the activator complex but do not affect
the ability of the protein to form a functional activator complex with Glu-Plg. (Liu et
al., 2000, Kim et al., 2000, Wakeham et al., 2002). Furthermore, non-conserved amino
acid changes between residues 113-134 (6 in total) have not been examined in SKc and
could also potentially effect type-2b SK activity (Figure 3.1).

Here we examined the importance of the α domain for SK function by biochemically
examining the α domain swap chimera SKαT1. The α domains of type-1 (SKNZ131) and
type-2b (SKALAB49) SK display 82% sequence identity. SKALAB49 contains 17 nonconserved amino acid changes within α domain when compared to SKc. While, SKNZ131
has the ability to non-proteolytically activate Glu-Plg and displays very limited nonconserved amino acid changes in this region (2 in total) (Figure 3.1). Interestingly,
SKαT1 was able to interact with Glu-Plg and induce an active site in Glu-Plg. This
demonstrates that the α domain from type-1 SK contains specific residues that are
essential for non-proteolytic activation of Glu-Plg (Figure 5.4). The rate of active site
generation displayed by SKαT1 was slower than that observed for wild-type SKNZ131 (9.4
fold) which suggests active site generation is also influenced by the co-operation of the
β and γ domains during conformational rearrangement (Loy et al., 2001). To determine
if conformational changes in SKαT1 were affecting the ability of this variant to interact
with substrate Glu-Plg, SKαT1 was complexed with plasmin, bypassing the need to
conformationally modify Glu-Plg. The SKαT1-plasmin activator complex was able to
sequester and activate substrate Glu-Plg at a rate similar to SKALAB49-plasmin
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complexes (Figure 5.6). This showed that substrate Plg activation is not influenced by
the modified secondary structure of the chimeric SKαT1 molecule and suggests type 2bspecific variation within the β and γ domains of SK may also be influencing substrate
Plg acquisition and processing.

Future work completing the purification of all six chimeras used in this study will
facilitate the identification of other specific functional regions within the molecule.
Additionally, a similar strategy could be applied to the other GAS SK variants including
the type-1 and type-2a variants. Now that the biochemical differences of GAS SK
variants have been defined, chimeric proteins can also be screened for several different
phenotypic variations that can help to assign function to specific domains of the protein.
Additionally, the non-conserved amino acid residues within these variant domain
sequences represent a finite pool of candidates for specific site directed mutagenic
studies to definitively deduce the molecular mechanism of SK mediated Plg activation.
The information gained from such studies could also be readily applied to research
aimed at the development of improved thrombolytic therapeutics with restricted Plg
activation and reduced immunogenicity.
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As an early mammalian defence mechanism, invading bacterial pathogens are confined
to sites of infection through the deposition of fibrin networks, thereby allowing a
directed inflammatory response to specifically target the area of capture (Levi et al.,
2004). Subversion of the host Plg activation system is a well-documented pathogenic
mechanism used by GAS and other bacterial pathogens to generate soluble and cell
bound protease activity to circumvent capture by fibrin networks (Boyle and
Lottenberg, 1997, Coleman and Benach, 1999, Castellino and Ploplis, 2005). The
present study focused on the streptococcal Plg activating protein SK. Preliminary data
that lead to the development of this project, demonstrated that allelic variants of SK
produced by GAS displayed unique Plg activation properties (McArthur et al., 2008).
Given the importance of this virulence factor in GAS pathogenesis, a more
comprehensive understanding of how SK variation could influence this process was
required. The overall aim of this thesis was to undertake the first extensive phenotypic
study of SK variants produced by GAS. Investigating the role of SK polymorphism and
effect on GAS virulence has furthered our understanding of Plg activation specific
pathogenic mechanisms employed by GAS.

In this study we observed that type-1 and type-2a GAS SK variants display phenotypic
similarity to the therapeutic SKc; these include: a high affinity for native Glu-Plg, an
ability to form a functional activator complex with Glu-Plg independent of additional
cofactor ligands, and resistance of the activator complex to α2-AP inhibition (Table 6.1).
Type-2b SK variants display numerous phenotypic differences when compared to the
other SK variants. Interestingly, type-2b SK variants could not induce the formation of
an active site in Glu-Plg, a function that until now has been considered archetypal for
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SK proteins (Boxrud et al., 2000, Boxrud et al., 2004). Additionally Type-2b SK
variants have a 25-30 fold lower affinity for

Table 6.1: Summary of the phenotypic differences observed for the SK variants
investigated in this study
Attribute

SKc

Type-1 SK

Type-2a SK

Type-2b SK

Glu-Plg activation (i.e. conformationally
induce active site)









High Affinity for Glu-Plg









High Affinity for plasmin









Forms an activator complex with




plasmin
Activator complexes are resistant to



*
inhibition by α2-antiplasmin
Generates active sites in Glu-Plg in




plasma
Can initiate fibrin clot lysis




*These complexes are resistant to inhibition when in the presence of a fibrin clot or PAM in
combination with fibrinogen.

native Glu-Plg. Unregulated plasmin activity is another characteristic trait usually
displayed by SK-Pln activator complexes. However, while type-2b SK variants
displayed high affinity for plasmin and could form a functional type-2b SK-plasmin
activator complex, this activity was inhibited by α2-AP. Type-2b SK mediated Glu-Plg
activation was influenced by the conformation of Glu-Plg. Type-2b SK variants could
activate Glu-Plg when it was bound with fibrinogen, PAM, fibrinogen fragment D or
fibrin. Furthermore, in contrast to type-1 and type-2a SK, active type-2b SK-Plg-ligand
activator complexes were still inhibited by α2-AP unless bound to fibrin or to the GAS
cell surface via PAM in combination with fibrinogen (Table 6.1). These data suggest
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that type-2b SK Plg activation may be restricted to specific micro-environments within
the host such as fibrin deposits or the bacterial cell surface through the action of α2-AP.

This study confirms the importance of SK mediated Plg activation in GAS pathogenesis
and highlights a mechanism whereby variability in this important virulence factor can
influence the pathogenesis of this organism. Future comparative studies that assess GAS
SK sequence variation in relation to the phenotypic differences displayed by the SK
variants that have been characterised in this thesis represents a novel approach to further
elucidate the mechanism of SK-mediated Plg activation. Such studies will help to
identify critical residues involved in SK function and could assist the development of
novel therapeutics for treating GAS infections and the development of improved
thrombolytics. Preliminary studies here showed that the surface restricted Plg activation
displayed by type-2b SK focuses plasmin activity toward fibrin cleavage and prevents
plasma fibrinogen degradation which is an unwanted side-effect associated with the
current form of therapeutic SK. Additionally, on a broader scale, application of
knowledge from this study to a range of other bacterial pathogens (>20 species), which
use components of the Plg activation system as a virulence factor may show that
indirect regulation of Plg activation may also influence the pathogenesis of other
bacterial species.
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Preface

The information presented in the following appendices includes supplementary,
preliminary and supporting data to experiments that appear in the research chapters of
this thesis (Chapter 2, Chapter 3 and Chapter 4). While these experiments were not
included in the publications that came from each body of work, they do provide some
background and additional information to the experimental material that appear in the
results chapters. Brief methods for these experiments are also included where required.
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Appendix 1: DNA sequences of variant ska inserts in pQE-30::ska
constructs

A

B
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Figure A1.1 DNA sequence of mature streptokinase data from pQE-30::ska variant
constructs. A) SKc B) SKNZ131; C) SK5448; D) SKNS696; and E) SKNS88.2. One letter
designation of the predicted amino acid sequence is shown below the DNA sequence
data. Accession numbers for these sequences are given in the material and methods of
Chapter 3 (section 3.3.10)
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Appendix 2: Expression and Purification of Recombinant SK Variants
A.2.1 Expression and purification of SK using Ni2+-NTA affinity chromatography
The figures presented here are supplementary to the purification process outlined in
Chapter 2.3.4 and Chapter 3.3.2 for expression of the SK variants used in this thesis.

Figure A2.1.1: Expression and purification of native recombinant poly-histidine
tagged fusion protein SKNZ131 via FPLC Ni2+-NTA affinity chromatography. (A)
Elution profile from ÄKTAprime plus FPLC showing A280 trace (solid line) and
percentage elution buffer (dashed line) for SKNZ131. Point i represents injection of
cleared lysate. Point ii represents injection of binding buffer. Point iii represents
injection of wash buffer and point iv represents injection of elution buffer. (B)
Coomassie stained 10% SDS-PAGE of SKNZ131 purification process. Un-induced E. coli
whole cell lysate (lane 1), 2 h post induction E. coli whole cell lysate (lane 2) native
lysis pellet containing insoluble protein (lane 3), lysate supernatant containing soluble
protein (lane 4) Ni2+-NTA column flow through (lane 5), wash buffer Ni2+-NTA column
flow through (lane 6) and Ni2+-NTA column elution fractions (lane 7-11).
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Figure A2.1.2: Expression and purification of native recombinant poly-histidine
tagged fusion protein SKαT1 via FPLC Ni2+-NTA affinity chromatography. (A)
Elution profile from ÄKTAprime plus FPLC showing A280 trace (solid line) and
percentage elution buffer (dashed line) for SKαT1. Point i represents injection of cleared
lysate. Point ii represents injection of binding buffer. Point iii represents injection of
wash buffer and point iv represents injection of elution buffer. (B) Coomassie stained
10% SDS-PAGE of SKαT1 purification process. Un-induced E. coli whole cell lysate
(lane 1), 2 h post induction E. coli whole cell lysate (lane 2) native lysis pellet
containing insoluble protein (lane 3), lysate supernatant containing soluble protein (lane
4) Ni2+-NTA column flow through (lane 5), wash buffer Ni2+-NTA column flow
through (lane 6) and Ni2+-NTA column elution fractions (lane 7-11).

165

Appendices

Figure A2.1.3: Expression and purification of native recombinant poly-histidine
tagged

fusion

protein

SKc via

bench

top

column

Ni2+-NTA

affinity

chromatography. Coomassie stained 10% SDS-PAGE of SKc purification process. Uninduced E. coli whole cell lysate (lane 1), 2 h post induction E. coli whole cell lysate
(lane 2), lysate supernatant containing soluble protein (lane 3) Ni2+-NTA column flow
through (lane 4), wash buffer Ni2+-NTA column flow through (lane 5) and Ni2+-NTA
column elution fractions (lane 7-12).

Figure A2.1.4: Expression and purification of native recombinant poly-histidine
tagged fusion protein SK5448 via bench top column Ni2+-NTA affinity
chromatography. Coomassie stained 10% SDS-PAGE of SK5448 purification process.
Un-induced E. coli whole cell lysate (lane 1), 2 h post induction E. coli whole cell lysate
(lane 2), lysate supernatant containing soluble protein (lane 3) Ni2+-NTA column flow
through (lane 4), wash buffer Ni2+-NTA column flow through (lane 5) and Ni2+-NTA
column elution fractions (lane 7-12).
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Figure A2.1.5: Expression and purification of native recombinant poly-histidine
tagged fusion protein SKNS696 via bench top column Ni2+-NTA affinity
chromatography. Coomassie stained 10% SDS-PAGE of SKNS696 purification process.
Un-induced E. coli whole cell lysate (lane 1), 2 h post induction E. coli whole cell lysate
(lane 2), lysate supernatant containing soluble protein (lane 3) Ni2+-NTA column flow
through (lane 4), wash buffer Ni2+-NTA column flow through (lane 5) and Ni2+-NTA
column elution fractions (lane 6-10).

Figure A2.1.6: Expression and purification of native recombinant poly-histidine
tagged fusion protein SKNS88.2 via bench top column Ni2+-NTA affinity
chromatography. Coomassie stained 10% SDS-PAGE of SKNS88.2 purification process.
Un-induced E. coli whole cell lysate (lane 1), 2 h post induction E. coli whole cell lysate
(lane 2), lysate supernatant containing soluble protein (lane 3) Ni2+-NTA column flow
through (lane 4), wash buffer Ni2+-NTA column flow through (lane 5) and Ni2+-NTA
column elution fractions (lane 6-10).
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A2.2 Factor Xa cleavage of SK variants
The figures presented here are supplementary to the purification process outlined in
Chapter 2.3.4 for Factor Xa cleavage of the remaining SK variants used in this thesis.

(i)

(ii)

(iii)

(iv)
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(v)

(vi)

Figure A2.2.1: Factor Xa cleavage of recombinant poly-histidine tagged SK variant
fusion proteins. (i) SKNZ131; (ii) SKc; (iii) SK5448; (iv) SKNS696; (v) SKNS88.2 (vi) SKαT1.
(A) Coomassie stained 10% SDS-PAGE of SKALAB49 cleavage. Lane 1, SK T = 0 h;
Lane 2, SK T = 36 h without Factor Xa; Lane 3, SK T = 36 h Factor Xa added. (B)
Western blot of the duplicate samples using Ni2+-NTA HRP conjugate to detect
polyhistidine tags.
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A2.3 Additional anion exchange chromatography
The figures presented here are supplementary to the purification process outlined in
Chapter 2.3.6 for Anion-exchange FPLC of the remaining SK variants used in this
thesis.

(i)

170

Appendices

(ii)

(iii)
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(iv)

(v)
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(v)

Figure A2.3.1: Anion-exchange fast protein liquid chromatography of SK variants.
(i) SKNZ131; (ii) SKc; (iii) SK5448; (iv) SKNS696; (v) SKNS88.2 (vi) SKαT1. (A) Elution
profile from ÄKTA explorer FPLC showing A280 trace (solid line) and percentage of
Buffer B (0 -1 M NaCl) (dashed line). Generally three peaks were resolved in the A280
trace correlating to truncated SK (peak i), full length 47 kDa SK (peak ii) and a coelution of both species (peak iii). (B) Coomassie stained 10% SDS-PAGE of anion
exchange elution peaks. Elution peaks generally correlated to truncated SK (i), full
length ~47 kDa SK (ii) and co-elution of both species (iii). Variation in the peak
resolution and composition can be clearly identified by comparison of panels A and B
of the figure.
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A2.4 Denaturing purification protocol for recombinant SK proteins
Recombinant SK protein expression in transformed M15[pREP4] was induced by
addition of isopropyl-1-thio-b-D-galactopyranoside to log-phase cells in 1L culture
volume at a final concentration of 1 mM. Three hours later, cells were harvested by
centrifugation, resuspended in 5 mL of denaturing lysis buffer (Urea 8 M, NaH2P04 100
mM, Tris.Cl 100 mM,pH 8.0) and agitated at room temperature for 1 h. A further 5 mL of
denaturing lysis buffer was added to the solution and agitated for a further 15 min at room
temperature. The solution was incubated on ice for a further 15 min and subjected to
sonication using a Branson Sonifier 250® (Branson, USA) equipped with a micro tip (output
limit of 7) to lyse remaining intact cells. Cells were sonicated with a 50% duty cycle for 30
sec then chilled on ice for 30 sec for a total of 2 min sonication. The suspension was
centrifuged at 10,000 x g for 30 min to clear the lysate of cellular debris and the supernatant
removed for Ni2+-NTA affinity chromatography using denaturing purification buffers.

Purification of protein from cleared lysate was performed using an ÄKTAprime plus
fast protein liquid chromatography (FPLC) system (GE Healthcare Life Sciences,
Piscataway,NJ, USA) with two 1 mL HisTrap HP columns in series (QE Scientific,
USA). The resin was equilibrated with 10 column volumes of binding buffer (50 mM
NaH2P04, 300 mM NaCl, 10 mM Imidazole, pH 8) and once equilibrated, 50 mL of 0.22
μm syringe filtered lysate was loaded onto the column. The column was washed with
binding buffer until the A280 trace returned to a constant pre-sample injection baseline.
The column was then washed with 10 column volumes of washing buffer (Urea 8 M,
NaH2P04 100 mM, Tris.Cl 100 mM, pH 6.3) to remove non-specifically bound

contaminants. Column bound recombinant SK was eluted from the column by flowing
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20 column volumes of elution buffer (Urea 8 M, NaH2P04 100 mM, Tris.Cl 100 mM, pH
4.5) over the column resin and collected in 1mL elution fractions.
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Appendix 3: Enzyme Kinetic Analysis of SK variants

The biochemical experiments shown in this appendix were initially completed as a
method to assess differences in the amidolytic (Figure A3.1) and Plg activation
activities (Figure A3.2) of the SK variants used in this study. However, after these
experiments were completed plasmin was determined to bind with high affinity to SK
(several orders of magnitude tighter than Glu-Plg) resulting in preferential formation of
the SK-plasmin complex for all SK variants and generation of amidolytic activity via
‘Pathway II’. Thus, these considerations affected the kinetic parameters listed in Table
A3.1, where the SK variants and Plg were pre-incubated before measurement of the
rates of plasmin specific chromogenic substrate, S-2251, hydrolysis. As such, these
parameters likely reflect the SK-plasmin complex and not SK-Glu-Plg*, but do show
distinct differences between each variant and are valuable data to be considered for
future biochemical analyses.

The kinetic parameters listed in Table A3.2 for activation of Glu-Plg were achieved by
the addition of SK variants to excess Glu-Plg and S-2251 substrate. After completion of
these experiments it was noted that the chromogenic substrate, S-2251, used in these
experimentm inhibits the rate of both SK-Plg* and SK-plasmin activation of free GluPlg, as S-2251 binds to the active site of theses complexes and interferes with
proteolytic activity. While these reactions were appropriately analysed as parabolic
progress curves to obtain the initial rate of plasmin formation and subsequently fit by a
hyperbola to determine the kinetic parameters, the rates could not be corrected for
inhibition due to the presence of S-2251. As Table A3.1 suggests, the kinetic constants
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for S-2251 hydrolysis are different for the SK variants, and this may also suggest that
the corrections for inhibition by S-2251 will be different for SKc Type-1, 2a, and 2b SK
variants. Despite attempting to calculate these inhibition constants, these data could not
be successfully generated and as such these data were not considered suitable for
publication and were superseded by the S-2251 hydrolysis absorbance versus time
curves used in Chapters 2, 3 and 4.

A3.1 Steady state amidolytic kinetics analysis of SK-Plg variants
The amidase kinetic parameters of variant SK molecules were studied by the addition of
preformed SK-Plg complex (5 – 25 min, final concentration 20 nM) to assay buffer
containing S-2251 (30 µM – 2000 µM) in a total volume of 100 µL. The change in
absorbance was measured at 405 nm at 37°C. The data were plotted as velocity (µM
min-1) versus substrate concentration (µM) and analysed by hyperbolic curve fitting
using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). A molar extinction
coefficient of 10000 M-1 cm-1 was used for calculation p-nitroanilide concentration.
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Figure A3.1: Mechaelis-Menten kinetic analysis of the amidase properties of SK
variants complexed with Glu-Plg. (A) SKc; (B) SKNZ131; (C) SKNS696; (D) SK5448; (E)
SKALAB49 and (F) SKNS88.2. All panels: representative Michaelis-Menten curve fits of
velocity verses substrate concentration to determine Km and Vmax. The insert of each
figure displays the Linewearver-Burk plots from these data and used for kinetic constant
determination (shown in Table A3.1). The data presented here is representative of at
least three experiments.
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Table A3.1. Kinetic constants for amidolysis by variant SK-Plg complexes
SK Variant

Km (µM)

SKc
SKNZ131
SK5448
SKNS696
SKALAB49
SKNS88.2

414 ± 16
460 ± 33
118 ± 9
167 ± 31
133 ± 6
156 ± 17

Amidolytic Parameters
kcat (s-1)
kcat/Km (µM-1s-1)
26.4 ± 0.4
29.1 ± 0.8
28.4 ± 0.6
32.7 ± 1.7
18.2 ± 0.2
12.9 ± 0.4

0.064
0.063
0.241
0.196
0.137
0.083

Values represent the mean ± SEM.

A3.2 Steady state Plg activation assays
The kinetics of Plg activation were studied by the addition of variant SK (final
concentration 5-10 nM) to assay buffer containing Plg (300 nM – 1600 nM) and S-2251
(500 µM) in a total volume of 100 µL at 37°C. Initial reaction rates were obtained from
the first 300 s by plotting A405/min2 and apparent Michaelis and catalytic rate constants
were calculated by fitting the data to a hyperbolic curve as described previously by
Wohl et al. (1980) using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA).
Where the overall reaction consists of two separate reactions:

KPlg
SK + Plg

kPlg
SK.Plg
Ks

Pln + S-2251

SK + Pln

(1)

ks
Pln.S-2251

Pln + pNA + H-D-Val-Leu-Lys

(2)

These reactions occur independently of each other and pNA is the p-nitroanilide group
released from a chromogenic substrate S-2251 that is detected at an absorbance of 405
nm. Kplg and Ks are the dissociation constants for the activation of Plg by SK and for the
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hydrolysis of S-2251 by plasmin (Pln), respectively. kplg and ks are the catalytic rate
constants of the Plg activation and of the amidolysis, respectively. Below, k is the
apparent Plg activation rate (µM pNA/min2), k1 is the Plg activation rate (µM

[pNA]t =
[pNA]t =
where,

(3)

,

Pln/min), and k2 represents the plasmin activity toward S-2251 (µM pNA/min.µM
Pln/min). [SK]0, [Plg]0 and [S-2251]0 are the initial concentrations of SK, Plg, and S2251, respectively. [pNA]t is the concentration of p-nitroaniline at time t. The apparent
Plg activation rate k was determined by plotting the concentration of pNA released vs.
reaction time squared. The k2 value was calculated from equation 3 using the kinetic
parameters on the amidolytic activity of plasmin toward S-2251 as described in section
A3.3. The k1 value was calculated from the values of k and k2 for final determination of
kinetic constants of SK mediated Plg activation.
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Figure A3.2. Mechaelis-Menten kinetic analysis of the Plg activation activity of SK
variants (A) SKc; (B) SKNZ131; (C) SKNS696 and (D) SK5448. All panels: representative
Michaelis-Menten curve fits of velocity verses substrate Plg concentration to determine
Km and Vmax. The insert of each figure displays the plots of initial velocity of Plg
activation for each substrate concentration, from which the gradients of the lines were
used to fit to a modified Michalis-Menten equation that has been derived to determine
the kinetic constants of Plg activation specifically (shown in Table A3.2). The data
presented here is representative of at least three experiments.

Table A3.2. Kinetic constants for activation of Plg by variant SK-Plg complexes
Activation Parameters
Activator
Km (nM)
kcat (min-1)
kcat/Km (uM-1 min-1)
333 ± 60
1.7 ± 0.1
5.1
SKc
432 ± 42
2.3 ± 0.1
8.3
SKNZ131
112 ± 15
1.5 ± 0.1
13.4
SK5448
127 ± 22
1.2 ± 0.1
9.5
SKNS696
Activates*
Activates*
N/A
SKALAB49
Activates*
Activates*
N/A
SKNS88.2
Activation experiments were conducted at 37°C as described above. Procedures’.
Values represent the mean ± SEM. N/A = Not Applicable. * Delayed Plg activation (>
30 min lag phase due to plasmin contamination) before significant generation of
activation resulting in indeterminable kinetic constants.
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A3.3 Calculation of plasmin amidase activity

The amidase kinetic parameters of plasmin used to determine the k2 value for equation 3
(section 3.2) were determined by the addition of plasmin (final concentration 20 nM) to
assay buffer containing S-2251 (30 µM – 3000 µM) in a total volume of 100 µL. The
change in absorbance was measured at 405 nm at 37°C. The data were plotted as
velocity (µM/min) versus substrate concentration (µM) and analysed by hyperbolic
curve fitting using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). A
molar extinction coefficient of 10000 M-1 cm-1 was used for calculation p-nitroanilide
concentration. From this experiment the Km and Vmax of plasmin hydrolysis of S-2251
were determined to be 319.5 µM and 27.7 µM/min, respectively.

0 .4

20

0 .3

1 /V

V e lo c it y (u M /m in )

30

10

0 .2

0 .1

- 0 .0 0 5

0 .0 0 0

0 .0 0 5

0 .0 1 0

0 .0 1 5

0 .0 2 0

0 .0 2 5

1 /[ S ]

0
0

500

1000 1500 2000 2500 3000 3500

[S 2 2 5 1 ] (u M )

Figure A3.3. Mechaelis-Menten kinetic analysis of the amidase activity of plasmin
Representative Michaelis-Menten hyperbolic curve fit of velocity of pNA generation
verses substrate concentration to determine Km and Vmax. The insert displays the
Linewearver-Burk plot from these data, which was used for kinetic constant
determination. The data presented here is representative of at least three experiments.
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Appendix 4: Binding Interaction Analysis of SK Variants to Glu-Plg
and plasmin

A4.1 Solid state binding assays of SK variants to Plg
A preliminary characterisation of the interaction between recombiant SK variant
proteins and Glu-Plg was achieved by solid phase microtitre Plg binding assay. 96 well
microtitre plates (Greiner Bio-one, Germany) were coated with 5 µg/mL Glu-Plg (50 uL
in 20 mM HEPES buffer, 150 mM NaCl, pH 7.4) at 4°C overnight. Following five
washes with washing buffer (20 mM HEPES buffer, 150 mM NaCl, 0.05% Tween-20,
pH 7.4), plates were blocked with 100 µL of blocking solution (20 mM HEPES buffer,
150 mM NaCl, 5% skim milk, pH 7.4) for 1 h at 37°C. Wells were washed as above and
SK (SKc = 105 nM, type-1 SK = 2150 nM, type-2a SK = 150 nM and type-2b SK =
2150 nM) was diluted in a two-fold titration across the plate in binding buffer (20 mM
HEPES buffer, 150 mM NaCl, 0.5% skim milk, 0.05% Tween-20, pH 7.4) and
incubated at 37°C for 1.5 h. Following SK binding, microtitre plate wells were washed
five times and 50 µL of α-SK rabbit polyclonal sera (Jason Mcarthur, Univerity of
Wollongong, NSW, Australia) diluted 1:5000 in binding solution was added to all wells
and incubated for 1.5 h at 37°C. After five washes with washing buffer, 50 µL
secondary α-rabbit HRP conjugate antibody (Pierce, USA) was added to all wells of the
microtitre plate at a 1:4000 dilution in binding buffer and incubated at 37°C for 1 h.
After five washes with washing buffer the reactions were developed by the addition of
50 µL of o-phenylenediamine (Sigma-Aldrich, Sydney, NSW, Australia) substrate (8
mM Na2HPO4, 2.2 mM o-phenylenediamine, 3% H202, pH 5.5). Colour development
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was stopped by addition of 50 µL of 10 M HCl and the plates were read at 490 nm using
a Spectramax 250 spectophotometer plate reader (Molecular Devices, USA). For the
calculation of equilibrium binding dissociation constants (KD), a non-linear regression,
one site binding (hyperbola) was fit to the data using GraphPad Prism v5 (GraphPad
software, CA, USA).

A b s o rb a n c e a t 4 9 5 n m

A

SKc
1 .6
1 .4
1 .2
1 .0
0 .8

Bmax
Kd

0 .6

1.607
7.351

0 .4
0 .2
0 .0
0

25

50

75

100

125

C o n c e n t r a t io n ( n M )

A b s o rb a n c e a t 4 9 5 n m

B

T y p e -1 (S K N Z 131)
1 .2
1 .0
0 .8
0 .6

Bmax
Kd

0 .4

1.235
75.38

0 .2
0 .0
0

500

1000

1500

2000

2500

C o n c e n t r a t io n ( n M )

186

Appendices

A b s o rb a n c e a t 4 9 5 n m

C

T y p e -2 a (S K N S 696)
1 .3
1 .2
1 .1
1 .0
0 .9
0 .8
0 .7
0 .6
0 .5
0 .4
0 .3
0 .2
0 .1
0 .0

Bmax
Kd

0

10

20

30

40

1.238
1.566

50

60

70

C o n c e n t r a t io n ( n M )

A b s o rb a n c e a t 4 9 5 n m

D

T y p e -2 b (S K A LA B 49)
0 .6
0 .5
0 .4
0 .3

Bmax
Kd

0 .2

1.120
1817

0 .1
0 .0
0

500

1000

1500

2000

2500

C o n c e n t r a t io n ( n M )

Figure A4.1.1 Solid state binding analysis of SK variants to immobilised
recombinant Glu-Plg. SK binding to immobilised recombinant Glu-Plg (A) Group C
SK (SKc); (B) Type-1 SK (SKNZ131); (C) Type-2b SK (SKNS696) and (D) Type-2b SK
(SKALAB49). Equilibrium binding dissociation constants (KD) were calculates using a
non-linear regression, one site binding (hyperbola) analysis and was fit to the data using
GraphPad Prism v5 (GraphPad software, CA, USA).
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A4.2 Surface plasmon resonance studies to determine affinity constants for variant
SK interaction with Glu-Plg and plasmin
The figures presented here are supplementary to the generation of binding affinity
constants given in Table 3.3.6 as outlined in Chapter 3.3.6 for surface plasmin
resonance experiments.
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F

Figure 4.2.1 Surface plasmon resonance analysis of the interaction between SK
variants and immobilised Glu-Plg. (A) Biosensorgram data for the interaction of 200
– 6.25 nM SKc;(B) Biosensorgram data for the interaction of 400 – 25 nM SKNZ131; (C)
Biosensorgram data for the interaction of 200 – 12.5 nM SKNS696; (D) Biosensorgram
data for the interaction of 200 – 12.5 nM SK5448; (E) Biosensorgram data for the
interaction of 1600 – 100 nM SKALAB49 and (F) Interaction of 1600 – 100 nM SKNS88.2.
All panels: (top inset) [SK] dose dependent response of specific binding used for kinetic
constant determination and (bottom inset) representative fits of the two-component
heterogeneous surface model to the association portion of the biosensorgram data. The
data presented here is representative of at least three experiments.
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Figure. A4.2.2 Surface plasmon resonance analysis of the interaction between SK
variants and immobilised plasmin. (A) Biosensorgram data for the interaction of 200
– 1.25 nM SKc; (B) Biosensorgram data for the interaction of 200 – 1.25 SKNZ131; (C)
Biosensorgram data for the interaction of 200 – 1.25 nM SKNS696; (D) Biosensorgram
data for the interaction of 200 – 1.25 nM SK5448 (E) Biosensorgram data for the
interaction of 200 – 12.5 nM SKALAB49; (F) Interaction of 200 – 12.5 nM SKNS88.2. All
panels: (top inset) [SK] dose dependent response. The data presented here is
representative of at least three experiments.
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Appendix 5: Effect of Fibrin on SK Amidolytic Activity and Clot Lysis
Capacity

A.5.1 Effect of fibrin on SK variant amidolytic activity
The figure presented here is supplemental to that in Chapter 4.2.5 for additional SK
variants not included in that section of the publication.
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Figure A5.1 Generation of amidolytic activity and the effect of variant SK-Plg
complexes formed in the presence of a fibrin clot (A) Complex formation was
initiated by addition of variant SK (40 nM) to assay buffer (10 mM HEPES, 150 mM
NaCl, 0.01% Tween-20, pH 7.4) containing Glu-Plg (20 nM) and chromogenic
substrate S-2251 (500 µM) then monitored at A405. (B) Fibrin clots were formed for 4 h
at RT in a 96-well plate by the addition of thrombin (0.8U/mL) and CaCl2 (20 mM) to
recombinant fibrinogen (3 µM). Plg (20 nM) was bound to the fibrin clots for 1 h at
37°C. Bound Plg was washed before complex formation was initiated and monitored at
A405 by addition of variant SK (40 nM) to assay buffer (10 mM HEPES, 150 mM NaCl,
0.01% Tween-20, pH 7.4) chromogenic substrate S-2251 (500 µM) at 37°C.
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A.5.2 Plasma clot lysis capacity of SK variants
The figure presented here is supplemental to that in Chapter 4.2.6 for additional SK

C lo t T u r b id it y ( % )

variants not included in that section of the publication.
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Figure A5.2. Induction of plasma clot lysis by SK variants. Fibrin clots were formed
in pooled EDTA treated human plasma by the addition of thrombin (0.8U/mL) and
CaCl2 (20 mM). Variant SK molecules were then suspended in fresh plasma to a final
concentration of 50 nM over the plasma clot and lysis was monitored by measuring a
reduction in turbidity at 340 nm at 37°C
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Appendix 6: Buffers, Media and Solutions

Growth and Nutrient Media
Luria Bertani (LB) Broth
Bactotryptone
Yeast Extract
NaCl

10 g/L
5 g/L
10 g/L

LB Agar
Bactotryptone
Yeast Extract
NaCl
Agar

10 g/L
5 g/L
10 g/L
15 g/L

Todd-Hewitt Broth (THY)
Todd-Hewitt Broth powder
Yeast Extract

30 g/L
10 g/L

THY Agar
THY
Agar

1L
15 g/L

E.coli Glycerolisation Solution
Casamino acids
Glycerol

1% (w/v)
10% (v/v)

Agarose Gel Electrophoresis
1X TAE Buffer
Tris-base
Glacial Acetic acid
EDTA (pH 8.0)

40 mM
20 mM
1 mM

0.85% Agarose Gel
Agarose
Tris-base
EDTA
Glacial Acetic acid

0.85% (w/v)
40 mM
1 mM
5.71 %(v/v)

Agarose Loading Buffer
Bromophenol blue
Glycerol

0.005% (w/v)
75% (v/v)
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TE Buffer

25% (v/v)

Ethidium Bromide Solution
Ethidium bromide
dH20

1 μg/mL

SDS-PAGE Gel Electrophoresis
2 X Cracking Buffer
Tris.HCl
Bromophenol blue
Glycerol
SDS
β-mercaptoethanol

90 mM
0.02% (w/v)
20% (v/v)
2% (w/v)
1% (v/v)

10% Resolving Gel
Bis-acrylamide (37.5:1)
Tris.HCl 1.5 M (pH 8.8)
SDS
TEMED (add last)
Ammonium Persulphate (add last)

10% (w/v)
25% (v/v)
0.1% (w/v)
0.05% (v/v)
0.015% (w/v)

4% Stacking Gel
Bis-acrylamide (37.5:1)
4%w/v)
Tris-HCl 0.5 M (pH 6.8)
SDS
TEMED (add last)
Ammonium Persulfate (add last)
(w/v)
1X SDS-PAGE running buffer
Tris-base
Glycine
SDS
pH 8.3

25% (v/v)
0.1% (w/v)
0.5% (v/v)
0.015%

50 mM
196 mM
0.1% (w/v)

Coomassie Blue Stain
Coomassie Brilliant Blue R-250
Methanol
Glacial Acetic acid

0.2% (w/v)
40% (v/v)
10% (v/v)

Rapid Destain
Methanol
Glacial Acetic acid

40% (v/v)
10% (v/v)
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Wizard® Plus SV Minipreps DNA Purification
Cell resuspension solution
Tris.HCl
EDTA
RNase A
pH 7.5

50 mM
10 mM
100 μg/mL

Cell lysis solution
NaOH
SDS

200 mM
1% (w/v)

Neutralisation solution
Guanidine Hydrochloride
Potassium Acetate
Glacial Acetic acid

4.09 M
0.759 M
2.12 M

Column wash solution
Aotassium Acetate
Tris-HCl (pH 7.5)
EDTA (pH 8.0)
Ethanol

60 mM
8.3 mM
0.04 mM
60% (v/v)

Alkaline Lysis DNA Purification
Solution 1
Glucose
Tris-HCl
EDTA
RNase A

50 mM
25 mM
10 mM
0.1 mg/mL

Solution 2
NaOH
SDS

0.2 M
1% (v/v)

Solution 3
Potassium Acetate
Glacial Acetic acid

3M
11.5% (v/v)

Qiagen-100 Tip Column Buffers
Wash Buffer
NaCl

1.0 M

198

Appendices

Isopropanol
pH 7
Elution Buffer
NaCl
Tris.HCl (pH 8.5)
Isopropanol

15% (v/v)

1.25 M
50 mM
15% (v/v)

Native Ni2+-NTA Purification
Native Lysis Buffer
Lysozyme
PMSF
MgCl2
DNase I
Triton X-100
Imidazole
NaH2P04
NaCl
pH 7.4

1 mg/mL
0.1 mM
10 mM
5 μg/mL
0.1% (v/v)
10 mM
50 mM
300 mM

Binding Buffer
NaH2P04
NaCl
Imidazole
pH 8

50 mM
300 mM
10 mM

Wash Buffer
NaH2P04
NaCl
Imidazole
pH 8

50 mM
300 mM
20 mM

Elution Buffer
NaH2PO4
NaCl
Imidazole
pH 8.0

50 mM
300 mM
250 mM

Western Blot Analysis
Western Transfer Buffer
Methanol
Tris-base
Glycine

20% (v/v)
23 mM
192 mM
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SDS

0.001% (v/v)

PBST
NaCl
Na2HPO4
KCl
KH2PO4
Tween-20
pH 7.4

137 mM
4.3 mM
2.7 mM
1.4 mM
0.05% (v/v)

TBST
Tris.Cl
NaCl
Tween-20

20 mM
500 mM
0.05% (v/v)

Blocking Buffer
Skim milk powder
Made up in PBST

5% (w/v)

Dilution Buffer
Skim milk powder
Made up in PBST

0.5% (w/v)

DAB developing solution
Diaminobenzidine
Tris.Cl
H2O2
pH 7.4

0.5 mg/mL
100 mM
0.05% (v/v)

Factor Xa Cleavage
Dialysis Buffer
Tris.Cl
NaCl
pH 8.0

25 mM
500 mM

QB Buffer
Tris.HCl
NaCl
CaCl2
pH 6.5

50 mM
50 mM
1 mM

Anion Exchange Chromatography
Buffer A
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Bis-Tris
pH 6.6
Buffer B
Bis-Tris
NaCl
pH 6.6

20 mM

20 mM
1M

ESI-MS
ESI-MS Sample Buffer
Ammonium Acetate
Formic acid
pH 6.8

10 mM
0.1%

Biochemical Assay Buffers
MUGB Assay Buffer
Tris-HCl
NaCl
pH 7.4

50 mM
100 mM

S-2251 Assay Buffer
HEPES
NaCl
Tween-20
pH 7.4

10 mM
150 mM
0.01%

BIAcore Assays
Activation Solution
N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide
N-hydroxysuccimide
Running Buffer
HEPES
NaCl
P-20
pH 7.4
Regeneration Buffer
HEPES
NaCl

100 mM
25 mM

10 mM
150 mM
0.01%

10 mM
150 mM
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P-20
Urea

0.01%
6M

Hyaluronic Acid Capsule Assays
Stains-All Solution
Stains-All
Galacial Acetic acid
50% Formamide

20 mg
60 µL
100 mL

Plasma Fibrinogen Depletion Assay
Precipitation Solution
Sodium Sulphite

10.5% (w/v)

Resuspension Solution
Urea
NaOH

4M
0.1 N

General Buffers
PBS
NaCl
Na2HPO4
KCl
KH2PO4
pH 7.4

137 mM
4.3 mM
2.7 mM
1.4 mM

TBS
Tris.HCl
NaCl
pH 7.4

10 mM
350 mM

TE Buffer
Tris-HCl
EDTA (pH 8.0)

10 mM
1 mM

Phosphate buffer (10 mM)
Na2HPO4
NaH2PO4

0.336 g/L
1.02 g/L
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Appendix 7: Plasmids Used in this Study

Figure A7.1. Plasmid map of pHSGXceIS1, an augmented form of pHSG398 that has
had NspI restriction sites removed. NspI site were removed from the plasmid backbone
by restriction digest with NspI (Fermentas, Pittsburgh, PA, USA) followed by treating the
DNA preparation with S1 nuclease (Thermo Fischer Scientific, Scoresby, VIC, Australia)
to remove single strand over-hangs. The plasmid was then re-ligated with T4 ligase
(Fermentas, Pittsburgh, PA, USA) resulting in deletion of NspI sites. This vector was used
for construction of the chimeric ska gene in Chapter 5.

Figure A7.2: Plasmid map of pQE-30 expression vector. PCR primers were designed to
incorporate BamHI and PstI restriction sites at the 5’ and 3’ ends of the amplified ska
genes used in this study. This allowed cloning into pQE-30 (Qiagen, Valencia, CA, USA)
for expression of recombinant SK as a poly-histidine tagged fusion protein.
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Appendix 8: Construction of DNA Standard Curve
Using molecular weight markers, standard curves were constructed to allow for the
estimation of the size of DNA bands observed on agarose gels. The standard curve
constructed based on the markers in Figure A.1.1.1 is shown below (Table A8.1 and
Figure A6.1).
Table A8.1: Mobility of DNA markers GeneRuler™ DNA Ladder (Fermentas,
Pittsburgh, PA, USA) used for construction of a standard curve (Figure A8.1). The
data here is based on the markers present on the gel in Figure A1.1.1

log10 Molecular Weight (kb)

Molecular Weight (kb)
10
8
6
5
4
3.5
3
2.5
2
1.5
1
0.75
0.5
0.25

log10 Molecular Weight
1
0.903
0.778
0.699
0.602
0.544
0.477
0.398
0.301
0.176
0
-0.125
-0.301
-0.602

1.2
1
0.8
0.6
0.4
0.2
0
-0.2 0
-0.4
-0.6
-0.8

Mobility (mm)
3
4.5
11
14.5
18
20.5
23
26.5
31
36
43
47
52
58
y = -0.0267x + 1.0867
2

R = 0.988

10

20

30

40

50

60

70

Mobility (mm)

Figure A8.1: Standard curve constructed using GeneRuler™ DNA Ladder
(Fermentas, Pittsburgh, PA, USA) from the gel in Figure A.1.1.1
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Appendix 9: Construction of Protein Standard Curve
Using molecular weight markers, standard curves were constructed to allow for the
estimation of the size of proteins observed on SDS-PAGE gels. The standard curve
constructed using the molecular weight markers in Figure 2.4.1B is shown below.
Table A9.1: Mobility of PageRuler™ Unstained Protein Ladder used for
construction of a standard curve (Figure A9.1). The data here is based on the
markers present on the gel in Figure 2.4.1B
Molecular Weight (kDa)
250
130
100
70
55
35
27

log10 Molecular Weight
2.3979
2.1139
2
1.8451
1.7403
1.5440
1.4314

Mobility (mm)
10
14
21
27
38
47
58

log10 Molecular Weight (kDa)

3

y = -0.0183x + 2.4298
R² = 0.9384
2.5
2

1.5
1
0.5
0

0

10

20

30

40

50

60

70

Mobility (mm)

Figure A9.1: Standard curve constructed of PageRuler™ Unstained Protein
Ladder (Fermentas, Pittsburgh, PA, USA) from the gel in Figure 2.4.1B
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